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Abstract
The body is constantly exposed to many different external chemicals (xenobiotics). 
Cytochrome P450 enzymes and drug transporters form part of the core protection 
system for the body, regulating entry of xenobiotics, and increasing clearance rates of 
chemicals that do enter the body. It is therefore important to know how these systems 
will respond to novel chemicals, with human cell lines commonly used in both drug 
metabolism and gene expression studies. In this study we have determined the 
transcript levels for several cytochrome P450s or drug transporter from human liver 
(Huh7), intestine (CaCo-2) and lung (A549) cell lines, and compared them to adult 
and foetal levels in the respective tissues. Basal expression of the selected GYP genes 
and drug transporters is significantly lower in these cell lines than in either adult or 
foetal primary tissue. We have also examined the effect of xenobiotic exposure on the 
expression of these transcripts, showing that whereas some cell lines have maintained 
their ability to show genome-base activations of gene expression, others are refractory 
- a fact that has important implications for drug studies carried out in these cell lines. 
Finally, we have examined how two of these genes, CYP3A4 and MDRl, are 
regulated in different tissues and cell types. Current evidence suggests that in certain 
tissues these genes show positive coordination of their response to xenobiotic 
exposure, whereas in other negative or no coordination is seen. Using reporter gene 
constructs for the proximal promoters of these two genes we examined the molecular 
mechanisms underlying these complex responses to chemical exposure to individual 
polychlorinated biphenyls (PCBs). The polychlorinated biphenyls (PCBs) comprise a 
group of 209 congeners varying in the number of chlorine atom and substitution 
patterns. These compounds have been shown to induce an array of effects in exposed 
organisms and tend to be biomagnified in food webs. The structural characteristics of 
the PCBs influence their potency as well as their mechanism of action. PCB 
congeners with zero or one ortho-chlorine substituent can bind to the aryl 
hydrocarbon receptor (AhR receptor), thus mimicking the action of 2,3,7,8- 
tetrachlorodibenzo-/7-dioxin (TCDD). The effects of these PCB congeners (such as 
PCB 77, 126 and 169) appear to be mediated primarily via the AhR receptor. PCB 
congeners with ortho chlorine substituents can bind to the constitutive androstane 
receptor (CAR) and/or the pregnane X receptor (PXR) and they are called 
phénobarbital (PB)-type PCBs (for example PCB 87, 99, 153, 180, 183 and 194).
Other ortho substituted PCB congeners interact with both the aryl hydrocarbon (AhR) 
and the CAR receptor and they are called mixed type PCBs (for example, PCB 128, 
138, 170). Six PCBs (77, 99, 138, 153, 180 and 194) had been selected from the three 
categories and their properties were examined by looking at the possible induction of 
CYP3A4 and MDRl genes through the human pregnane X receptor (hPXR) as well 
as their effects on the regulation of the human PXR gene expression itself in 
transiently transfected Huh7, Caco-2 and A549 cell lines. In summary, this work 
demonstrate that non-coplanar PCBs may act as direct activators of the nuclear 
receptor PXR and they are able to activate target gene expression in a tissue and 
substituent dependent manner. Such work will help improve prediction of body 
responses to PCBs exposure, as well as increase the accuracy of current risk 
assessment methodologies.
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1 Introduction
1.1 Regulation of the Body’s Homeostasis in Response to Chemical 
Exposure
1.1.1 Introduction
The human body must monitor the levels of both endogenous (endobiotic) or foreign 
(xenobiotic) chemicals as maintaining the correct balance of these chemicals is vital 
for both the normal cellular function and prevention of toxicity (Plant 2003). Body 
homeostasis is maintained by specialist proteins involved with monitoring and 
controlling the absorption, distribution, metabolism and excretion (ADME) of both 
endo- and xenobiotics. The major features of ADME processes will be considered 
below.
1.1.2 Absorption
Absorption is simply defined as the passage of a drug into the plasma from its site of 
administration. There are three main routes by which chemical can reach the 
bloodstream; absorption through the skin, lung or intestine. The latter is the most 
common route of absorption as many individuals are exposed to many chemicals 
within their diet and many drugs are taken via the oral route. To enter the body via 
any of these routes, the chemical must first cross a cell membrane to enter the plasma. 
This can be achieved via passive diffusion, facilitated diffusion or active transport 
(Plant 2003). Figure 1.1 shows the three mechanisms of absorption of a molecule a 
cross a cell membrane.
1.1.3 Distribution
Once a chemical is absorbed into the bloodstream, it will be distributed around the 
body to most of the organs. The highly perfused organs are more exposed to 
chemicals (i.e. liver, heart, lungs, etc.). Differences in blood flow to each organ result 
in unequal distribution around the body, whereby the most perfused organs receive 
the largest percentage of any chemical entering the body. The liver is the major site of 
metabolism within the body and has the highest concentration of drug metabolizing 
enzymes (Plant 2003). Extrahepatic metabolism also occurs but to a lesser degree in
the mucosa of the gastrointestinal tract, in kidney and in the lung (Krishna and Klotz 
1994). The passage of a drug can be passive (Ayrton and Morgan 2001), but most 
drugs uptake is mediated by membrane transports. These transporters are localized on 
the surface of the cells of different organs; examples of such transporters include the 
P-glycoprotein (P-gp) or multidrug resistant (MDR) protein which is usually 
coexpressed and coinduced with CYP3A in liver and intestine. P-glycoprotein plays 
an important role in reducing drug absorption and enhancing drug elimination back to 
the gut lumen (Xu et al., 2005). Other examples of membrane transporters include the 
organic anion transporter proteins (OATPs), which transport organic anions into the 
cells (Hsiang et al. 1999) and organic cation transporters (OCTs), which conversely 
transport cations (Gorboulev et al. 1997). These membrane transporters are 
themselves regulated by regulatory proteins in which pregnane X receptor is one of 
the key regulator of these genes (Guo et al., 2002; Staudinger et al., 2003; Anapolsky 
et al,. 2006). This step of the uptake of drugs is considered a very important key step 
in the mechanisms of clearance, and the need to study the molecular mechanisms of 
regulation of transporters proteins is of big importance (Ayrton and Morgan 2001) 
and will be considered in more detailed later in the chapter.
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Figure 1.1 Mechanisms of absorption
Molecules may cross a cell membrane by passive diffusion, facilitated diffusion or active 
transport (Plant, 2003). Passive and facilitated diffusion occur along a concentration gradient, 
while active transport derives energy from the hydrolysis o f ATP and can therefore transport 
molecules against a concentration gradient.
1.1.4 Metabolism
Drug metabolism is the proeess that converts lipophilic molecules that were ideal for 
absorption across a cell membrane into hydrophilic molecules that can be excreted 
from the body in the urine or faeces. Drugs and xenobiotics are transformed by two 
phases: Phase I (or functionalisation reactions) and Phase II (or eonjugative 
reactions). Phase I ‘funetionalises’ the drug by producing or uncovering a chemically 
reactive functional group on which the phase II reactions can occur. This increases the 
polarity of the metabolite, facilitating their exeertion and hence inactivation (Gibson 
and Skett, 2001). Alternatively, if the parent drug contains a suitable functional group 
it may be directly modified by phase II reactions without first being metabolised by 
phase I enzymes. However it should be noted that metabolism of xenobiotics can 
bioactivate inert compounds producing reactive intermediates. These can cause toxic 
effects, such as mutations, cell damage, carcinogenesis and cell death if not further 
detoxified (Gibson and Skett, 2001). There are also phase III reactions that involve 
the further processing of phase II metabolites, such as the further metabolism of some 
glutathione conjugates to form mereapturie acids prior to excretion. Together the 
enzymes of these reactions form a drug metabolising system capable of catalysing 
virtually every chemical reaction that a compound can undergo (Gibson and Skett, 
2001).
1.1.4.1 Phase I
Phase I drug metabolising enzyems (DMEs) consist mainly of the cytochrome P450 
(CYP) superfamily of microsomal enzymes, found abundantly in the liver, 
gastrointestinal tract, lung and kidney. These enzymes superfamily are classified into 
families and subfamilies based on their amino acid sequences identities or similarities 
(Nelson et al., 1996). Phase I drug metabolism includes the oxidation, reduction, 
hydrolysis and hydration reactions of substrates, increasing chemical reactivity and 
preparing substrates for Phase II metabolism (Gibson and Skett 2001). Oxidative 
reactions are the most predominant, with the majority being catalyzed by the 
cytochrome P450 enzymes.
1.1.4.2 Phase II
In phase II of drug metabolism, which is also termed the conjugation reactions, chemicals 
are further modified by the addition of large complex hydrophilic moieties (conjugates)
generally leading to water-soluble product which can be excreted in bile or urine (Gibson 
and Skett 2001). Many different reactions are involved in this eonjugative phase, 
including glucuronidation, glyeosidation, sulfation, méthylation, acétylation, 
glutathione conjugation, amino acid conjugation, and fatty acid conjugation (Gibson 
and Skett 2001) ; however, the majority of reactions are catalysed by one of three 
families, namely glucuronidation, glutathione conjugation and sulphation. Table 1.1 
shows the major enzyme classes involved in phase II reactions. These reactions may 
be further sub-divided into type I reactions, involving high energy conjugates and 
type 2 reactions that utilize low energy conjugates (Plant 2003). Glucuronidation and 
sulphation reactions are referred to as major type I or ‘high energy’ reactions because 
their conjugated molecule contains the reactive energy and will react with relatively 
unreaetive groups such as the hydroxyl groups introduced by phase I reactions. 
Glutathione tends to be conjugated to molecules with high chemical reactivity, as it is 
relatively unreaetive itself. Glutathione conjugation is a major type 2 reaction or Tow 
energy’ phase II reaction and is usually used to detoxify highly reactive chemical 
substrates that might otherwise easily damage cells by reacting with DNA and cause 
toxicity (Gibson and Skett, 2001).
Table 1.1 Enzymes involved in Phase II reactions
Reaction Enzyme
Glucuronidation UDP-Glueuronosyltransferase
Glyeosidation UDP-Glyeosyltransferase
Sulfation Sulfotransferase
Méthylation Methyltransferase
Acétylation Aeetyltransferase
Amino acid conjugation
Glutathione conjugation Glutathione-S-transferase
Fatty acid conjugation
Condensation
(Adapted from Gibson and Skett, 2001)
Together phase I and II enzymes provide a drug metabolising system capable of 
catalysing almost any chemical reaction that a drug can undergo. The type of reaction 
depends on the substrate itself, the enzymes available and also the presence of 
co-factors.
1.1.5 Excretion
The two major routes of excretion of compounds from the body are urinary and 
biliary excretion, which are water based, hence the requirement for metabolism of 
drug molecules to produce metabolites with a higher hydrophilicity. However these 
polar hydrophilic molecules cannot pass through the membrane by passive diffusion 
therefore active transport plays a more important role in excretion than in absorption. 
Transport proteins play a vital role in excretion by pumping out chemicals from the 
body. These proteins exist in the canalicular membrane of hepatoeytes and the renal 
tubular membrane in the kidney in order for chemicals to be excreted in the bile or 
urine, but also in the intestine, where they act as the ‘first line of defense’ (Plant, 
2003). Table 1.2 shows some protein transporters in the liver, kidney, and intestine.
Table 1.2 Transporter proteins used in excretion in the liver, kidney and 
intestine
Intestinal efflux Biliary excretion Renal secretion
P-gp, MRPl, MRP2, 
OCTl, 0ATP3
P-gp, MDR3, MRP2 OATl, 0AT3, OATP, : 
OCTl, 0CT2, P-gp, MRPl
(Adapted from Plant, 2003)
MDR, multidrug resistance protein; MRP, multidrug resistance related protein; P-gp, P- 
glycoprotein; OAT, organic anion transport; OATP, organic anion transport protein; OCT, 
organic cation transporter.
1.2 Cytochrome P450
1.2.1 General Introduction
Cytochrome P450s (P450) constitutes a multigene family of heamproteins responsible 
for the metabolism of numerous xenobiotics, including therapeutic drugs, 
environmental chemicals, and dietary constituents, as well as endogenous compounds 
as steroids and bile acids (Gonzalez et ah, 1993). Cytochrome P450s are present in 
both prokaryotes and eukaryotes, which underlines their importance for organisms 
survival (Plant, 2007), showing a high degree of evolution/conservation (Nelson et ak, 
1996). They are present in all mammalian tissues, with the highest concentrations in 
liver endoplasmic reticulum, where they act as mono-oxygenases as part of the 
microsomal mixed function oxidase system (MFO), (Gibson and Skett, 2001). They 
were first discovered in 1958 and isolated in 1964 (Klingerberg, 1958; Omura and 
Sato, 1964a; Omura and Sato, 1964b). The protein was named cytochrome P450 
because it exhibited a spectral absorbance of 450 nm when eomplexed with carbon 
monoxide in a reduced form. Cytochrome P450 is the terminal oxidase component of 
an electron transfer system present in the endoplasmic reticulum responsible for the 
oxidation of almost all drugs and is classified as a haem-eontaining enzyme (a 
haemoprotein) with iron protoporphyrin IX as the prosthetic group (Gibson and Skett, 
2001).
1.2.2 Evolution and Nomenclature of P450
The first P450 gene arose more than 3.5 billion years ago and P450s have been 
identified in all of the major phyla including the animalia, plantae, fungi, protoctista 
and monera (bacteria) kingdoms (Nelson et ak, 1996). About 57 putative functional 
cytochrome P450 genes and more than 58 pseudogenes have been identified in the 
human genome (Wang et ak, 2011). It is proposed that P450 gene expression was 
initially required for steroid biosynthesis and therefore essential for membrane 
integrity, but, later in evolution, the development of digestive tracts led to the 
extension of P450 function to include detoxification of numerous foreign substances 
(Nebert and Gonzalez, 1987). A standard system of nomenclature was recommended 
and adopted (Nelson et ak, 1996).
Nelson website, (http://dmelson.utmem.edu/CytoehromeP450.html) provide up to 
date information on cytochrome P450 nomenclature. The P450 enzymes are divided
into families and sub-families based on the degree of DNA sequence similarity. 
Within a given cytochrome P450 family all the component genes in that family are 
greater than 40% identical in their sequence to each other. Individual gene families 
are further sub-divided into gene sub-families where two cytochromes P450 belong to 
the same gene sub-family when they are 70% (or greater) similar in their sequence. 
For example, CYP3A4 (CYP for cytochrome P450) describes only one gene encoding 
a specific protein and is the fourth gene to have been sequenced in the 3A sub-family 
(Gibson and Skett, 2001). Table 1.3 provides a general overview of some of P450 
families and subfamilies and their enzyme functions in various species.
Table 1.3 Examples of the function of some P450 families
P450 FAMILY FUNCTION
CYPl Dioxin (TCDD) inducible, metabolism of polycyclic aromatic 
hydrocarbons, halogenated and heterocyclic hydrocarbons and 
aromatic amines
CYP2 Metabolism of drugs and environmental chemicals
CYP3 Metabolism of drugs and environmental chemicals
CYP4 Fatty acid hydroxlases
CYP5 Thromboxane synthase
CYP6 Metabolism of plant products and pesticides
CYP7A Cholesterol 7a-hydroxylase
CYP7B Unknown functions
CYP8 Prostacyclin synthase
CYPll Cholesterol side-ehain cleavage, steriods II(3-hydroxlase, 
aldosterone synthase
CYP17 Steroid 17a-hydoxylase
CYP19 Aromatisation of androgens
CYP21 Steroid 21-hydroxylase
CYP24 Steroid 24-hydroxylase
CYP27 Steroid 27-hydroxylase
CYP51 Steroid biosynthesis
CYP52 Alkane hydroxylases
CYP73 Cinnamic acid hydroxylase
(Adapted from Nelson et al., 1993,1996 and http://drnelson.utmem.edu/CytochromeP450.html)
1.2.3 Funetion of Cytochrome P450
They have an important role in the metabolism (both anabolic and catabolic) of 
endogenous compounds, including fatty acids, steroids and bile acids (Nerbert et al.
1987; Goodwin et al. 2002). They are also involved in the metabolism of xenobiotics, 
such as environmental pollutants, carcinogens, and therapeutic drugs (Nelson et al. 
1996).The P450s enzymes play a major role in phase I drug metabolism, increasing 
the polarity of compounds by producing a chemically reactive functional group on 
which the phase II reactions can occur. The microsomal mixed function oxidase 
system (MFO) dominates the catalysis of many phase I reactions. The complete MFO 
system consists of cytochrome P450, NADPH-cytochrome P450 reductase and lipid. 
The stoichiometry of the monooxygenase reaction is as follows:
NADPH + H + RH + O2 ^  NADP^ + H2O + ROH
Where RH represents the substrate and ROH is the oxidised product. Cytochrome 
P450 is both the substrate and oxygen-binding locus in the MFO reaction. The key 
feature of the catalytic cycle is the oxidation/reduction reaction of the heam iron, as 
outlined in figure 1.2. The catalytic cycle can be divided to six phases and begins with 
the drug binding to the oxidised form of P450. This is followed by haem reduction 
using an electron derived from NADPH H  ^ and transferred by the flavoprotein 
NADPH- cytochrome P450 reductase in the following manner:
NADPH H  ^—> FAD (NADPH-cytochrome P450 reductase) FMN cytochrome P450 
Oxygen binding, electron rearrangement, oxygen insertion and product release follow 
this (Gibson and Skett, 2001).
Figure 1.2 The catalytic cycle of cytochrome P450
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(Adapted from Gibson and Skett, 2001)
1.2.4 Cytochrome P450 Regulation
The field of P450 regulation really developed with the advent of DNA technology and 
molecular biology. Although many details are still unknown, what has emerged today 
is a generalised paradigm of primarily transcriptional regulation, controlled by trans- 
acting factors; although other factors contribute as well (Guengerieh, 2002). The 
expression of P450s can be regulated by both endogenous and exogenous compounds 
(Nebert and Gonzalez, 1987). Such regulation is important for the rapid elimination of 
toxic compounds as well as the homeostasis of endogenous compounds. Figure 1.3 
shows a generalised model for regulation of P450 genes by induction.
Coaetiv
P450 gene
DNA DNA
RNA pol
(movement to nucleus?)
P450 gene
(increased access to promotor, start site)
Increased transcription
Figure 1.3 Generalised model for regulation of P450 genes by induction
Nuclear receptor when activated by a ligand, translocates to the nucleus and form a dimer 
with another nuclear receptor molecule, either a homodimer or heterodimer is formed. The 
complex then binds to response element within target genes and induces transcriptional 
activation and protein synthesis. L=ligand, R=receptor, R '=partner protein for heterodimer o f 
R, Coactiv^coactivator, RNA pol=RNA polymerase II.
(Adapted from Guengerieh, 2002)
P450 can be induced or inhibited by a wide range of different compounds. Induction 
of cytochrome P450 can occur by several mechanisms. These regulation mechanisms 
can take place at
■ The protein level e.g. protein stabilisation.
■ The transcriptional level e.g. gene activation.
■ The post-transcriptional level e.g. mRNA stabilisation.
Table 1.4 shows examples of some CYP450 inducers and their mechanisms of 
induction.
Table 1.4 CYP P450 induction mechanisms
CYP450 INDUCER MECHANISM OF INDUCTION
lA l 3 -methylcholanthrene Transcriptional activation via AhR
1A2 3 -methylcholanthrene mRNA stabilisation
2B1 Phénobarbital Transcriptional activation
2E1 Ethanol Protein stabilisation
3A1 Dexamethasone Transcriptional activation
3A1 Troleandomycin Protein stabilisation
4A1 Clofibrate Transcriptional activation via PPAR
(Adapted from Waxman and Azaroff, 1992)
Inhibition of P450 can also occur by several mechanisms:
■ Inactivation of the enzyme e.g. by parathion (Butler and Murray, 1993).
■ Destruction of pre-existing P450 e.g. by ethylene (Ortiz de Montellano and 
Mico, 1980).
■ Inhibition of enzyme synthesis e.g. by cobalt (Eaton et ak, 1980).
1.3 The Human Cytochrome P450 Superfamily
Metabolism by one or more P450 isozyme is often the first line of defense of an 
organism against the toxic or mutagenic effects of administered drugs or 
environmental pollutants (Smith et ak, 1998). P450 proteins are predominantly 
expressed in the liver, although specific isozymes are also expressed in many 
extrahepatic tissues, including the lung, kidney and gastrointestinal tract (Raunio et 
ak, 1995).
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1.3.1 The Major Drug Metabolising P450s
There are four major families of P450 enzymes, in each mammalian species, with a 
total of approximately 20 members that are able to metabolise a wide array of 
xenobiotics (Lewis et al., 1998). Of the 57 CYP gene present in humans, only 
members of families CYPl, 2, 3 and 4 are involved in xenobiotic metabolism (Plant, 
2007) and they exhibit broad but overlapping substrate and product specificities that 
may vary between corresponding forms from different species (Guengerieh, 1997; 
Nelson et al., 1996). Among them, the CYP3A enzymes are the most abundant P450s 
in human liver and the most significant group which is involved in the metabolism of 
endogenous substrates and xenobiotics (Lewis et al., 1998; Xiao et al., 2011; Plant,
2007).
1.3.2 Cytochrome P450 CYPl
1.3.2.1 CYPlAl
This P450 subfamily consists of two members, CYPlAl and CYP1A2 in human. 
CYPlAl is predominantly expressed in extrahepatic tissues including lung and 
intestine (Antilla et al., 1992), where it metabolises, and is induced by a large group 
of environmental chemicals (Table 1.5), including polycyclic aromatic hydrocarbons 
(PAH) such as benzo(a)pyrene (Shimada et al., 1989).
Table 1.5 Polycyclic aromatic hydrocarbon-like inducers of cytochrome P450
Polycyclic aromatic hydrocarbons 
3-methylcholanthrene 
benzo(a)pyrene 
benzo(a)anthracene 
dibenzo(a,h)anthracene 
Phenothiazines
p-Naphthoflavone and other flavones 
Plant indoles
indole-3 -acetonnitrile 
indole-3-carbinol 
Ellipticine
Charcoal-broiled beef 
Cigarette smoke 
Crude petroleum 
Polychlorinated biphenyls 
Polybrominated biphenyls 
Halogenated dibenzo-p-dioxins 
Halogenated dibenzofiirans________
Derived from Okey, A.B. (1990) Pharmacol. Therapeut. 45,241-298
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1.3.2.2 CYP1A2
CYP1A2 is expressed almost exclusively in the liver, although low levels of 
expression have been detected in brain, duodenum and umbilical vein endothelia. 
CYP1A2 metabolises nitrosamines and arylamines (Wakabayashi et ah, 1992) and is 
one of the isozymes which catalyses the hydroxylation of Aflatoxin B l. CYP1A2 
expression is inducible on exposure to cigarette smoke (Sesardic et ah, 1988) and 
following consumption of charbroiled foods and cruciferous vegetables (Guengerich 
1994). Also CYP1A2 metabolizes several drugs such as phenacetin, acetaminophen 
tacrine and caffeine.
1.3.2.3 CYPIB
Cytochrome P450 CYPIB 1 is the only known member of the CYPIB subfamily. In 
humans, CYPIB 1 was shown to be transcriptionally upregulated by dioxin and it was 
isolated from keratinocyte cell line. Comparison of the CYPIBI gene with the other 
members of the CYPIA subfamily (CYPlAl and CYP1A2) showed 40% homology 
with these genes. Despite the low degree of similarity with the known members of the 
CYPl family, the P450 nomenclature committee assigned this P450 to a new CYPl 
subfamily. Unlike other cytochrome P450 CYPIB 1 is not expressed in human liver, 
although it may be expressed at low levels in normal extrahepatic tissues. CYPIB 1 is 
expressed at much higher levels in tumour cells compared to the surrounding non­
tumour tissues (loannides, 2008).
1.3.3 Cytochrome P450 CYP2
1.3.3.1 CYP2B
The human CYP2B subfamily contains two genes, CYP2B6 and CYP2B7. CYP2B6 
is the only member of the CYP2B family to be expressed in human liver; the 
expression of CYP2B7 is restricted to the lung (Nhamburo et ah, 1989). Although 
historically human CYP2B6 was thought to play only a minor role in drug 
metabolism, more recent studies suggest that CYP2B6 is involved in the metabolism 
of nearly 25% of drugs on the market, such as the anticancer drugs tamoxifen and 
procarcinogens such as the environmental contaminants aflatoxin Bl and 
dibenzanthracene.
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1.3.3.2 CYP2E
The human CYP2E subfamily contains a single gene, CYP2E1. CYP2E1 protein 
expression in man has been detected in a number of tissues, including liver, lung, 
placenta, skin and brain (Farin and Omiecinski 1993; Botto et al., 1994). CY2E1 
accounts for approximately 10% of total P450 in liver (Gibson and Skett, 2001) and is 
involved in the metabolism of 2% of the drug on the market. CYP2E1 plays a major 
role in toxicology as many of its substrates are bioactivated to reactive metabolites, 
such as paracetamol and low molecular weight substrates such as benzene, carbon 
tetrachloride and ethylene glycol, which result in liver and kidney toxicity (Gibson 
and Skett, 2001).
1.3.4 Cytochrome P450 CYP3A Subfamily
Hepatic microsomal cytochrome P450 CYP3A is one of the major microsomal 
enzymes that is responsible for the metabolism of both endogenous substrates and 
xenobiotics (Plant, 2007; Xiao et al., 2011). These CYP3A enzymes are of major 
importance in both human biology and clinical therapeutics (loannides, 2008). The 
CYP3A subfamily of cytochromes P450 in humans is composed of four enzymes; 
CYP3A4, CYP3A5, CYP3A7 and CYP3A43 (Nelson et al. 1996). The genes 
encoding these enzymes are located in a cluster on the long arm of chromosome 7 
(http://dmelson.utmem.edu/human.genecount.htmlk and similarities between amino 
acid sequences are shown in table 1.6. CYP3A proteins are abundant in mammalian 
liver and intestine and are also expressed in a number of other tissues.
Table .6 Amino acid sequence similarities in the human CYP3A snb-fami
CYP 3A5 CYP3A7 CYP3A43
CYP3A4 84% 88% 75%
CYP3A5 81% 75%
CYP3A7 70%
(Adapted from Plant, 2007)
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1.3.4.1 CYP3A4
CYP3A4 is the major human CYP3A enzyme expressed in adult liver and small 
intestine (Schuetz et ah, 1994). It is undetectable in foetal liver but rapidly appears in 
neonatal liver to become the major adult P450 in the liver, with 30-50% of total liver 
P450 being CYP3A4 (Schuetz et al., 1994; Plant, 2007). CYP3A4 is responsible for 
the metabolism of over 60% of clinical pharmaceuticals and is therefore a key enzyme 
with respect to the action and duration of drugs (Cholerton et al., 1992). Because 
CYP3A4 can be induced by many of its substrates, it may also play a role in drug- 
drug interactions (Pichard et al., 1989).
1.3.4.2 CYP3A5
CYP3A5 is a polymorphically expressed enzyme, present in approximately 25% of 
livers in the adult human population (Gervot et al., 1996). CYP3A5 is also present in 
foetal liver with the same individual distribution (Schuetz et al., 1994). It is more 
limited in its metabolic capacity than CYP3A4, being less active and is not induced 
by prototypical CYP3A inducers such as rifampicin (Schuetz et al., 1993).
1.3.4.3 CYP3A7
CYP3A7 is the major CYP3A in human foetal liver. It is thought to protect the foetus 
from the effects of endogenous steroids such as testosterone and progesterone 
(Komori et al., 1988; Schuetz et al., 1993). After birth, CYP3A7 activity is replaced 
by other CYP3As, most notably CYP3A4 (Kitida et al., 1985), but is polymorphically 
expressed in 54% of adult livers, although at very low levels (Schuetz et al., 1994).
1.3.4.4 CYP3A43
CYP3A43 is the most recent discovered member of the human CYP3A subfamily, 
whose amino acid sequence is 70% similar to CYP3A4 and 71% similar to CYP3A7 
and is expressed at comparatively low levels in adult and foetal liver, kidney, 
pancreas, skeletal muscle, testis and prostate (Domanski et al., 2001; Westlind et al., 
2001). In liver, CYP3A43 expression appears to be relatively low, with levels 
approximately 0.1-0.2 % of those seen for CYP3A4 and CYP3A5 respectively 
(Westlind et al., 2001).Very little is known about the metabolic activity and 
importance of this enzyme, although published data suggests that it possesses very 
limited activity towards prototypical CYP3A substrates (Domanski et al. 2001).
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Taken together, the low expression levels in liver, prostrate and testis and low activity 
of CYP3A43, therefore CYP3A43 has been considered not to play a significant role in 
drug metabolism (Westlind et ah, 2001; Gellner et ah, 2001). There is no functional 
significance of CYP3A43 identified to date (loannides, 2008).
1.3.5 Cytochrome P450 CYP4
In human, two CYP A4 have been identified CYP4A11 and CYP4A22 and the 
hepatic expression of CYP4A11 is substantially greater than for CYP4A22 
(loannides, 2008). CYP4A catalyse the co-hydroxylation of medium and long chain 
fatty acids including lauric acid, palmitic acid and asachadonic acid (Smith et ah, 
1998). Both CYP4A1I and CYP4A22 are regulated by PPARa, which is a ligand 
activated transcription factor.
1.3.5.1 CYP4A11
CYP4A11 is expressed in human liver and kidney. Although CYP4A11 was initially 
cloned from human kidney, mRNA analysis shown a 2.5 fold higher expression in 
liver compared to kidney. Other human tissues found to express CYP4A11, but at 
lower levels, include small intestine, brain, lung and reproductive organs (loannides,
2008).
1.4 Regulation of Human Cytochrome P450 3A
1.4.1 Introduction
Members of the cytochrome P4503A (CYP3A) subfamily play a pivotal role in the 
metabolism of clinically used drugs and certain toxic environmental chemicals and 
are highly expressed in human liver and intestine (loannides, 1996). CYP3A4 is 
predominantly expressed in human liver and intestine where it comprises between 30 
and 50% of the total cytochrome P450 population in these tissues (Watkins, 1994). 
This isoform is highly inducible in man by synthetic glucocorticoids, macrolide 
antibiotics and phenobarbitone, amongst others, and, in addition to metabolising a 
number of endogenous compounds such as testosterone and environmental 
xenobiotics such as aflatoxins; it has been estimated to be responsible for 
approximately 60% of the cytochrome P450-mediated metabolism of pharmaceuticals
15
in therapeutic use today. In addition, CYP3A activity is inhibited by several clinically 
used drugs such as erythromycin, gestodene and ketoconazole (Gibson et al., 2002).
1.4.2 Assessment of CYP3A4 induction
Historically much of the assessment of xenobiotic induction of the CYP3 A subfamily 
has been carried out using in vivo and in vitro preclinical studies in animals. In man, 
induction in vivo has been the subject of much of interest and debate. Extrapolation of 
animal in vivo/in vitro data to man can be problematical as marked species differences 
have been demonstrated in response of the CYP3A subfamily to inducers. To 
overcome this problem of species differences, human-derived in vitro systems have 
been used, particularly human hepatocytes (Le Cluyse, 2001), in addition to human 
liver slices or human-derived cell lines. Some human-derived cell lines such as 
HepG2 cells are responsive to CYP3A4 inducers (Fukuda et al., 1992, Schuetz et al., 
1993) as are HuH-7 cells for CYP3A5 and CYP3A7 expression (Pickwell et al., 1996, 
Schuetz et al., 1996). The ability of xenobiotics to regulate gene expression may be 
studied using in vitro reporter gene constructs in human liver cell lines. In this 
approach, the regulatory elements (promoter and/or enhancer regions) of the gene of 
interest are genetically engineered into a plasmid vector containing a readily assayed 
reporter gene enzyme. The expression of the reporter gene is thus directly regulated 
by the target gene regulatory elements, allowing the assessment of the ability of a 
compound to regulate the expression of the gene at the transcriptional level. HepG2 
cells (human liver-derived) are commonly used as they contain constitutive and 
inducible CYP3As and have been successfully used to transactivate the CYP3A4 
promoter (Gibson et al., 2002).
1.4.3 Inducers
The first inducer identified was pregnenolone 16a-carbonitrile, which provided the 
earlier name for this subfamily, P450pcn (Lu et al., 1972). Since its identification as 
an inducer, a wealth of evidence has accrued on the PCN-mediated induction of 
CYP3A. Characteristic CYP3A metabolic activity and CYP3A protein has been 
shown to increase in various strains of mature rats, of both sexes both in vivo and in 
vitro after treatment with PCN (Eberhart et al., 1992; Lu et al., 1972; Shimada and 
Guengerich, 1985; Sonderfan et al., 1987; Williams et al., 1987). Although CYP3As
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were originally described as PCN-inducible P450s, Shimada and Guengerich (1985) 
described dexamethasone as the most effective inducers of CYP3A enzyme activity in 
rat liver microsomes. Dexamethasone induces CYP3A4 protein and mRNA, both in 
vitro and in vivo in human hepatocytes (Fukuda et al., 1992; Schuetz et al., 1993; 
Watkins et al., 1985). Other endogenous glucocorticoids but not sex hormones or 
mineralocorticoids also stimulate the induction of CYP3A (Schuetz and Guzelian,
1984). It should be noted that since then, more efficacious CYP3A inducers have been 
described. Several of these, plus other classical CYP3A inducers are listed in table 
1.7. It can be seen that they belong to a wide range of chemical classes and show little 
similarity in terms of structural groups or molecular size (Swales, 2002), that 
highlights one of the most fascinating facets of the CYP3A sub-family, which is, the 
ability of structurally unrelated chemicals to stimulate transcription of these genes.
1.4.4 Species Differences in CYP3A Induction
There are marked differences in the induction of rat CYP3A23, rabbit CYP3A6 and 
their human orthologue CYP3A4 by xenobiotics (Williams et al., 1994). For example, 
rifampicin has been identified as one of the most potent inducres of CYP3A4 
expression and activity and is also a potent inducer of CYP3A6 in rabbits, but has no 
induction effect on rat CYP3A23 in vivo or in vitro (Kocarek et al., 1995; Lange et al., 
1984; Sonderfan et al., 1987; Williams et al., 1994; Wrighton et al., 1985). PCN 
induces CYP3A23 but fails to induce CYP3A6 in rabbits (Kocarek et al., 1995; 
Wrighton et al., 1985). It has been reported that CYP3A4 is induced by PCN in some, 
but not all human liver hepatocytes (Barwick et al., 1996; Kocarek et al., 1995). This 
may indicate two human CYP3A4 populations, one responsive to PCN, like rats, and 
the other non-responsive, like rabbits. These differences in CYP3A4 inducibility by 
PCN are unlikely to be due to allelic differences and are more likely to be due to 
differences in receptor or liver transcription factor availability. Barwick et al. (1996) 
investigated these differences by transpecies gene transfer of the 5’ flanking 
sequences of CYP3A2, CYP3A4, CYP3A5, CYP3A6, CYP3A7 and CYP3A23 
coupled to a chloramphenicol acetyltransferase (CAT) reporter gene. Rifampicin 
increased the CAT activity of all the CYP3A reporter genes transfected into rabbit 
hepatocytes but not in rat hepayocytes. This indicated that in addition to gene 
structure, host cellular environment dictates the pattern of CYP3A inducibility. CAT 
activity was increased in rat hepatocytes but was not affected by PCN treatment in
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rabbit hepatocytes. Dexamethasone treatment increased CAT activity in both rabbit 
and rat hepatocytes (Barwick et al., 1996). In general, the human CYP3A4 induction 
profiles resemble most closely those of rabbit CYP3A6. However selected inducers, 
including spironolactone, cyproterone acetate and clotrimazole have been reported to 
induce both rat and human CYP3A but not rabbit (Kocarek et al., 1995). Therefore it 
would appear that neither rat nor rabbit could completely duplicate human CYP3A 
induction profiles (Swales, 2002). There are striking interspecies differences in the 
efficacy of inducers. For example, SR12813 is a strong inducer of CYP3A4 and 
CYP3A6 but only weakly induces CYP3A23 (Kocarek et al., 1995; Wrighton et al.,
1985). There appear to be many interspecies differences in induction that may be 
transcriptional, pharmacokinetic or pharmacodynamic, which indicate that there are 
different regulation mechanisms between species. These species-dependent regulatory 
aspects need to be fully dissected to allow proper testing and assessment of new 
compound entities (Swales, 2002) thus extensive analyses of these species-dependent 
regulatory aspects are required to allow effective data extrapolation from animal 
models to humans.
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1.4.5 Human CYP3A Promoter Regions
The proximal promoter regions of CYP3A4, CYP3A5 and CYP3A7 share a high 
degree of identity (Plant, 2007). The 5’ flanking regions of the CYP3A gene contains 
a high number of putative binding sites for various transcription factors (Hashimoto et 
al., 1993; Goodwin et al., 1999a). Hashimoto et al., (1993) compared the 5’ flanking 
region of CYP3A7 with that of CYP3A4. There was a 91% identity between the two 
sequences up to -1 kb so all of the response elements in the CYP3A4 proximal 
promoter are probably present in the CYP3A7 promoter. Both promoters contain an 
ER6 motif that binds PXR/RXRa heterodimers and also an imperfect DR3 motif 
(Barwick et al., 1996; Paseussi et al., 1999). A C/EBPa site have been identified in 
both promoters, that can bind C/EBPa and this activation is potentiated by HNF3 
(Ourlin et al., 1997; Saito et al., 2001). However NFl can also bind to this site in the 
CYP3A4 promoter and interferes with YY1 repressor protein action, thus promoting 
its expression. CYP3A7 contains an NFKB-like element that is able to bind Spl or 3, 
which activate gene expression (Saito et al., 2001). Indeed, both CYP3A4 and 
CYP3A7 also share a region of identity beyond the proximal promoter, a xenobiotic 
responsive enhancer module (XREM), approximately -8  kbp upstream of the 
proximal promoter, which contains three ER6 motifs that enhance CYP3A induction 
by xenobiotics by PXR-mediated gene activation (Goodwin et al., 1999a; Bertilsson 
et al., 2001). CYP3A5 is not as similar as the other human CYP3A forms CYP3A4/7; 
as first 1.5 kb of the CYP3A5 proximal promoter shares only 60% and 59% identity 
with the corresponding CYP3A4 and CYP3A7 regulatory regions (Plant, 2007). A 
second difference between CYP3A5 and CYP3A4/7 is that both CYP3A4 and 
CYP3A7 proximal promoters contain a classical TATAA-box and basic transcription 
element (BTE) (Hashimoto et al., 1993) while the CYP3A5 proximal promoter has a 
modified TATAA-box (CATAA) and BTE (Iwano et al., 2001) which is often 
associated with lower selectivity/multiple positions for the transcription start site 
(Plant, 2007). Only the full-length cDNA for CYP3A43 gene has been published 
(Domanski et al., 2001) and the promoter region has not been sequenced or 
characterized.
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1.4.6 Factors Involved in the Regulation of CYP3A and Other ADME Genes
Cytochrome P450, phase II conjugating enzymes and membrane transporters play 
important roles in the body in order to maintain homeostasis. As the liver is the main 
site of CYPs expression and activity, it is not surprising that liver enriched 
transcription factors (LETFs) are involved in regulating their expression: the effect of 
one of these factors, hepatocyte nuclear factor 4 (HNF4) will be discussed in section 
1.4.6.1. These nuclear receptors are involved in the regulation of genes for different 
metabolic pathways and are collectively known as ligand-activated transcription 
factors (LATFs), and the role of some of these factors in regulating gene expression 
will be discussed in section 1.4.6.2. There are 48 members of the nuclear receptor 
superfamily expressed in humans (Zhang et al., 2004), which have been historically 
divided into two groups depending on their localization in the cell when not bound to 
ligand. Type I nuclear receptors are generally localised in the cytoplasm and 
translocate into the nucleus upon binding their ligand and include the progesterone 
(PR), gluticorticoid (GR), and estrogen (ER) receptors (Welshons et al., 1984; Tyagi,
2003), as well as the aryl hydrocarbon receptor (AhR) (Ramadoss et al., 2005). Type 
II nuclear receptors are not dependent on ligand binding for their subcellular 
localisation; ligand binding causes a conformational change in the receptor allowing 
co-activators to bind and activate target gene expression (Onate et al., 1995; Glass et 
al., 1997). Nuclear receptors in this group include the vitamin D receptor (VDR) and 
the 9-cis retinoic acid receptor (RXR) (Schoonjans et al., 1996). Many members of 
the nuclear receptor superfamily have known endogenous ligands; however there is a 
third sub-group called orphan nuclear receptors for whom endogenous ligands are 
unknown: this group includes transcription factors such as the pregnane-X receptor 
(PXR), the peroxisome proliferator-activated receptor (PPAR), the constitutive 
androsterone receptor (CAR) and the farsenoid-X receptor (FXR) (Schoonjans et al., 
1996). All members of the nuclear receptor family of transcription factors share a 
number of structural features. The general structure of a nuclear receptor is shown in 
figure 1.4 (Bourguet et al. 2000). These features include a less conserved ligand 
binding domain (LBD), which mediates the interactions with the ligand (Toison et al., 
2010) and contains the AF-2 AD region that interacts with coactivator and eorepressor 
proteins to initiate transcription (Bourguet et al. 2000; Glass et al., 1997). The G 
region represents the highly conserved DNA binding domain (DBD), that links the 
receptor to specific sequences of DNA of their target genes promoter regions; called
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response elements (RE), which consist of hexameric repeats of the sequence 
AG(G/T)TCA separated by 1 -  8 nucleotides. Figure 1.5 shows the response element 
of nuclear receptors. The repeat can be arranged as a direct repeat (DR), an everted 
repeat (ER) or an inverted repeat (IR). The LBD and the DBD are linked via the hinge 
region D. The F region function is currently not known.
Figure 1.4 The structure domains of nuclear receptor superfamily
AF-1
A-B
N-
D
L
DNA binding 
domain
AF-2
I
AF-2 AD
Ligand binding 
domain
Nuclear receptors may be divided into six domains (A, B, C, D, E  and F) based on structure 
and function similarities. The N-terminal contains the A-B region that contains a cell- and 
promoter-specific transactivation function termed AF-1. Region C represents the DNA 
binding domain (DBD) which functions to recognise DNA response elements within 
promoter o f  target genes. Region E  represents the ligand binding domain (LBD) which 
funtions to recognise ligands and mediates dimerization and a ligand dependent 
transactivation function (AF-2). AF-2 activation domain (AF-2 AD) has been shown to be 
required for ligand-dependent transactivation, dimerization and binding to co-activator or co­
repressor. Region D is considered as a hinge domain and links the C and E  domains. The F 
region function is poorly understood.
(Figure adapted from Bourguet et al, 2000)
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Figure 1.5 The response element of nuclear receptors
AG(G/'I)TCA 11,, AG(G/T)TCA Direct Repeat (DR)  : ^   1^
ACT(T/G)GA 11, AG(G/T)TCA Everted Repeat (ER) 
<   ^
AG(G/T)TCA n, ACT(T/G)GA Inverted Repeat (IR) 
 ► <--------------
The repeat can be arranged as a direct repeat (DR), an everted repeat (ER) or an inverted 
repeat (IR). The nuclear receptor binding sequence o f  AG(G/T)TCA is spaced by x 
nucleotides (n).
1.4.6.1 Liver Enriched Transcription Factors
The liver enriched transcription factors (LETFs) are highly expressed in the liver, and 
have been reported to play important roles in the regulation of cytochrome P450s 
(Gonzalez and Lee 1996). These include the hepatic nuclear factors HNF-1, HNF-3 
and HNF-4, although the latter factor is sometimes classified as a nuclear receptor, 
and the CCAAT/enhancer-binding protein (C/EBP). These LETFs play important 
roles in the constitutive and tissue-specific expression of many hepatic genes 
(Akiyama and Gonzalez 2003). Only HNF4a will be discussed below.
1.4.6.x.1 Hepatocyte Nuclear Factor 4
The hepatocyte nuclear factor (HNF4a, NR2A1) is often classified as an ‘orphan’ 
receptor since an endogenous or exogenous ligand for this receptor has yet to be 
identified, though it has been reported that long-chain fatty acids directly modulate its 
transcriptional by way of their acyl-coA thioesters binding to the ligand binding 
domain (Hertz et al., 1998). HNF4a is a highly conserved member of the nuclear 
receptor superfamily that is expressed in liver, kidney, stomach, intestine, and 
pancreas (Cereghini 1996). HNF4a is indispensable for the constitutive expression of 
many key hepatic genes encoding enzymes involved in fatty acid and cholesterol 
metabolism and lipid transport (Hayhurst et al., 2001); it plays a significant role in the 
constitutive expression of some CYP genes. Moreover, induction of gene transcription 
by PXR or LXR appears to require HNF4a activity (Tirona and Kim, 2005).
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1.4.6.2 Role of Ligand Activated Transcription Factors in Transcriptional 
Regulation
In order to cope with constant risks presented by xenobiotics, an arsenal of gene 
superfamily has been set-up, which consists of two types of gene (Paseussi et ah,
2004). First, those endcoding xenobiotic metabolizing and transport systems (XMTS), 
including the superfamily of cytochrome P450 (CYP1-CYP3), conjugation enzymes 
and transporters. A central feature of these genes whose protein products are involved 
in the XMTS of chemicals is that their expression levels can be altered (Goodwin et 
al., 2002). Such a feature is essential to allow an efficient response to changes in 
chemical levels within the body, increasing production of proteins that help to remove 
increased level of specific chemicals/xenobiotics, and then returning to normal after 
the chemical stimulus has been removed. Second genes, those encoding specific 
receptors capable of controlling the coordinated expression of XMTS in response to 
xenobiotics (Paseussi et al., 2004). This activation is controlled to a large extent by a 
family of ligand-activated transcription factors (LATFs), which can be ‘switched-on’ 
by chemicals, and bind to response elements within the regulatory regions of genes 
involved in XMTS and activate transcription. Some of these receptors will be 
discussed in more detailed below.
1.4.6.2.1 Aryl Hydrocarbon Receptor (AhR)
AhR is expressed in every tissue as well as in most cell lines whatever their origin 
(Paseussi et al., 2004). Unlike the other LATFs (1.4.6.2.2 -1.4.6.2.5), the aryl 
hydrocarbon receptor (AhR) is not by definition, a nuclear receptor, which utilises a 
basic helix-loop-helix structure rather than a zinc-finger to bind to DNA. The inactive 
AhR (e.g. with no ligand/agonist present) is associated with heat shock protein 90 
(HSP90) in the cytoplasm. A conformational change occurs upon ligand binding and 
HSP90 is released and the nuclear localization signal (NLS) revealed. When AhR 
translocate to the nucleus, it forms a heterodimer with the aryl hydrocarbon receptor 
nuclear translocator (ARNT) and binds to its response element (AhREs) in the 
regulatory regions of target genes and activates transcription (Gonzalez and 
Fernandez-Salguero 1998). Ligands for the AhR include a broad spectrum of 
xenobiotics such as environmental compounds such as polychlorinated biphenyls 
(PCB) and polycyclic aromatic hydrocarbons (PAH) e.g. 2,3,7,8-tetrachlorodibenzo- 
p-dioxin (TCDD) (Gonzalez and Fernandez-Salguero 1998; Toison et al., 2010). As
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many of these chemicals are bioactivated by the AhR target genes CYPlAl and 
CYP1A2 to form highly reactive intermediates, exposure to PAHs and PCBs is often 
associated with increased rates of carcinogenesis (Fernandez-Salguero et al. 1995). 
AhR is also activated by clinical drugs such as omeprazole and endogenous 
breakdown by products like bilirubin (Toison et al., 2010). In addition to regulating 
expression of CYP genes, AhR is also involved in the transcriptional activation of 
several phase II enzymes, including UDP-glucuronosyltransferase and glutathione S- 
transferase family members, which also play a role in the AhR-mediated handling of 
pro-carcinogenic chemicals within the body (Hankinson 1995). Such data implicates 
AhR in both endobiotic and xenobiotic metabolism, suggesting this receptor possess 
roles in both toxicity and maintaining the cell homeostasis (Gonzalez and Fernandez- 
Salguero 1998).
1.4.6.2.2 Pregnane X receptor PXR
The Pregnane X receptor (PXR, NRII2), an orphan nuclear receptor, plays an 
important role in CYP3A4 gene regulation for several xenobiotic and endobiotic 
inducers in several species. It was first identified in mouse (Kliewer et al., 1998) and 
subsequently in man (Bertilsson et al., 1998; Lehmann et al., 1988), rat, rabbit and 
chicken. The PXR is a member of the nuclear receptor family, the important structural 
features being a C-terminal, ligand (inducer)-binding domain and a DNA-binding 
domain (Gibson et al., 2002). Human PXR (hPXR) binds, as a heterodimer with 
RXRa, to an ER6 binding motif found in the CYP3A4 proximal promoter, is 
differentially expressed in the same tissue as CYP3A4 and is activated by a wide 
range of chemicals known to induce CYP3A4 expression (Bertilsson et al., 1998; 
Blumberg et al., 1998; Lehmann et al., 1998). The binding of hPXR to the ER6 
response element, located approximately 150 bp upstream from the transcription start 
site in the CYP3A4 proximal promoter, causes gene transactivation. Goodwin et al., 
1999a also demonstrated that hPXR/RXR heterodimers bound to an imperfect DR3 
and an ER6 motif within the distal xenobiotic enhancer module (XREM) of the 
CYP3A4 5’ flanking region, approximately 7 to 8kb upstream from the transcriptional 
start site. This binding cooperates with proximal promoter activation to enhance the 
induction response, although the precise mechanism of this cooperatively is unclear.
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1.4.6.2.3 The Constitutive Active Receptor
The constitutive active receptor (CAR, NR1I3) is the constitutive activated/androstane 
receptor, abundantly expressed in the liver that mediates the induction of CYP2B by 
xenobiotics (Waxman, 1999). It is also expressed in the small intestine, heart, lung 
and muscle (Baes et al., 1994). CAR-RXR heterodimers have been reported to bind to 
ER6 elements in the CYP3A4 promoter and when transfected into HepG2 cells, 
human CAR produces a 13-fold enhancement of constitutive CYP3A4 gene 
expression. This latter CAR-dependent enhancement appears to reside in both the 
distal enhancer and the proximal promoter of CYP3A4 and there appear to be a 
fimctional synergism between the distal and proximal promoters, the precise 
molecular details of which remain to be clarified. CAR interacts stereospecifically 
with two steroids, androstanol and androstenol that inhibits its transcriptional activity 
by causing the dissociation of the nuclear receptor coactivator SRC-1 (Forman et al., 
1998; Moore et al., 2000). It is believed that PB-like inducers abolish androstane 
binding, de-repressing CAR transcriptional activity. PB can promote translocation of 
CAR to the nucleus without direct binding, so PB may activate CAR through an 
indirect mechanism (Moore et al., 2000). CAR is promiscuous with respect to DNA 
binding since it is able to bind to an imperfect DR4 element overlapping the ER6 
motif (PXR response element), and is able to activate CYP3A4 upon binding to this 
motif (Goodwin et al., 1999b). Phénobarbital is also able to induce CYP3AI1 in the 
PXR null mice, but not CAR null mice (Wei et al., 2000; Xie et al., 2000). Several 
studies have demonstrated that PXR and CAR have the potential to cross-regulate 
CYP3A gene expression by two independent mechanisms: 1) sharing of some ligands 
and 2) binding of PXR and CAR to each other’s DNA response elements (Quattrochi 
et al., 2001).
1.4.6.2.4 The Glucocorticoid Receptor
The glucocorticoid receptor (GR, NR3C1) is a member of the steroid hormone 
receptor superfamily, which includes steroid hormone receptor as well as vitamin D, 
thyroid and retinoid receptors (Evans, 1988). An important unanswered question is 
whether the GR plays a role in the regulated expression of CYP3A. Some lines of 
evidence suggest that induction of CYP3A by GCs can also occur through a pathway 
distinct from the PXR. For example, there is a functional glucocorticoid response 
element (GRE) in a region of the rat CYF3A23 gene ~2kb upstream of the PXR/RXR
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binding site. In addition, the human CYP3A5 gene promoter contains two GRE half­
sites, separated by 160 bp, that confer GC responsiveness to reporter genes (Schutez 
et al., 1996). Conversely, studies in a GR-null mouse model suggest the opposite. 
Schuetz et al. (2000), used mice containing a targeted disruption of the GR to test its 
role on induction of CYP3A. They found that CYP3A induction by GC, RU486, or 
RIF can occur in the absence of the GR. However, since the concentrations of Dex 
used in these studies, 50 mg/kg, may have activated the PXR, it is not possible to 
discern whether the induction of CYP3A in the wild type or null mice is mediated 
through the PXR. Moreover, in as much as dose response data were apparently not 
obtained, this study does not exclude the possibility of involvement of the GR to 
augment the induction process. In fact, several studies demonstrating the ability of 
Dex to increase PXR levels in hepatoma cell lines and primary hepatocytes (Huss and 
Kasper, 2000; Paseussi et al., 2000) lend support to the concept that the GR plays a 
role in the induction process. Finally, it should be noted that the mouse CYP3A 
promoters have not been characterised as extensively as the rat or human promoters. 
Thus, the possibility that the GR plays a role in the induction of rat CYP3A23 and/or 
human CYP3A4 cannot be excluded. Indeed, cotransfected GR was shown to enhance 
the GC induction of a CYP3A4 reporter gene construct in transfected HepG2 cells 
(El-Sankary et al., 2000).
1.4.6.2.5 Peroxisome Proliferator Activated Receptor a (NRICI)
The peroxisome proliferator-activated receptors (PPARs) are very important orphan 
receptors which are involved in the expression of genes involved in lipid metabolism 
(Francis et al. 2003). Peroxisomes are small cytoplasmic organelles that perform both 
p-oxidation of fatty acids and cholesterol metabolism (Gorton et al. 2000). There are 
three isoforms of PPAR that have been identified: PPAR a, PPARp or 5 and PPARy. 
PPARa is the major family member, and plays a role in fatty acid metabolism in 
several organs, particularly in the liver, kidney and intestine, where it is highly 
expressed (Gorton et al. 2000). Like other orphan receptors PPARs forms a 
heterodimer with RXRa when activated, with the resultant complex binding to an 
imperfect direct repeat of AGGTGA separated by one nucleotide (DRl) (Johnson et 
al. 2002). PPARa is activated by both endogenous ligands such as fatty acids, both 
saturated and unsaturated fatty acids, with a preference for higher acyl chain length 
species and by xenobiotic ligands such as hypolipidemic drugs like the fibrates, as
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well as some herbicides, plasticizers and food flavourings (Francis et al. 2003). 
Previous work in our lab revealed that transcriptional activation of human PXR was 
mediated by PPARa via a binding site located approximately 1.3 kb upstream of the 
putative transcription start site (Aouabdi et al. 2006). Taken together, it is clear that 
PPARa regulates several endogenous processes, including bile and cholesterol 
metabolism, and in doing so its functions overlap with those of the pregnane X 
receptor.
1.4.6.3 Summary of CYP3A Mechanisms of Induction
Regulation of CYP3A genes is complex, mainly due to the regulatory elements found 
in both the distal enhancer and proximal promoter (figure 1.8). Cellular receptors play 
an important role in regulation of CYP3A gene expression, the most important of 
which is the pregnane X receptor (PXR). The PXR plays an important role in 
CYP3A4 gene regulation for several xenobiotic and endogenous steroids inducers in 
several species first identified in mouse and subsequently in rat, rabbit and man. The 
PXR is a member of the nuclear receptor family, the important structural features 
being a ligand (inducer)-binding domain and a DNA-binding domain. In man and 
other species, a PXR/ retinoid X receptor (RXR) heterodimer is essential for the 
activation of CYP3A4 reporter gene constructs by xenobiotics and naturally occurring 
pregnane steroids. In addition, two further receptors mediate induction of the 
CYP3As, namely the glucocorticiod receptor and the constitutive androstane receptor 
(CAR), the latter also forming a heterodimer complex with the RXR. Although the 
CAR has been clearly shown to bind inducers, followed by binding of the inducer- 
receptor complex to the corresponding response element in CYP3A promoters, the 
precise role of the glucocorticoid receptor still remains a matter of speculation. Thus, 
the regulation of CYP3A genes is complex process, involving several cellular 
receptors, wherein inducers may show preferential specificity for one receptor or 
promiscuously interact with more than one receptor, as summarised in figure 1.6 
(Gibson and Skett, 2001).
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Figure 1.6 Receptor-dependent regulation of the CYP3A4 gene
Xenobiotic or 
Steroid inducer
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Abbreviations used: PXR, pregnane X receptor; RXR, retinoid X receptor; GR, 
glucocorticoid receptor; CAR, constitutive androstane receptor; A, constitutive CAR steroid 
ligands (androstanol and androstenol). Xenobiotic or steroid inducers can bind either 
comparatively selectively to one o f the receptor systems or promiscuously to more than one 
receptor with differing affinities. The receptor-inducer complex binds to specific regions in 
either the distal enhancer or proximal promoter modules, as dictated by the DNA-binding 
domain o f the receptors.
(Adapted from Gibson and Skett, 2001)
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1.5 Drug Transport Proteins
1.5.1 General Introduction
There has been a signifieant inerease in the molecular characterization of transport 
proteins in animals and man over the last years. This has led to a better understanding 
of the importance of transport proteins in the disposition of endogenous compounds, 
drugs and other xenobiotics in many organs such as the intestine, liver, kidney and 
brain. The distribution of drugs in the body is controlled by permeability across tissue 
membranes. For example, the gastrointestinal tract and blood-brain barrier (BBB) 
provide efficient barriers to the permeability of drugs (Goldstein and Betz 1989, 
Smith et ah, 1996). The extent of membrane permeability is largely governed by the 
physiochemical properties of drugs, and lipophilicity is generally considered as a key 
determinant in extent of drug absorption, hepatic transport and brain penetration. 
However, increased lipophilicity is not always predictive of increased permeability 
due to the contribution of transport proteins (Ayrton et al., 2001). In the liver, the role 
of carrier proteins on the canalicular membrane in the biliary excretion of drugs and 
metabolites has long been recognised (Petzinger 1994; Müller and Jansen 1997). 
However, it is now clear that there are many transport proteins involved in the uptake 
of drugs from blood to liver, across the sinusoidal membrane, that need to be 
considered in the context of hepatobiliary distribution and excretion (Yamazaki et al., 
1996, Kullak-Ublick 1999, Kim 2002). In the intestine and brain it is now appreciated 
that transport proteins such as P-glycoprotein, play a significant role in the extrusion 
of drugs from these organs thereby attenuating drug absorption and brain penetration 
(Schinkel 1999, Suzuki and Sugiyama 2000).
1.5.2 Major Types of Membrane Transport Proteins
There are three major types of membrane transport proteins:
1) ATP-powered pumps are ATPases that use the energy of ATP hydrolysis to move 
ions across a membrane against a chemical concentration gradient or electric 
potential. This type of ion movement is referred to as active transport. 2) Channel 
proteins transport water or specific types of ions down their concentration (or electric 
potential) gradients, energetically favourable reactions. 3) Transporters move a wide 
variety of ions and molecules across membranes. Transporters, in contrast to channel 
proteins, bind only one or a few substrate molecules at a time; after binding substrate
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molecules, the transporters undergoes a conformational change such that the bound 
substrate molecules, and only these molecules, are transported across the membrane. 
Three types of transporters have been identified. Uniporters, transport one molecule at 
a time down a concentration gradient. In contrast, antiporters and symporters catalyse 
movement of one type of ion or molecule against its concentration gradients coupled 
to movement of a different ion or molecule down its concentration gradient (Lodish et 
al., 1995).
1.5.3 Human ABC Transporter Proteins Superfamily
ABC (ATP binding cassette) proteins form one of the largest transporter families and 
its members has been found in every organism examined so far. ABC proteins are 
defined by the ABC unit, a 200-250 amino acid ‘mini’ protein, which harbors two 
short, conserved peptide motifs (Walker A and Walker B), both involved in ATP 
binding, and present in many other ATP utilising proteins as well. A third conserved 
sequence, diagnostic to the ABC unit, is located between the Walker A and B 
sequences, and called ‘ABC signature’ (Klein et al., 1999).
Most ABC proteins are membrane transporters translocating various substrates to 
various compartments; they are responsible for the transport of a wide variety of 
substrates, including ions, phospholipids, steroids, polysaccharides, amino acids and 
peptides across biological membranes. As membrane transporters, this class of 
molecules contains membrane-embedded, transmembrane domains (TMDs). These 
transmembrane domains are usually composed of six transmembrane (TM) helices. 
The minimal structural requirement for an active ABC transporter seems to be two 
TMD and two ABC units. These may be present within one polypeptide chain (‘full 
transporter’), or within a membrane-bound multiprotein complex. In the group of 
active transporters, like the multidrug resistance proteins, the energy of ATP 
hydrolysis is utilised for transport by a mechanism, which involves positive 
cooperativity between the two ABCs, and a tight molecular ‘coupling’ of the TMDs to 
the ABCs. These couplings ensure the transmission of the conformational changes 
caused by substrate binding and by the hydrolysis of ATP to active transport. The 
ABC family is of considerable clinical importance. A highly informative website for 
human ABC proteins has been established at the University of Groningen by Micheal 
Muller’s group thttp://www.med.rug.nl/mdl/humanabc.htm). Table 1.8 lists the most 
important data and family relationships of the human ABC transporters.
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Table 1.8 An inventory of human ABC proteins, May 1999
N am e N om enclature C hrom osom e Protein
(aa)
D om ain
Arrangement
D isease
Phenotype
O M IM  number®
M D R /TA P
subfam ily
P g p l, M D R l A B C B l 7q21 1280 (T M D -A B C )2 171050
TA PI A B C B 2 6p21.3 686 T M D -A B C 170260
TAP2 A B C B 3 6p21.3 748 TM D -A BC 170261
Pgp3, M DR3 A B C B 4 7q21 1279 (T M D -A B C )2 PFIC3 1 7 1 0 6 0 ,6 0 2 3 4 7
A B C 7 A B C B 7 X q l3 .1 -1 3 .3 752 TM D -A BC X L SA /A 3 0 0 1 3 5 ,3 0 1 3 1 0
M -A B C l A B C B 8 7q35-36 718 TM D -A BC
BSEP, SPGP A B C B l 1 2q24 1321 (T M D -A B C )2 PF1C2 6 0 3 2 0 1 ,6 0 1 8 4 7
A LD
Subfam ily
A L D , A LD P A B C D l Xq28 745 T M D -A B C A L D 300100
A L D L 1,A L D R A B C D 2 1 2 q ll 740 T M D -A B C 601081
P X M P l, A B C D 3 lp 2 1 -2 2 659 T M D -A B C ZW S2 170995
PX M P70
PX M P IL , P70R A B C D 4 14q24.3 606 T M D -A B C 603214
M RP/CFTR
Subfam ily
M R Pl A B C C l 16P13.12-13 1531 T M D 0(T M D -A B C )2 158343
M RP2, CM OAT A B C C 2 10q23-24 1545 T M D 0(T M D -A B C )2 DJS 6 0 1 1 0 7 ,2 3 7 5 0 0
M RP3,
M O A T-D A BC C 3 17q21.3 1527 T M D 0(T M D -A B C )2
M RP4,
M O AT-B A B C C 4 13q31-32 1325 (T M D -A B C )2
M RP5,
M O AT-C A BC C 5 3q27 1437 (T M D -A B C )2
M RP6
CFTR A B C C 6 16p l3 .1 1503 T M D 0(T M D -A B C )2 CF
S U R l A BC C 7 7q31 1480 (T M D -A B C )2
SUR 2 A BC C 8 l l p l S . l 1581 T M D 0(T M D -A B C )2 PHHI 6 0 0 5 0 9 ,601820
A B C C 9 12p l2 .1 1549 T M D 0(T M D -A B C )2 601 4 3 9
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Table 1.8 (contd.)
A B C l
Subfam ily
A B C l
A B C 3, A B C -C  
A B C R
K IA A 0822
A B C A l
A B C A 3
A B C A 4
A B C A 7
9q22-q31
16p l3 .3
lp 2 2
17
2201
1704
2273
1581
(T M D -A B C )2
(T M D -A B C )2
(T M D -A B C )2
(T M D -A B C )2
S T G D l/F F M  
A R M D 2, R P19, 
COD, CRD
600046
601615
6 0 1 6 9 1 ,2 4 8 2 0 0  
153800, 601718
W hite subfam ily
A B C 8 W hite 
M X R l, BRCP, 
A BC P
A B C G l
A B C G 2
21q 22.3
4q22
638
655
A B C -T M D
A B C -T M D
603076
603756
O A BP subfam ily
R N A seLI, O A BP A B C E l 4q31 599 (A B C )2 601213
A N S A  subfam ily
A N S A l
A N S A 2
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348
A B C
A B C
GC N 20
subfam ily
A B C 50 A B C F l 6p21.33 807 (A B C )2 603429
The proteins are grouped by subfam ilies. A ll com m on nam es o f  the A B C  proteins are included. Phenotype refers to the  
abbreviation o f  the genetic d isease in w hich mutations o f  the g iven  A B C  protein’s gene is involved: Stargard macular dystrophy  
(S T G D l); fundus flavim aculatus (FFM ); age-related m acular degeneration (A R M D 2); retinitis p igm entosa 19 (R P19); con e  
dystrophy (COD); conerod-retinal dystrophy (CRD); progressive fam iliar intrahepatic cholestasis type 2 and type 3 (PF1C2 and  
PFIC3); X -linked sideroblastic anem ia and ataxia (X L SA /A ); D ubin-Johnson syndrom e (DJS); cystic  fibrosis (CF); persistent 
hyperinsuliném ie hypoglycem ia o f  infancy (PHHI); adrenoleukodystrophy (A LD); cerebro-hepato-renal syndrom e o f  Z ellw eger  
(ZW S2).
® O M IM  num ber is the reference to the OM IM  (O nline M endelien  Inheritance in M an, http://w ww .ncbi.nlm .nih.gO v/O m im /l 
entry to the gene (bold) or to the protein (plain).
(Adapted from Klein et al., 1999)
1.5.3.1 The MDR/TAP Subfamily
Members of this subfamily are full transporters, like MDRl, MDR3 and SisterPgp, or 
half transporters, like TAP and TAP2, or the two-mitochondrial transporters, M- 
ABCl and ABC7 (Klein et ah, 1999). MDR is a term used to describe the 
phenomenon characterised by the ability of drug resistant tumours to exhibit 
simultaneous resistance to a number of structurally and functionally unrelated 
chemotherapeutic agents (Krishna et al., 2000).
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1.5.3.1.1 MDR/Pgpl
The multidrug transporter/P-glycoprotein (MDRl or Pgpl) was the first human ABC 
protein cloned (Chen et al., 1986), and it is still one of the most intensively studied 
proteins of the family. This special attention was attracted by the fact that multidrug 
resistance of eancer cells was found to be caused by this protein. MDRl is localized 
in the plasma membrane, on the apical (or luminal) surface of polarized epithelial 
cells. These include the brush border membrane of intestinal cells, the biliary 
canalicular membrane of hepatocytes, and the luminal membrane in proximal tubules 
of the kidney. MDRl is also present at the pharmacological barrier of the body, e.g. at 
the blood-brain barrier and at the choroid plexus. The MDRl transporter can extrude a 
wide range of structurally unrelated hydrophobic toxic compounds from the cell. On 
the basis of its localisation and its ability of vectorial transport of a range of toxic 
molecules, it is suggestive that the physiological function of MDRl is the protection 
of the cells and organism against toxie compounds (Klein et al., 1999).
1.5.3.1.2 sPgp/ BSEP and MDR3
Two members of this family, ‘the sister of P-glycoprotein’, sPgp or ‘bile salt export 
pump’ (BSEP) and MDR3 are both involved in different types of progressive familiar 
intrahepatic cholestasis, PFIC2 and PFIC3, respectively. Both MRD3 and sPgp are 
full transporters with close sequence relationship to MRDl, with 75% and 50% 
identical amino acids, respectively. sPgp functions as an ATP-dependent bile salt 
transporter. This protein is expressed exclusively in the canalicular microvilli of the 
liver. These data strongly support that sPgp is the eanalicular bile salt export pump of 
the liver. MDR3 is a phospholipid (phosphatidyl choline) translocator, with a highly 
specific expression pattern in the canalicular membrane of the liver. It is interesting to 
note that in spite of the high level of sequence identity between MDRl and MDR3, 
the latter one is not implied in multidrug resistance (Klein et al., 1999).
1.5.3.2 The MRP/CFTR Subfamily
The MRP-CFTR subfamily is currently the largest in the human ABC family, 
consisting of nine members (Klein et al., 1999). Some of these MRPs are also known 
by other names, as summarized in figure 1.7 (Borst et al., 1999).
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Figure 1.7 Overview of the MRP family and alternative names used in the 
literature for the individual members
The mammalian MRP family
MRPl = ABCCl = MRP
MRP2 -  ABCC2 = cMOAT = cMRP = EBCR (rabbit)
MRP3 = ABCC3 = MOAT-D = cMOAT-D = MLP-P
MRP4 = ABCC4 = MOAT-B
MRP5 = ABCC5 = MOAT-C = p ABC 11 = (sMRP*)?
MRP6 = ABCC6 = MLP-1 = (ARA*)?
MRP7 = ABCC10 
*Only 3’ end
(Adapted from Borst et al., 1999)
It has become apparent that anionic conjugates of endogenous and exogenous 
substances cannot exit from cells into the extracellular space at a sufficient rate unless
a MRP-type transporter is present in the plasma membrane. Figure 1.8 below
illustrates the uptake; biotransformation and MRP mediated export of both 
endogenous and exogenous compounds.
Figure 1.8 Uptake, biotransformation, and MRP-mediated export of endogenous 
substances, drugs, and carcinogens 
(Adapted from Konig, et al., 1999)
UPTAKE
OXIDATION
CONJUGATION
EXPORT
Substance
CYPs ro.
Oxidised substance
.G SH
Transferases u d p g i c U A
PAPS
M R P s
1.5.3.2.1 MRPl
Conjugate
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The discovery of the human multidrug resistance associated protein (hMRPl), 
conferring a multidrug resistant phenotype to tumour cells, was a landmark in the 
understanding of the molecular basis of multidrug resistance (Cole et ak, 1992). It 
subsequently became clear that the majority of non-P-glycoprotein mediated 
multidrug resistance is due to the overexpression of hMRPl. hMRPl probably 
transports both hydrophobic antieancer agents and anionic (e.g. glutathione) drug 
conjugates. Its physiological functioning may provide a wide range of cellular 
xenobiotic resistance and MRPl plays a key function in mediating the LTC- 
dependent inflammatory response (Klein et al., 1999). MRPl also plays a role in 
detoxification in tissues including the liver, lung and kidney. This protein is mainly 
localized to the canalicular membrane of hepatocytes and in addition, in several other 
apical membranes of kidney proximal tubule epithelia (Konig, et al., 1999).
1.5.3.2.2 MRP2 (cMOAT)
MRP2 is involved in biliary, renal, and intestinal secretion of numerous organic 
anions, including endogenous compounds such as bilirubin and exogenous 
compounds such as drugs and toxic chemicals (Payen et al., 2002). Detoxification of 
many endogenous and xenobiotic lipophilic compounds in the liver is accomplished 
by conjugation with glutathione, glucuronide, or sulfate moieties, resulting in 
negatively charged, amphiphilic compounds that are secreted into bile or urine. 
Hepatobiliary excretion of these conjugates is mediated by cMOAT, located 
exclusively in the canalicular membrane of the hepatocyte (Klein et al., 1999).
1.5.3.2.3 MRP3, MRP4, MRP5 and MRP6
The physiological function of MRP3, MRP4, MRP5 and MRP6 is currently not 
known. MRP3 (MOAT-D) is expressed in the liver, in the colon and in the kidney, 
and it is inducible by phénobarbital in HepG2 cells (Kiuehi et al., 1998). MRP4 
(MOAT-B) is expressed in the prostate, but it is not found in the liver. MRP5 
(MOAT-C) is expressed at the highest level in skeletal muscle and at intermediate 
levels in kidney, testis, heart and brain. Only a low abundance of the MRP5 transcript 
was detected in liver. MRP6 is specifically expressed in the liver and kidney, and it 
was suggested that MRP6 is not involved in conferring multidrug resistance to tumour 
cells (Klein et al., 1999).
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1.5.4 Organic Anion Transporting Polypeptides Superfamily
Organic anion transporting polypeptides (rodents: Oatps; human: OATPs) are a group 
of membrane solute carriers with a wide spectrum of amphipathic transport substrates. 
Although some important members of this transporter superfamily are selectively 
expressed in rodent and human livers, where they are involved in the hepatic 
clearance of albumin-bound compounds from portal blood plasma, most 
Oatps/OATPs are expressed in multiple tissues including the blood-brain barrier 
(BBS), choroid plexus, lung, heart, intestine, kidney, placenta and testis. Only a 
portion of the Oatps/OATPs so far identified have been characterized in detail on the 
fimctional, structural and genomic levels. However, initial studies with individual 
Oatps/OATPs indicate that many members of this transporter family represent 
polyspecific organic anion carriers with partially distinct substrate preferences for a 
wide range of amphipathic organic solutes including bile salts, organic dyes, steroid 
conjugates, thyroid hormones, anionic oligopeptides, numerous drugs and other 
xenobiotic compounds (Hagenbuch and Meier, 2003).
1.5.4.1 Classification of Oatp/OATP Genes
Currently, 11 rat, 8 mouse and 9 human Oatps/OATPs have been identified. Their 
genes are currently classified within the solute carrier family 21A (rodents: Slc21a; 
human: SLC21A) of the human (http://www.gene.ucl .ac.uk/) and mouse
(http://www.infbrmatics.iax.org/) genome nomenclature databases. Table 1.9 shows 
the Oatps/OATPs gene classification.
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Table 1.9 Oatp/OATP gene classification as 
mouse gene nomenclature committees
implemented by the human and
Name Alias Human 
gene name
Rat
gene name
M ouse 
gene name
O atpl Oatp
—
Slc21al Slc21al
PGT hPGT (man), 
rPGT (rat), 
mPGT (mouse)
Slc21a2 Slc21a2
OATP-A 0A TP,0A TP1
— —
OAT-Kl
—
Slc21a4
—
Oatp2
—
Slc21a5 Slc21a5
OATP-C LST-1, 0A TP2, 
0A T P6
— —
Oatp3
—
Slc21a7 Slc21a7
OATPS LST-2 SLC 2\A 8
— —
OATP-B 0A TP-R P2 (man). 
M oat 1 (rat), Oatp9
5"ZC2MP 5!Zc27a9 —
Oatp4 rlst-1 (rat), mlst-1 
(mouse)
— Slc21alO
OATP-D 0A TP-RP3 (man), 
Pgt2 (rat), MJAM 
(mouse), O atpl 1
SLC21A11 S lc2 1 a ll S lc 2 1 a ll
OATP-E OATP-RPl (man), 
OatpE (rat), Oatp 12
S lc 2 1 a ll —
OatpS
—
OATP-F 0A TP-RP5 (man), 
B SA Tl (rat), Oatp2 
(mouse), Oatp 14
SLC21A14
OATP-J 0A TP-RP4 SLC21A14
— —
(Adapted from Hagenbuch and Meier, 2003)
Besides the members of the GAT? superfamily, there are additional organic anion 
transporters (OATs) and organic cation transporters (OCTs) that are classified within 
the solute carrier family 22A. These transporters are predominantly expressed in the
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kidney where they are involved in the renal excretion of small hydrophilic organic 
anions (OATs) and organic cations (OCTs), (Hagenbuch and Meier, 2003).
1.5.4.2 Functional Properties of Oatps/OATPs
Oatps/OATPs can mediate transmembrane transport of endogenous and exogenous 
amphipatics compounds; Oatps/OATPs can also mediate transport of numerous drugs 
including the endothelin receptor antagonist BQ-123, the thrombin inhibitor CRC-220 
the HMG-CoA reductase inhibitor pravastatin and the antihistamine fexofenadine. 
Therefore, these multispecific transporters (especially the members of the OATP 1A 
and IB subfamilies) are important drug transporters that, together with the P- 
glycoproteins and the multidrug resistance associated proteins (Mrps), seems to play 
an important role in overall drug absorption and drug disposition (Hagenbuch and 
Meier, 2003). While Oatps/OATPs can account for the hepatic clearance of larger 
amphipathic albumin-bound organic compounds, OATs/OCTs are responsible for 
active renal excretion of small hydrophilic organic substances. Hence, Oatps/OATPs 
and OATs/OCTs represent important drug carriers with complementary transport 
functions that have to be taken into account for rational drug design and targeting 
(Hagenbuch and Meier, 2003).
1.5.5 Regulation of Drug Transporter Gene Expression
As mentioned earlier, cytochromes P450 are involved in the oxidative metabolism of 
steroid hormones, bile acids, and prostaglandins. Additionally, a wide range of 
compounds including carcinogens, environmental pollutants, and drugs are 
metabolised by P450s. The net effect of such metabolism converts parent molecules 
into suitable substrates for drug transporter proteins in liver, kidney, and intestine. 
Thus, drug metabolism and drug transport function coordinately to prevent the 
accumulation of toxic chemical compounds (Staudinger et al., 2003). Biochemical 
studies suggest that PXR and CAR bind the same or overlapping enhancer elements 
within the promoters of CYP3A and CYP2B genes in liver cells in a competitive 
manner. Although much is known about the role these two receptors play in 
coregulating P450 gene expression, comparatively little is known about their role in 
coregulating drug transporter gene expression in vivo. To determine whether drug 
transporter gene expression is coregulated by PXR and CAR activation in vivo 
Staudinger et al., (2003) examined the expression levels of organic anion-transporting
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polypepitde {Oatp2, Slc21a5) and multi-drug resistance associated protein 3 {Mrp3, 
Abcc3) in liver following treatment with selective activators of PXR and CAR in 
wild-type mice and mice lacking PXR (PXR-KO). Selective activation of PXR or 
CAR induced Oatp2 and Mrp3 expression in wild-type mice but not in PXR-KO 
mice. Basal expression levels of Oatp2 and Mrp3 gene were significantly higher in 
PXR-KO mice when compared with wild-type mice. Additionally, phénobarbital 
(PB)-inducible Oatp2 and Mrp3 gene expression was significantly increased in the 
PXR-KO mice when compared with wild-type PB-treated mice. Staudinger et al., 
(2003) also examined the effect of PXR ablation on PB-inducible hepatic CYP3A 
activity in vivo. Microsomes isolated from PB-treated PXR-KO mice exhibited a 
significantly elevated rate of testosterone 6p-hydroxylation when compared with 
microsomes isolated from wild-type PB-treated mice. PB treatment produced 
significantly increased levels of hepatomegaly in PXR-KO mice when compared with 
wild-type PB-treated mice. These results suggest that nonliganded PXR plays a net 
negative role in coregulating shared PXR/CAR-target gene expression in vivo and 
extend the hypothesis that PXR and CAR coregulate not only drug metabolism but 
also drug transport possibly through active repression of or competition for enhancer 
elements within the promoters of shared PXR/CAR-target genes (Staudinger et al., 
2003). Transcriptional regulation has so far been studied for only a few Oatps/OATPs. 
In the rat, Oatp2 gene expression is induced by phénobarbital and pregnenolone-16a- 
carbonitrile (PCN), a well-known inducer of cytochrome P450 enzymes of the 3A 
family. The mechanism of PCN induction has been investigated in detail and several 
pregnane X receptor (PXR) response elements have been identified on the rat Oatp2 
promoter. Since lithocholic acid, a cholestatic secondary bile acid formed in the 
intestine by bacterial 7a-dehydroxylation of chenodeoxycholic acid, is an endogenous 
ligand of PXR, concomitant PXR-dependent up-regulation of Oatp2 (uptake) and 
CYP3A (hydroxylation) represents an important constitutive response in the hepatic 
detoxification of both cholestatic bile salts and xenobiotic chemicals. Hepatic 
expression of the human OATP-C gene has been shown to be dependent on the liver- 
enriched transcription factor HNF-la. Similarly, hepatic OATPS expression is 
dependent on HNF-la but, in addition, can be influenced by the bile acid nuclear 
receptor FXR/BAR. Whether human liver OATPs can also be regulated by the 
xenobiotic receptor PXR remains to be investigated (Hagenbuch and Meier, 2003).
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The observation that several inducers of CYP3A4 are also inducers of P-glycoprotein 
(encoded by the MDRl gene) would infer that both proteins share common elements 
in their regulation. The 5’-upstream regulatory region of the MDRl gene has a 
complex regulatory cluster at approximately -8  kbp, containing a DR4 motif that 
serves as a locus for the binding of PXR, thereby conferring a broader role for PXR in 
drug disposition (Gibson et al., 2002).MRP2 expression can be modulated in various 
physiopathological situations, notably being markedly decreased during liver 
cholestasis and upregulated in some cancerous tissues. In addition, MRP2 levels are 
altered in hepatocytes in response to hormones such as glucocorticoids and to 
structurally unrelated drugs such as rifampicin, phénobarbital, ritonavir, and cisplatin. 
Interestingly, most of the chemicals inducers of MRP2 act on drug-metabolising 
enzymes, indicating a coordinated regulation of these detoxifying proteins; cellular 
mechanisms involved are, at least partly, common and may be related to nuclear 
hormone receptors such as the pregnane X receptor. Owing to the major role played 
by MRP2 in elimination of drugs and endogenous compounds, modulation of its 
expression may lead to adverse effects or to changes in drug pharmacokinetics (Payen 
et al., 2002).
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1.6 Summary
In summary, the passage of a compound through the body requires different stages 
and each stage requires the compound to cross lipid bilayer membranes; therefore 
transport processes and their associated proteins are vital in the absorption of drugs 
and their distribution to the different sites of efficacy in the body. Phase I and II 
DME’s increase the hydrophilicity of compounds so these compounds can be excreted 
from the body in biliary or urinary excretion by efflux transporter proteins. Many of 
the ADME and transporter proteins are co-ordinately regulated at a transcriptional 
level by ligand activated transcription factors to ensure xenobiotics are cleared from 
the cell to reduce the risk of cellular toxicity.
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1.7 Aims and Objectives
To delineate the relationship between P450 inducing compounds and drug transporter 
profiles in intestine, lung and liver. The hypothesis of this work is that body responses 
to chemical exposure are optimized through the co-ordinated regulation of drug 
metabolism/transport proteins. Such regulation occurs in a tissue-dependant manner. 
The aim will be acheieved through a number of objectives:
• Culture appropriate cell lines to represent the three test systems.
• Quantitate the P450 and drug transporter systems in basal conditions and 
compare this to the in vivo tissue.
• Quantitate the P450 and drug transporter systems after exposure to 
prototypical CYP inducers.
• Carry out promoter analysis to provide explanation for the observed 
relationships.
• Generate reporter gene assays for MDRl to complement the existing CYP3A4 
assay
• Validate Taqman and reporter gene assays for measuring chemical-mediated 
alterations in gene expression in these three cell lines
• Select a group of chemicals to study, with particular reference to their 
potential interactions with DMEs/transporters in the three tissue models
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2 Materials and Methods
2.1 Materials
2.1.1 General Material and Plastic Ware
All chemicals and reagents used in this project were of highest purity available and of 
molecular biology or tissue culture grade as appropriate. All plastics used for RNA 
work were RNase free. Table 2.1 shows the list of chemicals, materials and molecular 
biology kits and their suppliers. The suppliers of the different cell lines used in this 
work are given in Table 2.2. Table 2.3 shows the list of human foetal and adult total 
RNA commercial suppliers, plus relevant clinical information for the samples.
All work involving carcinogenic chemicals was carried out under the auspices of the 
guidelines set out by the ‘Hazardous Chemicals Safety Officer’ of University of 
Surrey. All carcinogen chemicals whether in solid form or solutions were stored in 
double containers in the carcinogenic room at room temperature and protected from 
light.
2.1.2 Plasmids
Maps of the plasmids used in this project are shown in appendix 8. pSEAP2-MDRl 
promoters constructs were engineered in this project. The (pSEAP2 basic, pSEAP2- 
promoter and pEGFP-C3 vectors) were purchased from Clontech (Mountain View, 
CA, USA). The human PXR expression plasmid (hPXR-pSG5) was a gift from Dr 
Steven Kliewer (University of Texas Southwestern Medical Center, Texas, USA). 
The pSEAP2-Basic plasmid DNA with a 300 bp insert from the CYP3A4 XREM 
region (-7972/-7673) and the -301/+7 region of CYP3A4 promoter was engineered 
previously in this lab. The 2.2 kb human pSEAP2-PXR was kindly donated by Dr. 
Sihem Aouabdi. The expression plasmids used in this work are explained in the 
following paragraph. The vitamin D receptor (VDR) and HNF4a were a gift from Dr 
Richard B. Kim (Vanderbilt University, Tennessee, USA). Glucocorticoid receptor 
alpha (GRa) and peroxisome proliferator activated receptor alpha (PPARa) were a 
gift from Dr J. Tugwood (Astrazeneca, Macclesfield). The estrogen receptor alpha 
(ERa) was a kind gift from Dr. Pierre Chambon (Institut de Génétique et de Biologie 
Moléculaire et Cellulaire (IGBMC), Cedex, France). The constitutive activated
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receptor (CAR) was a gift from Professor M. Negishi (NIEHS, USA), the retinoid X 
receptor alpha (RXRa) was a gift from Professor P. Chambon (INSERM, Strasbourg, 
France) and the pCMV-cSPAP reporter plasmid fi*om Dr Mike Tarbitt (GSK, Ware).
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Table 2.1 Suppliers of items used in this project
1 Item Supplier
i LE Analytical Grade Agarose 
1 Human genomic DNA, Taq DNA polymerase, 
1 MgCli solution, T4 DNA ligase, T4 DNA ligase 
1 lOX Reaction Buffer, Restriction enzymes and 
1 their respective lOX Reaction Buffer, Oligo 
1 (dT)i5 Primer, RNase-free DNase, lOX DNase 
1 reaction buffer
Promega (Madison, USA)
1 Phosphate buffer saline (PBS) tablets,
1 Bacterial agar. Yeast extract, Tryptone
Oxoid (Basingstoke, UK)
1 DH5a™ E.coU competent bacterial cells 
1 DMEM with L-glutamine, MEM, Trypsin- 
1 EDTA, Foetal bovine serum, L-glutamine, non- 
1 essential amino acids, Pencillin/Streptomycin, 
1 gentamicin
j Ultra PURE™ Distilled Water DNAse, RNAse 
1 Free
I Platinum® Pfic DNA Polymerase, Superscript™ 
1 First-Strand Synthesis System for RT-PCR
Invitrogen (Grand Island , USA) 
............. ...... .........-..........
j  FuGENE 6, Cytotoxicity Detection Kit (LDH) Roche (Indianapolis, USA)
i  96 well optiplates, TopSeal™-A: 96-Well 
1 Microplates
PerkinElmer Life Sciences 
(Boston, USA)
j Aurora Alkaline Phosphatase Chemiluminescent 
{ Reporter Gene Assay Kit 
1 Clofibric acid
ICN Biomedicals Inc. (Costa 
: Mesa, USA)
ICN Biomedicals Inc. (Aurora,
USA) 1
1 QIÀprep® Spin MiniPrep Plasmid Preparation 
j  Kit, Endofree® Plasmid Maxi Kit, RNeasy®
1 Mini Kit
Qiagen (Crawley, UK)
11
1 RiboGreen™ RNA Quantification Assay Kit Invitrogen (Eugene, USA)
i Orange G Boehringer Mannheim (Germany) j
i
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1 Disposable pipette tips 1 Alpha Laboratories (Eastleigh,
1 UK)
' ........ ......
1 PCR primers, TaqMan primers and probes 1 MWG Biotech (Ebersberg, 
1 Germany)
j ABsolute™ QPCR Mix 1 Abgene (Epsom, UK)
1 Dimethylsulfoxide (DMSO), Ethidium bromide, 
1 p-Naphthoflavone, Rifampicin, Phénobarbital, 
i Diethylpyrocarbonate, 2-Mercaptoethanol
1 Sigma-Aldrich (St. Louis, USA)
j  Dextran T7Ô f Pharmacia AB (Uppsala, Sweden)
1 Propan-2-ol, Absolute Ethanol 1 Fisher Scientific (Loughborough, 
UK)
I  3,3',4,4'-Tetrachlorobiphenyl (PCB 77)
1 2,2',4,4',5-Pentachlorobiphenyl (PCB 99)
1 2,2',3,4,4',5'-Hexachlorobiphenyl (PCB 138) 
j  2,2',4,4',5,5'-Hexachlorobiphenyl (PCB 153) 
j 2,2',3,4,4',5,5'-Heptachlorobiphenyl(PCB 180)
1 2,2',3,3',4,4',5,5'-Octachlorobiphenyl (PCB 194)
[ LGC Promochem (Teddington, 
1 UK)
1
Table 2.2 Cell line used in this project
1 Intestinal cell line r Caco-2 r ÊCÀCC No. 86010202
1----------------------------------------------  ---------------
j Lung cell line | 'a M9 fECACC No. 86012804
!
1 Liver cell line j Huh? R in d  gift ofDr Steve Hood (
J...._  ' _____ __...:......:..—j___ __ _______ z—-----:—
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Table 2.3 Commercial suppliers of human foetal and adult total RNA samples
used in this project
I 'N o . ' I Type of total 
j RNA
pCompany
}
1 ^CatTNo." 1 Lot No. " ! Cone. 
1 Fg/Fl
1 !^x 1 Age
i 1 1 Foetal liver i Stratagene 1 738017 1 0110538 Fo.99 1 M i 18 weeks
! 2 1 Foetalliver fstratagene 1738018 1 0200652 r Ô.83 F r 1 20 weeks
! 3 i Foetal liver 1 BioChain 1 R1244149-50 1 A604419  ^ 2.3Ô 1" M 1 38 weeks
1 4 j Adult liver 1 Stratagene 1 735017 11010454 F0.95 Fhï 1 45 years
n rAdult liver 1 Stratagene 1 735018 1 0820606 1 1.10 FË ! 55 years
1 6 1 Adult liver 1 Stratagene 1 735018 1 0830508 1 0.90 FË 1 34 years
1 7 i Foetal lung 1 BioChain r R I2Æ 52-5O 1 A602155 1 1.96 F h T  " i 22 weeks
1 '
1 Foetal lung 1 Stratagene 1 73802Ô 1 Ô90ÔB9 1 Ï.Ô2 1 ^1
1 17,18,22
1 weeks
[ 9
1
1 Foetal lung 1 Stratagene 1738019 1 1200170 R Ô 2 1 M
1
1 18,20
j weeks
[10 1 Adult lung
I
1
r  Stratagene
1
1 735020 1 0320101
1
1 1.07
I
1
[F
1
I 28, 35, 
1 55,66
1 years
r n 1 Adult lung 1 BioChain 1 R1234152-50 r A509252 1 2.55 FM 1 29 years
1 12 j Adult lung 1 Stratagene 1 735019 r 0330369 1 0.90 F Ë T " 1 50 years
F " '
1 Adult colon 1 Stratagene
1
1 73Y009 [0420578 Fb.90
1
R 1 44,49
1 years
1 14 1 F\dult colon [ Stratagene 1 735010 [ 0330151 FTo FË 1 53 years
i n 1 Adult ascending 
i colon
[ Stratagene
1
1 735463 1 1010335 11.02 pp  —
1
1 39 years
1 16 1 Foetal colon 1 Stratagene 1 738009 f 06105h f 1.09 r M 1 22 weeks
r 17 " i Foetal colon 1 Stratagene 1 738010 1 0310485 1 0.83 FË i 20 weeks
F is " j Foetal colon r BioChain 1 R1244090-50 1 A711070 1 2.39 [ F i 20 weeks
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2.2 Methods
2.2.1 General Techniques
2.2.1.1 Sterilization Procedures
All glassware, plastic ware and solutions (where possible) for nueleie acid work, or 
bacterial or mammalian cell culture, were sterilised using a RSI series 32 automatic 
autoclave at 121 °C for 20 minutes at a pressure of 15 Ib/in .^
2.2.1.2 DEPC-Treatment of Solutions for RNA Work
All solutions used for RNA work were treated with diethylpyrocarbonate (DEPC) to 
reduce the risk of RNA being degraded by RNAses. 0.1% DEPC water (nuclease free) 
was prepared by the addition of 1 pi of DEPC per 1.0 ml of MilliQ-water and either 
incubated overnight at room temperature or for two hours at 37°C followed by 
autoclaving. The final solution was stored at -20°C freezer in 20 ml aliquots. DEPC- 
treated MilliQ-water was used to make solutions whenever it was not possible to 
autoclave the final solutions.
2.2.1.3 Agarose Gel Electrophoresis
The 1 % (w/v) general-purpose gels were prepared by dissolving 1.0 g agarose in 100 
ml IX TAE buffer (0.04 M Tris-Acetate, 0.01 M EDTA pH 8.3) by heating. Gels 
were pre-stained with ethidium bromide dye (0.2 pg/ml). Three microliter of samples 
were mixed with 3 pi of loading buffer (50% glycerol and 1% w/v Orange G dye) and 
loaded into the wells and run alongside a Ikb DNA step ladder (Promega) at 4- 
5 V/cm, until the Orange G dye reached 3/4 of the gel. All gels were visualised under 
ultraviolet light and photographed using the GeneGenius Bio Imaging System, 
controlled by GeneSnap version 4.01 software (Syngene).
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2.2.2 Cell Culture
2.2.2.1 Culture Conditions
The human hepatoma cell line Huh7, human colon adenocarcinoma cell line Caco-2 
and human lung adenocarcinoma cell line A549 were routinely cultured in 75 em  ^
flasks with vented lids (Nunclon™, Nune Brand products Nunclon) in 5% CO2 in air 
at 37°C. Huh7 cells were cultured in 15 ml Dulbeeeo’s Modified Eagle Medium 
(DMEM, with phenol red and L-Glutamine) supplemented with 10 % (v/v) FBS , 1% 
(v/v) non-essential amino aeids (NEAA) and penicillin/streptomycin (100 U/ml 
penicillin, 100 pg/ml streptomycin) (Invitrogen). Caco-2 cells were cultured in 
Minimum Essential Medium (MEM, with Earle’s salts, phenol red and without L- 
Glutamine) supplemented with 10 % (v/v) FBS, 2 mM L-glutamine, 1 % (v/v) non- 
essential amino aeids (NEAA) and gentamicin (100 pg/ml) (Gibeo BRL). Finally, 
A549 cells were cultured in Dulbeceo’s modified eagle medium (DMEM, with phenol 
red and L-Glutamine) supplemented with 10 % (v/v) FBS and penicillin/streptomycin 
(100 U/ml penicillin, 100 pg/ml streptomycin) (Invitrogen). The cells were sub­
cultured every 3-4 days (-90% confluence) depending on the growth rate and seeding 
density. The passage number upon receipt was 67, 40 and 91 for Huh7, Caeo-2 and 
A549 cells respectively; cells were subjected to a maximum of 10 further passages in 
order to maintain phenotype.
2.2.2.2 Subculture of Cells
Routine subculture is performed in order to keep the cells healthy and actively 
growing. When the cells reached 80 to 90% confluence, the medium was aspirated 
and the cell monolayer washed with 10 ml phosphate buffered saline (PBS, 1 tablet in 
100 ml milllQ-water). One millilitre of IX trypsin-EDTA was added and the flask 
was slowly rocked back and forth to ensure coverage of the cells by protease and 
incubated for -5  minutes (length of time depend upon cell line) at 37°C until cells 
were detached by gently tapping the sides of the flask and a single cell suspension 
was formed. Then, 4 ml of growth medium was added to the cell suspension to 
neutralise the trypsin-EDTA and the cells were split 1:4 by adding 1 ml of cell 
suspension to 14 ml of appropriate fresh medium in a new T-75 flask. The cells were 
incubated in a 5 % CO2 cell incubator at 37°C.
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2.2.2.3 Storage of Cells in Liquid Nitrogen
The storage of eells at temperatures below -130 °C is essential in order to preserve the 
material unaltered. An approximately 90% confluent flask of actively growing cells 
was washed with PBS, trypsinised and re-suspended in 10 ml of the appropriate 
medium. The cells were pelleted down by eentrifiigation at 1200 rpm for five minutes 
and re-suspended in 91% (v/v) FBS and 9% (v/v) DMSO (eoneentration ~ 4x10^ 
eells/ml). One milliliter aliquot of this suspension was dispensed into pre-labelled 
cryovials and frozen at -80°C overnight in a polystyrene box packed with cotton wool 
for insulation before placing them in liquid nitrogen freezer for long term storage.
2.2.2.4 Recovery of Cells from Liquid Nitrogen
When the eells were required, a eryovial was thawed at 37°C for 2 minutes and added 
to 10 ml of pre-warm medium. Cells were centrifuged for 5 minutes at 1200 rpm and 
resuspended in 7 ml medium and transferred to a 25 em^ vented tissue culture flask to 
allow rapid growing. Once the eells had grown to about 80-90% confluence, they 
were sub-eultured in 75 em  ^vented flasks and incubated in a 5 % CO2 cell incubator 
at 37°C. The medium was replaced after 24 hours to remove any residual DMSO and 
dead cells.
2.2.2.5 Cell Counting
Cell counts are necessary in order to monitor cell growth as well as to set up new 
cultures with known cell number. For routine counting, a flask of confluent cells was 
trypsinised with 1 ml IX trypsin-EDTA and re-suspended in 4 ml of fresh medium. 
The number of cells per ml and the total number of cells in the original culture 
medium was calculated using an improved Neubauer haemocytometer by placing 
drops of trypsinised cells under the edge of a cover slip on the haemocytometer until 
the counting chamber was covered by capillary action. Cells were counted manually 
from four squares and the average number was multiplied by 10"^ . Then, the total 
number of cells was calculated (Total cells= cells per ml * any dilution factor * the 
original volume of fluid from which cell sample was removed). A second count of 
cells from the counting chamber on the other side of the haemocytometer was done to 
improve the accuracy of the count.
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2.2.2.6 Charcoal Treatment of Foetal Calf Serum
Foetal calf serum (FCS) may contain steroid and hormonal contamination that could 
affect the assessment of induction of the CYP3A4 and MDRl genes as these 
chemicals are potential indueers. In order to remove steroid and hormonal 
contaminants, FCS was pre-treated with dextran coated charcoal (Fenske 1991).
50 mg of dextran and 500 mg of activated charcoal were added to 500 ml foetal calf 
serum bottle and the mixture was stirred for 30 minutes followed by centrifugation at 
1500 rpm for 15 minutes. The supernatant was passed through a 0.45 pm filter to 
remove any remaining solids and finally was filter sterilised under vacuum by passed 
through a 0.22 pm filter. The serum treated samples stored at -20°C until needed.
2.2.3 Transient Transfection Protocol for the Reporter Gene Assay 
Huh7, Caco-2 and A549 cells were cultured in 75 em  ^vented culture flasks following 
the method described in section 2.2.2.2. The pSEAP2-basie vector (secretory alkaline 
phosphatase) was used as a negative control in the transfection experiments since 
CYP3A4 and MDRl genes promoters had been cloned into it. Expression plasmids 
for the transcription factor HNF4a and the ligand-activated receptors, CAR, PXR, 
VDR, ERa, GRa, PPARa and RXRa, were used for the eo-transfeetion assays. 
Plasmid maps are shown in appendix 8.
2.2.3.1 Transfection Methodology
DNA can be introduced into culture mammalian eells by a number of different 
methods. One of the most widely used methods is lipofection reagents as high 
transfection efficiency can be achieved, and this approach has been applied to a wide 
variety of different cell lines. FuGENE™ 6 transfection reagent (Roche Diagnostics) 
was used to transfeet DNA into the cells. FuGENE™ 6 transfection reagent has been 
used successfully in a variety of established cell lines due to its high transfection 
efficiency and low toxicity. It is a multi-component lipid based transfection reagent 
that complexes with plasmid DNA and facilitate its transportation into the cells. A net 
positive charge must exist in the lipid-DNA complex in order for the lipid-DNA 
complex to interact and pass through the negatively charged cell membrane. 
Therefore the positive charge contributed by the cationic lipid must exceed the
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negative charge of DNA. The FuGENE 6 and DNA were ineubated in serum free 
medium were FuGENE™ 6 was added first to a sterile tube containing the required 
amount of serum free medium and then DNA was added and left to incubate for 30 to 
45 minutes at room temperature.
2.2.3.2 Optimisation of Transfection
Different cell lines are known to require different transfection conditions, both in 
terms of FuGENE: DNA ratio and total DNA used, in order to achieve the maximum 
level of transfection efficiency. Preliminary experiments are thus carried out to 
establish the optimum conditions for each cell line tested. In order to identify these 
best optimum transfection conditions, several cell concentrations and FuGENE: DNA 
ratios have been tested for the three cell lines. The starting DNA concentration used 
was constant at 0.05 pg/well. Cell concentration tested were 5 x 10\ 1 x 10^  and 2 x 
10^  eells/ml and the FuGENE: DNA ratios tested were 3:1, 3:2, 6:1, 6:2, 6:3, 12:1 and 
12:2. The ratio 3(FuGENE):1 (DNA) represent the following 0.05 pg of DNA and 
3X0.05 which equal 0.15 pi of FuGENE were used per well. The optimum condition 
for transfection Huh7 cells was identified as FuGENE: DNA ratio 6:2 and for Caco-2 
and A549 cells was 6:3 and a cell seeding concentration of 1 x 10^  cells/ml. DNA 
transfections were carried out when the eells were between 50 to 80% confluent 
within the wells for the three cell lines. The transfection mixture was added to the 
seeded cells without removing the existing medium and that is to avoid disrupting the 
cells.
2.2.3.3 Co-transfection with Expression Plasmids
The total DNA amount transfected per well was maintained at a constant for co­
transfections, being 0.1 pg for Huh7 eells and 0.150 pg for Caco-2 and A549 cells. 
For two-plasmid eo-transfeetions experiments the plasmids were added at a 1:1 DNA 
ratio; 0.05 pg of the reporter construct and 0.05 pg of the co-transfeeted plasmid for 
Huh7 and 0.075 pg of each plasmid for Caco-2 and A549. For multiple plasmid co- 
transfeetions (e.g HNF4a and PXR and reporter gene construct) the amount of the 
reporter construct was kept constant (0.05 pg or 0.075 pg), with the expression 
plasmids added at equimolar amounts for the remaining 0.05 pg or 0.075 pg.
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2.2.3.4 Xenobiotic Dosing
A lOOOx stock solution of xenobiotic was prepared for dosing transfected cells. 
Dosing medium was supplemented with DCC-treated FCS as described in section 
22.2.6. All chemical compounds were dissolved in 100 % DMSO.
2.2.3.5 Transient Transfection Protocol
The transfection protocol took place over a five day period. On day 1, eells were 
seeded into clear 96-well plates (Nunclon™, Nune Brand Products) at a density of 1 x 
10^  cells/mL (100 pL per well). The outside wells were not used because of potential 
evaporation of medium fi'om these wells that could cause variation in the results; 
instead these wells were filled with 200 pi water. The plates were then incubated 
overnight at 37°C and 5% CO2 to allow cell attachment. DNA transfections were 
carried out when the cells were between 50 to 80% confluence within the wells. On 
day 2, 100 pi of the transfection mixture was added to each well without removing the 
existing medium to avoid disrupting the eells. For basal expression experiments, cells 
were incubated for 48 hours till SEAP activity was measured and for dosing 
experiment medium was removed from the eells, on day 3, and transferred to a new 
96-well plate for pre-dose SEAP measurement later and replaced with either vehicle 
medium (0.1% DMSO) or dosed medium and incubated for 48 hours. On day 5, 
Luminescence of secreted alkaline phosphatase was measured as described below 
(Section 2.2.3.6).
2.2.3.6 Secretory Alkaline Phosphatase Reporter Assay
Alkaline phosphatase (AP) activity was measured using the AuroraA™ AP 
ehemiluminsecent reporter gene assay kit (ICN Biomedieals Inc., USA). The 
solutions were left to equilibrate at room temperature. Ten microliter of cell culture 
medium was assayed from each well and transferred to a 96-well OptiPlate^"  ^(Packard 
Bioscience). 18 pi of IX dilution buffer was added to each well and the plate sealed 
and centrifuged at 1000 rpm for one minute and then ineubated at 65°C for one hour 
to destroy endogenous AP activity. The Plate was cooled on ice for 2 minutes and left 
to equilibrate at room temperature for 15 minutes. Twenty-four miroliter of assay 
buffer was added and ineubated for 5 minutes at room temperature. Finally, 24 pi of 
the reaction buffer (containing the substrate: StarLight^’^  chemiluminescent) was
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added to each well and the plate was incubated at room temperature for 20 minutes. 
The dephosphorylation of the substrate by SEAP emitted light which can be measured 
at 477 nm. The chemiluminescence was measured using the LumiCount™ 
luminometer and the plate Reader Version 2.10 for windows software (Packard 
Instrument Co. Inc.), with optimal gain and photomultiplier settings automatically 
determined by the machine after screening the plate for the maximum and minimum 
luminescence values. Figure 2.1 highlights the transfections steps and the SEAP 
measurement.
Figure 2.1 Summary of transfection and Aurora assay
M easurement o f 
light emission giving RLU
Substrate Product
Eugene +rpLsm id
f
Micelle
plasmid
RLU: Relative Light Unit
Seap: secretory alkaline phosphatase
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2.2.3.7 Assessment of Compound Toxicity by Lactate Dehydrogenase (LDH) 
Assay
The assessment of eell viability was performed using the LHD cytotoxieity detection 
kit (Roche Diagnostics Ltd) according to the manufaeturer’s instructions. This 
colorimetric assay is widely used for the quantification of cell death and cell lysis 
based on the measurement of LDH activity released from the cytosol of damaged cells 
into the medium. The LDH activity is determined in an enzymatic test: in the first step 
NAD”^ is reduced to NADH/H^ by the LDH-eatalyzed conversion of laetate to 
pyruvate. Then in the seeond step, a catalyst (diaphorase) transfers H/H^ from 
NADH/H^ to the tétrazolium salt INT which is reduced to formazan (red). Therefore, 
amount of colour formed in the assay is proportional to the number of lysed eells.
The LDH assay was performed upon cell cultures treated as for transfeetion assays 
(section 2.2.3) but after 48 hours the dosed plates were centrifuged at 250 g for 10 
minutes to pellet eellular debris and the supernatant transferred to a new 96-well 
plates whieh can be kept at 4°C up to 5 days. The LDH activity was quantified by 
mixing equal amounts of the supernatant and the kit reagents [1:45 bottle 1 (catalyst): 
bottle 2(dye solution)] in a 96-well ELISA plate and ineubated to 30 minutes at room 
temperature (protected from light). The positive control was untreated cells that were 
subjeeted to eomplete lysis as induced by addition of Triton X-100 (2%) for 15 
minutes and the negative eontrol was the tested eell line incubated alone. The 
absorbances of the samples were read in a multi-well ELISA microplate reader (Bio- 
TEK ELx800). Results were adjusted for baekground (medium only) and compared to 
positive control of cells lysed in 2% Triton X-100. Cytotoxicity was calculated as 
follows: cytotoxicity (%) = (test value-negative control value) / (positive control 
value- negative control value) x 100
2.2.4 Cell Characterisation at the mRNA level by Real Time PCR
2.2.4.1 Xenobiotic treatment
The expression of the following genes have been studied in Huh7, Caco-2 and A549 
cells by real time PCR: CYP3A4, CYP3A5, CYP3A7, CYP3A43, CYPlAl, 
CYP4A11, MDRl, OATP-B, MRPl, MRP3, GAPDH and hPXR.
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The cells were cultured in 75 cm^ vented eulture flasks following the method 
deseribed in section 22.22. and seeded into 6 well plates (Nunclon™, Nunc Brand 
products) at a concentration of 1 X 10^  cells/ml. Two and a half milliliter of eell 
suspension was added per well, representing 2.5 X 10^  cells/ml. The plates were then 
incubated in a humidified ehamber (to prevent medium evaporation) in a 5 % CO2 eell 
incubator at 37°C and allowed to attach for 24 hours. Following attachment, and when 
the cells had reached >60% confluence, the medium was aspirated and eells were 
dosed in triplicates with either 10 pM rifampiein, P-naphthoflavone (p-BNF) and 
clofibric acid, vehicle (0.1% DMSO) or medium alone for 24 hours; resulting in a 
total eulture time of 48 hours. For basal mRNA expression levels medium was left 
for 48 hours. Xenobiotics and concentration of the stock solutions are shown in table 
2.4. Stoek solutions were lOOOX the working solution in vehiele (100% DMSO); 
henee, the final eoneentration of DMSO in all experiments was 0.1% (i.e. further 
dilution to 10 pM working concentration was done with the appropriate medium). 
Cells were harvested and RNA was extracted using RNeasy® Mini Kit as deseribed in 
seetion 2.2.4.3 for Q-PCR analysis.
Table 2.4 Xenobiotics used to treat cells
Stock concentration M W  (g/mol) M ass o f D rug Vehicle V olum e o f Solvent
50 mM Rifampicin 823.0 41.15 mg DMSO 1.0 ml
50 mM P-BNF 272.3 13.62 mg DMSO 1.0 ml
50 mM Clofibric acid 214.7 10.73 mg DMSO 1.0 ml
2.2.4.2 Effect of Selected Polychlorinated Biphenyls (PCBs) on the Expression of 
CYPlAl Gene
Polychlorinated biphenyls (PCBs) exhibit many negative biologic effects, they are 
ubiquitously distributed and they persist in the environment (Tabb et al. 2004). Six 
congeners had been selected to test their induction on CYP3A4, MDRl and CYPlAl 
genes. CYPlAl induction had been examined by RT-PCR (TaqMan). The same 
protocol as in section 2.2.4.1 was used. The PCBs were tested at a working 
eoneentration of 10 pM. All PCBs were prepared in DMSO. Table 2.5 shows the 
PCBs used in this work.
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Table 2.5 Preparation of the PCBs Doses
PCB
Stock
concentration
Mass of 
PCB
MW g/mol
Volume of 
DMSO
3,3',4,4'-Tetrachlorobiphenyl (PCB 77) 10 mM 3.2 mg 291.99 1096 pi
2,2',4,4',5-Pentachlorobiphenyl (PCB 99) 50 mM 5.0 mg 326.432 306 pi
2,2',3,4,4',5'-HexachIorobiphenyl (PCB 138) 10 mM 7.0 mg 360.88 1940 pi
2,2',4,4',5,5'-Hexachlorobiphenyl (PCB 153) 50 mM 10 mg 360.876 555 pi
2,2',3,4,4',5,5'-HeptachlorobiphenyI (PCB 180) 10 mM 1.6 mg 395.30 405 pi
2,2',3,3',4,4',5,5'-Octachlorobiphenyl (PCB 194) 10 mM 5.0 mg 429.766 1136.4 pi
2.2.4.3 Total RNA Extraction
Total RNA was extracted from each cell lines using the RNeasy® Mini Kit (Qiagen); 
the manufaeturer’s protocol for isolation of total RNA from <5X10^ animal cells was 
followed. Briefly, the cells were harvested by lysis, with a guanidine 
isothioeyanate-eontaining buffer (whieh inactivated RNases to ensure isolation of 
intact RNA) directly in the culture dish. The cell lysate was homogenised by passing 
through a 21 gauge needle ten times. The homogenised lysate was then added to the 
RNeasy mini spin columns (RNA purified by using an affinity chromatography 
column) where the total RNA bound to the silica gel membrane and the contaminants 
were washed away. The RNA was eluted in a final volume of 50 pi of RNase-free 
water. Total RNA samples were stored at -80°C.
2.2.4.4 Measurement of the Quality and Concentration of Total RNA
2.2.4.4.1 Measurement of RNA Quality
Three microliters of each total RNA extract was combined with 3 pi of Orange G load 
dye and the samples were separated by electrophoresis on a 1 % agarose gel 
containing ethidium bromide as described in seetion 2.2.1.3. The RNA was 
considered good quality if the ribosomal bands were sharp, with the 28S band 
appearing approximately twice as intense as the 18S band. If the ribosomal bands 
appeared as a smear of smaller sized RNAs, the RNA was presumed to have suffered 
degradation during preparation and was discarded. High molecular weight bands 
(>20,000 kb) indicated DNA contamination, which would be removed by DNase 
treatment prior to eDNA synthesis.
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2.2.4.4.2 RiboGreen™ RNA Quantitation Assay
The RibogreenTM RNA quantitation kit (Molecular Probes) was used to determine the 
eoneentration of the total RNA samples. Ribogreen'^'^ RNA quantitation reagent is an 
ultra-sensitive fluorescent nueleie aeid stain. Care was taken to protect the reagent 
from light to avoid photodegradation. A IX TE (10 mM Tris-HCl, 1 mM EDTA, pH 
7.5) working solution was prepared by diluting the concentrated buffer 20 fold with 
DEPC treated water (Seetion 2.2.1.2). This was used to dilute the supplied 100 pg/ml 
ribosomal RNA standard {E.coU) 100 fold to produce 1000 ng/ml RNA solution. A 
standard set of solutions for the standard curve were prepared in the left hand column 
of a 96-well blaek plate as follows: one hundred microlitres of the 1000 ng/ml RNA 
standard solution was aliquotted into the first two wells. Then, one hundred 
microlitres of IX TE was aliquotted into the seeond and the remaining seven empty 
wells of the column. Standards were double diluted by transferring 100 pi of the 
contents of the seeond well into the third well and so on until the 7* well, when the 
excess 100 pi was discarded to leave the final well as a buffer blank. This provided a 
dilution series for the standard RNA as follows: 1000 ng/ml, 500 ng/ml, 250 ng/ml, 
125 ng/ml, 62.5 ng/ml, 31.25 ng/ml, 15.6 ng/ml and 0 ng/ml. For RNA extracted from 
6-well plates, one microlitre aliquots of total RNA samples were diluted 30 fold with 
IX TE buffer. Five microlitres of these diluted solutions were added to 95 pi of IX 
TE buffer in the 96-well blaek plate (further 20 fold dilution, so the final dilution 
factor is 600). These dilutions ensured that the samples positioned within the range of 
the Ribogreen™ assay standard curve. One hundred microlitres of the Ribogreen™ 
RNA quantitation reagent (diluted 200 fold with IX TE buffer) was added to each 
well and the plate was mixed gently. The fluorescence was measured at 
excitation/emission wavelengths of 485/530 nm using a SpectraMax GeminiXS 
mieroplate fluorimeter controlled by SoftMax Pro version 4.0 software (Molecular 
Devices). The time for fluorescence measurement was kept constant for all samples in 
order to minimize the photobleaehing effect. Sample concentrations were calculated 
against the standard curve and corrected for the dilution factor.
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2.2.4.5 First-strand cDNA Synthesis Using Invitrogen Superscript First-Strand 
Synthesis System for RT-PCR
2.2.4.5.1 DNase Treatment
Total RNA samples were first treated with RQl RNase-free DNase (Promega) to 
remove any genomie DNA contamination prior to cDNA synthesis. One mierogram 
of each total RNA sample was aliquotted into a 0.5 ml nuelease-fi-ee mierofuge tube 
and made up to 8 pi with 0.1 % DEPC treated water. One mierolitre of 10 X DNase 
reaction buffer (400 mM Tris-HCl pH 8.0, 100 mM MgS0 4  and 10 mM CaCh) and 
1 pi of RQl RNase-free DNase were added per sample and incubated at 37°C for 30 
minutes. Then, 1 pi of stop solution (20 mM EGTA, pH 8.0) was added and the 
samples were incubated at 65°C for 10 minutes to inactivate the DNase. Samples can 
be stored at -20°C for short term or at -80°C for long term.
2.2.4.5.2 cDNA Synthesis
cDNA was synthesised by using Invitrogen’s Superscript First-strand Synthesis 
System for RT-PCR. The manufacturer’s protocol was followed with some changes.
1.5 pi oligo dT primer (0.5 pg/pl, Promega), 1.5 pi 10 mM dNTPs, and 1 pi of 
RNase-free water were added per sample of DNase-treated RNA. Reactions were 
incubated at 65°C for 5 minutes, followed by cooling on ice for at least 2 minutes 
before the addition of the following: 2 pi of 0.1 M DTT, 1.75 pi RNase-fi*ee water, 1 
pi RNaseOUT RNase inhibitor (40 U/pl) and 0.25 pi Superscript II reverse 
transcriptase (200 U/pl). The sample tubes were incubated at 42°C for 50 minutes, 
before terminating the reaction at 70°C for 15 minutes. The samples were chilled on 
ice. Eighty microlitres of RNase-free water was added to give a total volume of 100 pi 
per sample. Samples were stored at -20°C. For each sample, in addition to the 
standard reaction (RT+), a reaction containing no reverse transcriptase enzyme and no 
RNaseOUT RNase inhibitor was also carried out (RT-). Instead, equivalent volumes 
of water were added to keep the final reaction volume constant. This was used to 
identify any genomic DNA contamination that may be present within the RNA 
samples and would bias the Q-PCR data.
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2.2.4.6 Real Time PCR: (TaqMan®)
Real-time quantitative PCR is a rapid, accurate, specific and highly sensitive method 
that measures product accumulation in real time. It offers the opportunity to screen the 
expression of several genes in one sample. The system differs from a standard PCR 
procedure only in the addition of a fluorogenic probe designed to anneal to the target 
sequence. The probe is designed specifically to hybridise within the target sequence 
and to generate a signal that accumulates during PCR cycling in a manner 
proportional to the concentration of amplification products (Lee et al. 1993), (Gibson 
et al. 1996). By this principle, the measurement of fluorescence in each sample 
provides a homogenous signal that is specifically associated with the amplified target 
and quantitatively related to the amount of PCR.
Principle of 5' Nuclease Assay
TaqMan real time PCR methodology is based on the 5' Nuclease assay of (Holland et 
al. 1991). In 5' nuclease assay, a spécifié non-extendable oligonucleotide 
hybridisation probe is annealed to a target sequence located between the two primer 
binding sites (Lie and Petropoulos 1998). The probe contains F AM (6- 
carboxyfluorescein) as a fluorescent reporter dye covalently linked to the 5' end and a 
quencher dye TAMRA (6-earboxy-tetramethyl-rhodamine) is usually covalently 
linked to the 3' end of the oligonucleotide. Modification of the oligo probe with a 3'- 
blocking phosphate prevents extension of the annealed probe during amplification. 
When the probe is intact, the proximity of the reporter dye to the quencher dye results 
in suppression of the reporter fluorescence primarily by Forster resonance energy 
transfer (FRET) through space (Livak et al. 1995). During the PCR reaction, the 
primers and probe first specifically hybridise to the corresponding template. The 
probe is then cleaved by Taq DNA polymerase whieh has 5' to 3' exonuclease activity 
that allows it to cleave the terminal nucleotides of double-stranded DNA (Holland et 
al. 1991). This cleavage results in an increase of fluorescence emission of the F AM 
reporter without affecting the emission of the quencher dye (since the emission 
intensity of the quencher dye varies only minimally during PCR reaction, it is used to 
normalise variations in reporter dye emission intensities (Lie and Petropoulos 1998). 
The fluorescence is measured by an ABI Prism 7900 sequence detection system 
(SDS) that uses a charge-eoupled device (CCD) (Heid et al. 1996). The fluorescence 
signal is then normalised by dividing the emission intensity of the reporter dye to the 
emission intensity of a reference dye (ROX), included in the ABsolute™ QPCR Mix,
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by the SDS software to obtain a ratio known as Rn for each sample at the end of each 
thermal cycle. A baseline Rn value is produced by measuring the fluorescence 
between cycles 3 and 15, unless there is an increase in the amplification curve prior to 
cycle 15. A threshold (Th) above the baseline is set so that it falls within the 
exponential phase of amplification. The threshold cycle (Ct) for any measured sample 
is the fractional cycle number at which the normalised ratio Rn crosses the Th (Heid 
et al. 1996). For a given target gene, the copy number (Cn) is calculated by 
comparison of sample Ct values with those of standards with known copy number. A 
lower Ct value corresponds to a higher Cn value, since the higher the concentration of 
starting material in the sample, the sooner the amplification would reach exponential 
phase. Figure 2.2 below shows the steps of a typical TaqMan reaction.
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Figure 2.2 Quantitative PCR: The 5' Nuclease Assay (TaqMan)
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2.2.4.6.1 Primer and Probe Design
Primer and probe sets for human CYP3A4, CYP3A5, CYP3A7, CYP3A43, GAPDH 
and hPXR were designed using Primer Express software version 2 (Applied 
Biosystems, Poster City, CA, USA) by former PhD students: Dr A. Phillips and Dr K. 
Swales. Primer and probe sets for human CYPIAI, CYP4A11, MDRl, OATP-B, 
MRPl and MRP3 were designed in this project by Fadheela Al-Salman again using 
Primer Express software. The software designed primers and probes using the 
guidelines given in table 2.6. The sequences of the primers and probes are shown in 
table 2.7. Primers were supplied lyophilised by MWG-Biotech and were diluted to a 
100 pM stock concentration with 0.1 % DEPC water. Further dilution was made to 
prepare a working solution of 10 pM, this was then split into aliquots of 200 pi, in 
DNase RNase free micotubes (Axygen Scientific Inc.), to minimize contamination 
and any freeze-thawing effects. Probes were supplied ready to use with a reporter dye 
(6-FAM) at the 5’ end and a quencher dye (TAMRA) at the 3’ end (MWG-Biotech 
U.K. Ltd.). The probes were diluted to a working concentration of 5 pM. Primers and 
probes were stored at -20°C.
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Table 2.6 ABI Prism Primer Express software primer design guidelines
Primer
T m 58-60°C
9 - 4 0  bases in length 
2 0 -8 0 % G C
Less than 2° C difference in Tm between the two primers 
A maximum of two G/C’s in the last five bases at the 3’ end
Probe
Tm 10° C higher than the primer Tm 
9 - 4 0  bases in length
20 -  80 % GC
No G on the 5' end
Less than 4 contiguous G’s
Must not contain more G’s than C’s
Amplicon
50 -1 5 0  base pairs in length
The 3' end of the primer should be as close to the probe as possible
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2.2.4.6.2 Genomic DNA Standards
Human genomic DNA (Promega) was supplied at a concentration of 169.4 ng/pl 
which contains 2.0 xlO^ single stranded copies/pl; according to the theory in appendix 
8. The genomic DNA was sheared by passing through a 21-gauge needle 10 times. 
Then, the human genomic DNA was diluted to provide a stock solution of 10^  single 
strands per 5 pi (2 x lO'^  ss/pl). This standard was diluted further to prepare 10\ 10^ , 
10  ^and 10^  ss/5 pi standard solutions by a 10-fold serial dilution. All standards were 
prepared using 0.1% DEPC-treated water. For regular use, standard genomic solutions 
were stored at 4°C (as multiple freeze thawing may sheer the DNA) but for long-term 
storage aliquots were stored at -20°C.
2.2.4.6.3 Quantitative PCR
A bulk mix was prepared for each 96-well reaction plate in order to minimise 
pipetting errors, using the volumes given in table 2.8. Twenty microlitres of bulk mix 
were added into each well of a 96-well optical reaction plate (ABgene® Thermo- 
Fast®). Five microlitres of genomic standards and DEPC-treated water as sample 
blanks in duplicates were added per plate. Followed by addition of five microlitres of 
cDNA samples (RT +) and (RT -) per well. The reaction plate was firmly sealed with 
an optical adhesive cover (ABgene®) and centrifuged at 1000 rpm for 1 minute. The 
plate was then loaded onto ABI Prism 7000 sequence detection system (Applied 
Biosystems, Foster City, CA, USA). The plate layout was assigned within the SDS 
software and the appropriate detector (FAM/TAMRA) was selected. The reaction 
volume per well was set to 25 pL and the reactions were run under the thermal cycler 
conditions shown in table 2.9. The enzyme activation step at 95°C (Stage 2) was set 
manually for 15 minutes.
Table 2.8 Volume of reagents for TaqMan® 96-well plate
Com ponents V olum e p e r well (pi) V olum e p e r  96-well p la te  (pi)
Forward Primer (10 pM) 1 100
Reverse Primer (10 pM) 1 100
Probe (5 pM) 0.5 50
ABsolute'T^ QPCR Mix 12.5 1250
0.1 % DEPC H2O 5 500
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Table 2.9 Thermal cycler conditions for TaqMan® PCR
Stage T em p era tu re Tim e Cycles Function
1 50°C 2 min 1 UNO activation
2 95°C 15 min 1 Enzyme activation
3A 95°C 15 sec 40 Dénaturation
Annealing/Extension3B 60°C 1 min
Once completed, the run was analysed using the ABI Prism® software (Applied 
Biosystems) with a threshold within the exponential phase of the standard curves. 
This analysis provides Ct (threshold cycle) values and uses the standard curve 
generated (Logio [Copy number] vs. Ct) to calculate the copies of RNA per well from 
these Ct values. The analysed data was exported to Microsoft Excel for further 
analysis, which involved the calculation of number of copies of mRNA detected / ng 
total RNA for each sample. Values were then normalised to the expression of 
GAPDH for each sample, and the mean and standard error calculated for each sample 
group. This was then used to calculate fold change values compared to vehicle control 
(0.1% DMSO) and basal expression values.
2.2.5 Reporter Gene Construct Development
2.2.5.1 Introduction
The human MDRl gene has two promoters, a major downstream promoter and a 
distal up stream promoter and an enhancer element. The MDRl promoters and 
enhancer were identified using NCBI (National Centre for Biotechnology 
Information) and were amplified from unsheared human genomic DNA (Promega). 
Initially, the promoters were cloned separately into a secretory alkaline phosphatase 
(SEAP) reporter gene and then the enhancer was cloned upstream of each promoter.
2.2.5.2 Primer Design
Primers were designed using Vector NTI 4.0 (InforMax Inc.). Restriction sites were 
engineered into the primers to allow for directional cloning. Primer parameters were 
set at product length Ikb, primer length 18-30 bp and % GC content between 40 -60. 
The primers used are shown in Table 2.10, the product sizes given in Table 2.11.
Upon receipt, lyophilised primers (MWG-Biotech U.K. Ltd.) were resuspended in 
O.lx TE (Tris-EDTA, pH 7.0) to a stock concentration of 100 pM. The stock primers
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were diluted with O.lxTE to a working concentration of 10 pM. Stock and working 
concentrations were both stored at -20°C.
Table 2.10 Primers sequences used for PCR
M D R l G ene P rim er Enzym e P rim e r Sequence *
Downstream Promoter
Forward BanMl
V
5 ’-GTGGAAGG ATCCTCAGACTATGCAG-3 ’
Reverse Hind 111
T
5 ’-TCTGCTTCTTTAAGCTTGGA AGAGC-3 ’
Upstream Promoter
Forward Bgll\
T
5 ’-GGCCAGATCTCACAATACATACACA-3 ’
Reverse Hind 111
T
5 ’-TGCTTCCTGAAGCTTGTACTCCTA-3 ’
Enhancer
Forward Nhe 1
T
5 ’-GGTCTGCTAGCAGTGTTTCTTG-3 ’
Reverse Nhel
T
5 ’-ACTTTGCTAGÇTGCTGACA ATATG-3 ’
* Restriction sites are shown in red; mismatches are underlined
Table 2.11 PCR product sizes
MDRl Gene Amplicon Size (bp)
Downstream promoter 976
Upstream promoter 982
Enhancer 1048
2.2.S.3 Optimisation PCR Reactions
PCR reactions were initially optimised using Taq DNA polymerase due to its high 
tolerance to varying primer annealing temperatures and its low cost. PCR reactions 
were further optimized using the high fidelity Platinum® Pfx DNA polymerase. 
Optimization of the reaction conditions was attained by altering the number of PCR 
cycles and/or annealing temperature in order to obtain the correct amplicon. The 
optimised PCR reaction conditions for Taq DNA polymerase are given in Table 2.12 
and for Pjx DNA polymerase in Table 2.13. All PCR reactions were carried out in the 
PCR machine (MJ PTC-200 Thermal Cycler, GMI, USA) and the cycle parameters
69
are given in Table 2.14. PCR products were checked by separation in a 1% agarose 
gel with ethidium bromide (Section 2.2.1.3) and the size estimated by comparison to a 
DNA marker.
Table 2.12 Volumes used for Taq Polymerase PCR reaction
Reagent Volume (pi) Final Concentration
Taq enzyme (5 U/pl) 0.75 0.075 U/pl
Guy’s Buffer (lOX) 5 IX
Betaine (5.5 M) 10 1.1 M
dN T P s(lO m M ) 1 0.2 mM
BSA (10 pg/pl) 1 0.2 pg/pl
Forward primer (10 pM) 1 0.2 Mm
Reverse primer (10 pM) 1 0.2 pM
Human Genomic DNA (25 ng/ pi) 10 5 ng/ pi
Nuclease free- water Volume up to 50
Guy’s Buffer (lOX PCR buffer) is composed of 670 mM Tris-HCl pH 8.8, 160 mM 
(NH4)2S0 4 , 67 mM MgCl] and 69 mM P-mercaptoethanol.
Table 2.13 Volumes used for Pfx Polymerase PCR react ion
Reagent Volume (pi) Final Concentration
Pfx: enzyme (2.5 U/pl) 0.5 0.025 U/ pi
Pfx Amplification Buffer (lOX) 10 2X
Pfx PCRx Enhancer Solution (lOX) * 10 2X
dNTPs (lOmM) 1.5 300 pM
M gS04 (50 mM) 1 1 mM
Forward primer (10 pM) 1.5 0.3 pM
Reverse primer (10 pM) 1.5 0.3 pM
Human Genomic DNA (25 ng/ pi) 10 5 ng/pl
Nuclease free- water Volume up to 50
* Did not give product for M D R l enhancer and the desired product was amplified by 
substituting this with water.
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Table 2.14 Optimised cycle parameter for Pfx Polymerase PCR
Stage Temperature (”C) Time Cycles
1 94 5 mins 1
2 94 15 secs 35
55* 30 secs 35
68 90 mins 35
3 68 5 mins 1
* 50 °C for amplification of MDRl downstream promoter
2.2.5.4 Phenol Chloroform Extraction for DNA Purification
Phenol extraction is a common technique used to purify DNA samples. An equal 
volume of phenol: chloroform (pH 7.5) was added to an aqueous DNA sample (PCR 
product) in a microcentrifuge tube. The mixture was briefly vigorously vortexed, and 
then centrifuged for 5 minutes at 13,000 rpm to enact phase separation. The upper, 
aqueous layer carefully was removed to a new tube, avoiding the phenol interface. 
Followed this extraction, the DNA may be concentrated by ethanol precipitation.
2.2.5.5 Ethanol Precipitation
DNA sample was mixed with 1/10 volume of 3M sodium acetate NaOAc (pH 5.2), 
Ipl of t-RNA (10 mg/ml) as a carrier and three volumes of chilled absolute ethanol 
(stored in freezer). The tube was immediately centrifuged at 13,000 rpm at 4°C for 15 
minutes. This precipitation is performed by incubation overnight at -20°C to enhance 
DNA precipitation. DNA pellet was washed with 500 pi 70% ethanol EtOH, followed 
by a second centrifugation at 13,000 rpm for 5 minutes. The supernatant was removed 
and the pellet was left to air dry at room temperature and finally re-suspended in 10 pi 
of O.lXTE (1 pM Tris, 0.1 pM EDTA pH 8.0).
2.2.5.6 Restriction Digest of PCR Products
Cutting DNA by using restriction enzymes is one of the most common Molecular 
Biology techniques. For this purpose restriction sites were engineered into the primers 
to allow for directional cloning which will enable the restriction endonucleases to 
recognise and cut specific palindromic sequences (usually 4-6 bp) in the DNA 
plasmid. The sticky overhangs ends of both insert and vector are compatible in order 
to ligate these ends later. Restriction enzyme digestions were accomplished by 
incubating double-stranded DNA molecules with an appropriate amount of restriction
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endonuclease enzyme, in its relevant buffer as recommended by the supplier, and at 
the optimal temperature for that specific enzyme. Typical digestions included a unit of 
enzyme per microgram of starting DNA with one enzyme unit being defined as the 
amount of enzyme needed to completely digest one microgram of double-stranded 
DNA in one hour at the appropriate temperature. These reactions were incubated for 
1-4 hours, to ensure complete digestion, at the optimal temperature for enzyme 
activity, usually 37°C. Restriction digest reagent volumes are given in Table 2.15 and 
the restriction enzymes used are listed in Table 2.16. The restriction enzyme buffer 
composition for buffer B is (6 mM Tris-HCl, 6 mM MgCli, 50 mM NaCl and 1 mM 
DTT; pH 7.5 at 37°C and the restriction enzyme buffer composition for buffer E is (6 
mM Tris-HCl, 6 mM MgCl], 100 mM NaCl and 1 mM DTT; pH 7.5 at 37°C.
Table 2.15 Reagents for restriction digests and incubation time
Insert (40 pi Rxn) Vector (20 pi Rxn)
23 pi Nuclease-free water 11.5 pi Nuclease-free water
10 pi DNA 5 pi DNA plasmid (0.5 pg)
4 pi Enzyme buffer 2 pi Enzyme buffer
1.5 pi o f  each enzyme 0.8 pi o f  each enzyme
Incubation time Incubation time
~  4 hrs at 37°C ~  3 hrs at 37°C
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Table 2.16 Restriction Enzymes used and their corresponding buffers
MDRl Amplicon DNA Enzymes Buffer
Down stream promoter Insert: dsp Hind  III, B anM l E
(dsp) Vector: pBASIC-SEAP2 Hind  III, Bgl II B
Up stream promoter Insert: usp Hind  III, Bgl II B
(usp) Vector: pBASIC-SEAP2 Hind \ l \ ,B g l l l B
Enhancer Insert: en N he  1, N he  1 B
(en) Vector: dsp Nhe  1, N he  1 B
Insert: en N he  1, N he  1 B
Vector: usp N he  1, N he  1 B
22.5.1 Déphosphorylation of the 5' end
The vehicle DNA was prepared for cloning by restriction digest as described before 
(Section 2.2.5.6) then the cut ends were dephosphorylated using calf intestinal 
alkaline phosphatase (CIAP). This enzyme is used to prevent recircularization and 
religation of linearized cloning vehicle DNA by removing phosphate groups from 
both 5 '-termini.
Dephosphorylation reaction contained the following:
20 pi DNA (restriction digest)
25 pi of Milli-Q water 
5 pi of AP (lOx buffer)
1 pi of of phosphatase enzyme
The reaction mixture was incubated for 30 minutes at 37°C. An additional 1 pi of 
phosphatase enzyme was added and the reaction was incubated for another 30 minutes 
at 37°C. 50 pi of 1 X TE was added to the digested and dephosphatised vector and 40 
pi of 1 X TE was added to the insert followed by phenol: chloroform extraction as 
described in section 2.2.5.4.
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2.2.6 Cloning
2.2.6.1 Ligation of DNA
Ligations were carried out after running a gel with 1 pi of the vector and 1 pi of the 
insert to check for the ratios. The volumes used for ligation are shown in Table 2.17. 
The ligation reactions were then left overnight at 16°C.
Table 2.17 Volumes for ligallion reactions
Reagents Control (Vector only) Vector and Insert
Nuclease-free water 6.3 p i 2.3 p i
10 X T4 DNA ligase buffer * i p l 1 pi
Linearised vector (10 ng/ pi) 2 p i 2 pi
DNA Insert (variable cones)
—
4 pi
T4 DNA ligase (3 U/ pi) 0.7 p i 0.7 pi
*10 X T4 DNA ligase buffer (30 mM Tris-HCl pH 7.8, 10 mM M gCb, 10 mM  DTT and 
1.0 mM ATP)
2.2.6.2 Transformation of Bacteria
Transformations were made into competent DH5a™ cells, Escherichia coli bacterial 
cells. These cells allowed clean DNA preparation by eliminating non-specific 
digestion by endonuclease due to QndAX mutation and reduced occurrence of 
unwanted recombination in cloned DNA due to recAX mutation. Frozen competent 
cells were removed from -80°C and placed on ice for 5 minutes. Four microlitres of 
the ligation reaction (vector and insert) or vector alone (as a negative control) were 
mixed gently with 45 pi of competent cells and incubated on ice for 30 minutes. The 
suspensions were heat shocked for 45 seconds at 42°C and immediately recovered on 
ice for 2 minutes. Next, 450 pi of LB-Broth (5.0 g of tryptone, 2.5 g yeast extract, 5.0 
g NaCl, in 500 ml of water) was added and the cells incubated for 1 hour at 37°C in a 
shaking incubator at 200 rpm. Cells then were centrifuged at 7,000 rpm for 1 minute; 
400 pi of LB-Broth was discarded and the pellet re-suspended into the remaining 100 
pi LB-Broth. The bacteria were then spread on LB-Agar plate (same recipe as LB- 
Broth but with 7.5 g of Agar added) containing ampicillin (50 pg/ml) and incubated at 
37°C overnight.
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2.2.6.3 Rapid Screening for Recombinant Plasmids
A quick and easy screening technique was used in order to check individual colonies 
for the presence of plasmids with an insert. Overnight colonies were picked with a 
toothpick and inoculated into 5.0 ml LB-Broth containing 50 pg/ml ampicillin and 
incubated overnight at 37°C with shaking at 200 rpm. Next, 60 pi of culture was 
mixed with an equal volume of phenol/chloroform (1:1, pH 7.5) and 10 pi 5 X Orange 
G loading dye. Samples were briefly vortexed and centrifuged for 2 minutes at 13,000 
rpm. This resulted in two phases: a bottom organic phase (containing proteins) and an 
upper aqueous phase (containing plasmids and all bacterial nucleic acids). Twenty 
microliter of the top aqueous phase was analysed by agarose gel electrophoresis 
(Section 2.2.1.3) along with a DNA marker and 10 pi of vector plasmid (5 ng/ pi) as a 
control. The presence of an insert was confirmed by comparison with the vector 
plasmid and any culture with a larger plasmid was further analyzed to fully 
characterise the insert.
2.2.6.4 Minipreparation of Plasmids by Alkaline Lysis Methodology
This alkaline lysis method was used for general minipreparation of DNA and fast 
screening of recombinant plasmids. One milliliter of bacterial overnight mini-cultures 
was centrifuged for one minute at 13,000 rpm. The supernatant was removed and the 
bacterial pellet re-suspended in 100 pi solution 1. Two hundred microlitres of solution 
2 was added and mixed gently by inverting followed by incubation on ice for less than 
five minutes. Next, 150 pi of solution 3 was added and again gently mixed and 
incubated on ice for five minutes. The compositions of the three solutions used for 
this protocol are given in Table 2.18. The mixture was then centrifuged for five 
minutes at 10,000 rpm and the supernatant transferred to a clean microcentrifuge tube 
and 800 pi of absolute ethanol (EtOH) was added and centrifuged again for additional 
five minutes at 13,000 rpm. The pellet was washed with 800 pi of 70% ethanol, 
centrifuged for two minutes at 13,000 rpm and air-dried. Finally, the pellet was re­
suspended in 50 pi 1 X TE (Tris-EDTA, pH 8.0). Samples prepared by this method 
ean be stored up to 4 days at 4°C.
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Table 2.18 Solutions used in alkaline lysis method
Solution No. Component
Solution 1 (50 ml) 50 mM Glucose 0.45 g
25 mM Tris.HCl pH 8 1.25 ml IM  stock
10 mM EDTA 1 ml 0.5 M  stock
Solution 2 (100 ml) 0.2 M  NaOH 20 ml 1 M  stock
1 % SDS 10 ml 10% stock
Solution 3 (50 ml) 3 M  KOAc 14.7 g
11.5 % Glacial acetic acid 5.75 ml
2.2.6.S QIAprep® Spin Miniprep Plasmid Preparation
For salt sensitive application such DNA sequencing, high quality DNA 
minipreparation were carried out using the QIAGEN minprep kit; an affinity column 
based teehnique. The buffers used in this protocol were supplied with the kit.The 
protocol in the manufacturer’s technical manual was followed with an additional 
initial step to increase the concentration of DNA. At the start of the protocol, 1.5 ml 
of cell culture was centrifuged for 1 minute at 10,000 rpm and the supernatant was 
discarded. Then, another 1.5 ml was added and centrifuged again for 1 minute at
10,000 rpm. The supernatant was removed and the pellet re-suspended in 250 pi of 
lysis buffer PI (resuspention buffer; 50 mM Tris.Cl, pH 8.0, 10 mM EDTA, 100 
pg/ml RNase). Following the addition of 250 pi buffer P2 (lysis buffer; 200 mM 
NaOH, 1% SDS (w/v)) the tube was mixed gently by inversion 4-6 times until the 
solution become slightly clear and viscous. A white fluffy solution containing 
proteins, genomic DNA and cell debris was formed after the addition of 350 pi of 
buffer N3 (precipitation buffer). The tube was then centrifuged at 13,000 rpm for 10 
minutes and the supernatant which contains the DNA plasmid was transferred to a 
QIAprep spin column and centrifuged further for one minute at 13,000 rpm. The 
flow-through was discarded and 750 pi of buffer PE (wash buffer) was added to the 
column. In order to achieve higher plasmid purity, this buffer was incubated on the 
spin column for at least 5 minutes prior to column centrifugation for one minute 
which was done twice to remove any residual wash buffer. The column was then 
placed in a clean 1.5 ml tube and 50 pi of water was applied to the eolumn and 
centrifuged for one minute at 13,000 rpm in order to elute DNA. The yield was
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increased by incubating the water on column for one minute at room temperature 
before centrifugation. The final DNA concentration was measured either by 
spectrophotometer or the nanodrop (Agilent 2100 Bioanalyser; Compaq, UK).
2.2.6.6 Endotoxin-Free Maxipreparation
Plasmid DNA of the reporter genes plasmids were isolated from DH5a™ competent 
E.coli cells by using QIAGEN Endofree™ Maxi Kit. Endotoxin-free plasmids are 
required in large quantities for transfection experiments and are essential to increase 
the transfection efficiency in sensitive eukaryotic cells and removal of endotoxin 
contamination of DNA before transfection has previously been shown to be critical 
for optimal transfection of cell lines. Fifty microliter of overnight E.Coli cell culture, 
which was transformed with the reporter gene construct, were grown up in 200 ml 
LB-Broth culture containing 50 pg/ml ampicillin and incubated for 12 hrs in a shaker 
at 37°C. The bacterial cells were harvested by centrifugation at 6000 x g for 15 
minutes at 4°C and then re-suspended in 10 ml buffer PI. Ten millilitres of buffer P2 
(lysis buffer) was added and the tube was gently mixed by inversion 6 times. After 5 
minutes incubation at room temperature, 10 ml of chilled neutralisation buffer P3 was 
added and the tube was mixed immediately by inversion. The lysate was poured into a 
QIAfrlter cartridge and incubated for 10 minutes at room temperature. The cell lysate 
was then filtered into a 50 ml tube and the bacterial endotoxins, which may impair the 
DNA transfection process, were removed by adding 2.5 ml of buffer ER and 
incubating on ice for 30 minutes. After equilibrating the QIAGEN-tip with 10 ml 
buffer QBT, the filtered lysate was applied and allowed to enter the resin by gravity 
flow. The plasmid DNA bound to the column was washed twice with 30 ml endotoxin 
free buffer QC and eluted with 15 ml buffer QN and then precipitated with 10.5 ml of 
isopropanol. The precipitated DNA was collected by immediate centrifugation at
15,000 X g for 30 minutes at 4°C. The supernatant was removed carefully and the 
pellet was washed with 5 ml of endotoxin-free, room temperature 70% ethanol and 
centrifugation at 15,000 x g for 10 minutes. Finally, the pellet was air-dried and re­
suspended in 250-500 pi of endotoxin-free buffer TE. DNA concentration was 
measured by nanodrop machine and the samples were stored at -20°C.
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2.2.6.7 Glycerol stocks
Glycerol stocks were prepared to enable long-term storage of the correct clones. 150 
pi of sterile glycerol was added to 850 pi of overnight cultures in LB-Broth medium 
containing 50 pg/ml ampicillin. The tube was briefly vortexed to ensure complete 
mixing and the stocks were frozen at -80°C. When the clone was needed, a sterile 
inoculating loop was scraped across the surface of a frozen stock and then streaked 
onto LB-Agar ampicillin (50 pg/ml) plate for growth as described in section 2.2.6.2.
2.2.6.S Diagnostic Restriction Digest
A diagnostic digest was performed to confirm the correct orientation of the insert. The 
size of the insert was confirmed by running the digest reaction with a molecular DNA 
marker on a 1% agarose gel. The screening for orientation was carried out by 
choosing one enzyme that will cut within the insert and the other within the vector 
SEAP. Restriction enzymes sites are shown in plasmids maps in appendix 8. The 
restriction digests used for the four constructs are shown in Table 2.19 for 15 pi 
reaction. Restriction digests were performed on empty vectors as a negative control.
Table 2.19 Volumes used for diagnostic digest
Component Volume (pi)
DNA (0.25 pg) 0.20 to 1.25 pi
10 X Buffer 1.5 pi
Enzyme 0.5 pi
W ater Up to 15 pi
2.2.7 DNA Sequencing
Fidelity of all inserts generated in this study was confirmed by automated sequencing 
using a 2000 XL DNA analysis system and the CEQ 2000 dye terminator cycle 
sequencing with quick start kit (Beckman Coulter). The sequences were performed in 
house by Dr. Kate Plant. The sequencing method used was the “Termination 
reaction”. Four different fluorescent dye labels were integrated into extended DNA 
products using 3’ dye-labelled dideoxynucleotide triphosphates, products separated by
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capillary electrophoresis and detected by fluorescence emission. The primers used 
being the 3' and 5' multiple cloning site SEAP primers.
Sequences of the primers used:
3’ MCS: CCTCGGCTGCCTCGCGGTTCC 
5’ MCS: CTAGCAAAATAGGCTGTCCC
Two hundred nanogram of DNA in 12 pi water were mixed with 3.2 pmol of either 
primer. Later on, the sequence identity to the target gene sequence was confirmed by 
blasting against the human genome using BLAST (Basic Local Alignment Search 
Tool) algorithm (www.ncbi.nlm.nih.gov/BLAST).
2.3 Statistical Analysis
Statistical significance of results was calculated using the most suitable statistical 
measurement for each experiment (refer to figure legends for details) using GraphPad 
Prism software (version 4.00, San Diego, CA, USA).The results obtained from 
xenobiotic experiments were analysed for significance using a two way ANOVA with 
Bonferroni all means post hoc test. The results of all other data sets were analysed 
using a one factor ANOVA with Bonferroni all means post hoc test. Where results are 
an average of several biological repeats, the mean and the standard error of the mean 
(SEM) were used. The number of biological repeats is written in the figure legends. 
Results from dosing experiments are given as fold/net fold induction above the 
control to allow inter-experiment comparison. Principal components analysis (PCA) 
was performed using the MultiVariate Statistical Package (MVSP version 3.1, 
Kovach Computing Services) for the basal drug transporters in the three test systems 
for both in vivo and in vitro tissues and for the genes of interest after xenobiotic 
treatment. PCA is a way of identifying patterns in a large volume of data, and 
expressing this data in such a way as to highlight the major variables.
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3 Quantitative Analysis of Selected Genes at the mRNA 
Level in Three Different Human Tissues by Real-Time PCR
3.1 Introduction
An emerging concept in toxicology is that of co-ordinate regulation. In this hypothesis 
several different cellular pathways are regulated in a co-ordinated manner with each 
other, providing a concerted response to xenobiotic exposure. An example of such co­
ordinated regulation is seen in the induetion of CYP3A4 gene (a drug metabolising 
enzyme) and MDRl gene (a multidrug transporter) in response to xenobiotic 
exposure. Importantly, recent evidence suggests that the mode/degree of this co­
ordination is dependent upon the cellular environment; hence different tissues may 
respond in different ways to the same chemical. To examine this, we have studied the 
three major ‘first exposure’ organs in the body; namely intestine, lung epithelium 
(barrier function) and liver hepatocytes (metabolic function) by charcterising the gene 
expression profile for Caco-2, A549 and Huh? cell lines with respect to major drug 
metabolising enzymes (DMEs), drug transporters and nuclear receptors.
Therefore, my initial investigation on the coordinate regulation of drug metabolising 
enzymes (DMEs) and drug transporters in different tissues involved the validation of 
the three models by quantitative RT-PCR (2.2.4.6) a well-known method for gene 
expression assessments. Accordingly, the mRNA expression level of twelve genes: 
CYP3A4, CYP3A5, CYP3A7, CYP3A43, CYPlAl, CYP4A11, MDRl, MRPl, 
MRP3, OATP-B, PXR and GAPDH was measured for in vivo foetal and adult liver, 
colon, lung tissue samples as well as for treated and untreated Huh7, Caco-2 and 
A549 cell lines. The PXR ligand/CYP3A4 inducer (rifampicin), the AhR 
ligand/CYPlAl inducer (P-naphthoflavone) and the PPARa ligand/CYP4A inducer 
(clofibric acid) were selected for this work representing three transcriptional mediated 
pathways.
3.2 Cell Characterization at the mRNA Level
In this study, the mRNA expression of CYP3A4, CYP3A5, CYP3A7, CYP3A43, 
CYPlAl, CYP4A11, MDRl, MRPl, MRP3, OATP-B, PXR and GAPDH was 
investigated in three test organs by using real-time PCR. Validation of the test
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systems for in vivo and in vitro tissues first involved the measurement of the purity 
and integrity of all RNA samples (section 2.2.4.4.1) before running TaqMan assay. 
All total RNA samples whether extracted from cell lines or purchased from 
commercial suppliers were found to be of good quality and maintained their integrity 
wherein the ribosomal bands were sharp with the 28S ribosomal band appearing twice 
as intense as the 18S band (for agarose gel of total RNA see appendix 8, figure 8.1). 
These total RNA samples where then used to synthesize cDNA as described earlier in 
section 2.2.4.5.2. In order to exclude the presence of any genomie DNA amplification, 
all RNA samples were performed with and without reverse transcriptase (RT) 
enzyme. All RT negative controls show no evidence for DNA contamination (data not 
shown); consequently all amplification results in these assays were from the RNA 
only (refer to appendix 8, figure 8.2 for TaqMan (RT-) amplification plots).
3.2.1 TaqMan Probe/Primer Set Validation
TaqMan efficiency was initially validated for the eleven target genes and an 
endogenous reference, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), by 
generating standard curves using human genomic DNA standard solutions at the 
following concentration 10^ , 10 ,^ 10\ 10 ,^ 10^ 10^  ss/5 pi. Figures 3.1 and 3.2 show 
the standard curves for all primers and probes sets used in this investigation with the 
Logio [Copy number, CN] {x axis) vs. Ct (y axis). The resulting standard curves of Ct 
against Logio CN highly linear; as revealed by the values of the correlation 
coefficients (R^) of > 0.99. The Ct values decrease with increasing total DNA input. 
In addition, the PCR high efficiency of amplification was demonstrated by the slopes 
of all standard curves wherein the slopes were very close to each other and near to the 
ideal value (theoretical optimum) of -3.32, reflecting similar and optimum PCR 
efficiencies (Langmann et al. 2003) and corresponding to 100 % efficiency of 
amplification (Yin et al. 2001). Finally, this approach clearly gives highly accurate 
results because unknown copy numbers of mRNA detected are interpolated from the 
standard curves.
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Figure 3.1 Validation of probe/primer sets for quantitative PCR: CYP target 
genes
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Each probe and primer set to be used in subsequent investigations (A-F) was tested against 
genomic human DNA. Following amplification, Ct values were derived from the ABI 
proprietary software and linear regression undertaken to assess the quality o f the probe/primer 
set. Sets were only accepted if  a linear regression gave > 0.99 over at least three orders o f 
magnitude.
82
Figure 3.2 Validation of probe/primer sets for quantitative PCR
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Each probe and primer set to be used in subsequent investigations (G-L) was tested against 
genomic human DNA. Following amplification, Ct values were derived from the ABI 
proprietary software and linear regression undertaken to assess the quality o f the probe/primer 
set. Sets were only accepted if  a linear regression gave > 0.99 over at least three orders o f 
magnitude.
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3.3 Basal mRNA Expression Levels of Major Drug Metabolising 
Enzymes, Drug Transporters and PXR
Real-time RT-PCRs were performed on the basal level to provide an overview of the 
gene mRNA expression profiles in advanee of investigating the effect of inducers on 
gene expression. The results of absolute mRNA levels are described in more details in 
the following sections.
3.3.1 Basal mRNA Expression Levels of Human Foetal, Adult Liver and Huh? 
Cells
cDNA was synthesised from untreated Huh? cells, adult and foetal liver and 
quantitative PCR was performed as described in 2.2.4.5.2, to determine the basal 
expression levels of the human target genes. The results of this absolute basal mRNA 
levels in adult liver, foetal liver and Huh? cells are shown in figure 3.3, where the 
values are expressed as transcripts detected per nanogram of total RNA.
Figure 3.3 Basal mRNA expressions of different genes in liver
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Total RNA was extracted from Huh? cells, or purchased from commercial suppliers (Adult 
and Foetal samples). RNA samples were converted to cDNA and quantitative PCR was used 
to determine transcript levels for the indicated targets. Values are expressed as mean 
transcript number per nanogram o f total RNA. Each data point represent the mean for three 
biological repeats (n=3). n.d = not detected.
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CYP3A4 mRNA which is the major CYP3A form was expressed at significantly 
higher levels than some CYPs genes and transporters (CYP3A43, CYPlAl, 
CYP4A11, MDRl, MRPl, MRP3 and PXR) in adult liver (p<0.05) while CYP3A7 
which is the major CYP3A form in foetal liver was expressed at significantly higher 
levels (p<0.001) compare to the other genes. In Huh? cells, CYP3A5 and CYP3A? 
are both expressed at relatively higher level than the other CYPs forms and the 
expression of all genes except for GAPDH and CYPlAl were lower than adult liver. 
CYP4A11 is highly expressed in both adult and foetal liver while it was not detected 
in Huh? cells. Different expression levels of drug transporters have been seen 
between the different tissues. MDRl was expressed higher in adult liver than foetal 
liver while OATP-B gave similar expression in both adult and foetal liver and in both 
tissues they were expressed higher than in Huh? cells. MRP3 was expressed higher in 
adult liver than in foetal liver and Huh?cells. The nuclear receptor, PXR was 
expressed higher in adult liver compare to foetal liver and Huh? cells. Huh? cells 
gave much lower gene expression compare to the adult and foetal liver samples. In 
summary all target genes had been expressed in the three cell types except for the 
CYP4A11 gene which was not detected in Huh? cells.
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3.3.2 Basal mRNA Expression Levels of Human Foetal, Adult Colon and Caco-2 
Cells
cDNA was synthesised from untreated Caco-2 cells, adult and foetal colon and 
quantitative PCR was performed as described in 2.2.4.5.2, to determine the basal 
expression levels of the human target genes. The results of this absolute basal mRNA 
levels in adult colon, foetal colon and Caco-2 cells are shown in figure 3.4, where the 
values are expressed as transcripts detected per nanogram of total RNA.
Figure 3.4 Basal mRNA expressions of different genes in colon
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Total RNA was extracted from Caco-2 cells, or purchased from commercial suppliers (Adult 
and Foetal samples). RNA samples were converted to cDNA and quantitative PCR was used 
to determine transcript levels for the indicated targets. Values are expressed as mean 
transcript number per nanogram o f total RNA. Each data point represent the mean for three 
biological repeats (n=3). n.d = not detected.
No significant changes of mRNA between genes were observed in the three cell types. 
CYP3A4 was expressed higher in adult colon compare to foetal colon. The drug 
metabolizing enzymes CYP3A4, CYP4A11 and CYP3A43 were not detected in 
Caco-2 cell line. OATP-B, MRPl, MRP3 and PXR gave similar pattern in adult colon 
and foetal colon. PXR is expressed at similar levels in both adult and foetal colon and 
higher than Caco-2 cells.
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3.3.3 Basal mRNA Expression Levels of Human Foetal, Adult Lung and A549 
Cells
cDNA was synthesised from untreated A549 eells, adult and foetal lung and 
quantitative PGR was performed as described in 2.2A.5.2, to determine the basal 
expression levels of the human target genes. The results of this absolute basal mRNA 
levels in adult lung, foetal lung and A549 eells are shown in figure 3.5, where the 
values are expressed as transcripts detected per nanogram of total RNA.
Figure 3.5 Basal mRNA expressions of different genes in lung
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Total RNA was extracted from A549 cells, or purchased from commercial suppliers (Adult 
and Foetal samples). RNA samples were converted to cDNA and quantitative PCR was used 
to determine transcript levels for the indicated targets. Values are expressed as mean 
transcript number per nanogram o f total RNA. Each data point represent the mean for three 
biological repeats (n=3). n.d = not detected.
In A549 cells both CYP3A4 and CYP4A11 were not detected, a similar result to what 
has been observed earlier in Caco-2 eells. OATP-B was the major gene expressed in 
adult lung wherein its level of expression was significant with p < 0.01 compare to 
CYP3A4, CYP3A7, CYP3A43, CYP4A11, MRPl and PXR and with p < 0.05 
compare to CYPlAl, MDRl and MRP3. No significant differences in the basal level 
of mRNA expression were observed in A549 cell line but the overall mRNA 
expression levels were lower than the m vivo tissues. In summary, adult and foetal
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lung tissues gave quite similar pattern while very low level of expression of mRNA 
levels was observed in A549.
3.4.4 Summary of Basal mRNA Expression Levels
The transcript levels for several cytochrome P450s, drug transporter and the nuclear 
receptor PXR from human liver (Huh7), intestine (Caeo-2) and lung (A549) cell lines 
were determined and compared to adult and foetal levels in the respective tissues as 
shown in figure 3.6. The total expression of drug metabolising enzymes and drug 
transporters in the cell lines is a much lower percentage than seen in vivo. This 
suggests a limitation of this approach.
Figure 3.6 Relative eontributions of each gene in the three tissues
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3.3.5 Principal Component Analysis of Drug Transporters Expression
Principal component analysis (PCA) is a multivariate statistical technique that finds 
the major patterns in data variability was selected in this project because it reduces the 
dimensionality of the multivariate data and can be represented graphically either as 
2D or 3D PCA scatter plots. In PCA, a large dataset is analysed and the sources of 
variability identified within the dataset. This is represented on two levels; graphically 
and numerically. Initially a two- or three-dimensional graph is produced that 
represents the data in the simplest possible way so that the longest axis (the axis with 
greatest variance) is the first PCA axis, the second PCA axis is the second longest axis 
perpendicular to the first axis, and so forth. Eigenvalues are then produced and they 
indicate the amount of variance accounted by each PCA axis. The eigenvalue for the 
first axis will be the largest, the second the second largest, and so on. The percentage 
of the total variance of each axis is also calculated, together, the axes make up 100 % 
total variation between samples, each accounting for a certain percentage of the total 
variation. In turn each axis is made up of variation from each transporter and this is 
expressed as a percentage of the individual axis. At a coarse level, points that cluster 
closely on the graph are similar and those that do not are distinct. Hence, such an 
analysis can be used to identify all the genes whose expression reacts in the same way 
to xenobiotie treatment, or a group of xenobiotics that cause the same overall profile 
in gene expression. While this graphical representation allows an impression of the 
overall profile to be gained it does not inform the user which individual data points 
are important in generating this profile and which are not. The second output of PCA, 
the numerical output, assigns the degree of contribution that each data point makes to 
the overall profile seen. So each variable is assigned a variable loading value which 
indicates the relative importance of that variable so it is therefore easy to identify 
those data points that are important and might control the system under study. In 
summary, principal component analysis (PCA) and three-dimensional scatter plots 
were used in this project to identify the underlying drug transporters expression 
patterns/profiles in liver, lung and intestine cells, to reduce gene data dimensions, and 
to visualize the final results interactively in 3D space (Yang et al. 2003).
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3.3.5.1 Principal Component Analysis of the Drug Transporters mRNA Levels in 
Normal Liver Tissues and Huh? Cells
The first results of the PCA analysis is shown in Figure 3.7. This three-dimensional 
scatter plot was drawn from the PCA of absolute gene mRNA expression (MDRl, 
MRPl, MRP3, and OATP-B). Figure 3.7 PCA ease scores shows the clustering of 
Huh7 cell line samples away from the human adult sample and the adult liver samples 
were separated distinctly from both the foetal liver samples and Huh7 cells. Huh7 
cells clusters together, which is expected as they represent one cell type. The foetal 
liver samples do show some similarity to Huh7 eells and they cluster closer to one 
another and far from the adult liver samples. It is worth noting that the adult and 
foetal human liver samples were purchased from three different sources, as mentioned 
earlier in table 2.3.
Figure 3.7 3D Scatter plot of principal component analysis case scores of drug 
transporters mRNA levels in Huh? cells, foetal and adult human liver tissues
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PCA compares Huh? cells with adult and foetal human liver and arranges them 
according to similarities in their drug transporter mRNA levels.
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PCA variable loadings for the liver drug transporter genes are listed in table 3.1. The 
major variable for axis 1 is OATP-B with a percentage of total variance of 73.957, the 
major variable for axis 2 is MRP3 with a percentage of total variance of 22.563. And 
the major variable for axis 3 is MDRl with a percentage of total variance of 3.469 
respectively.
Table 3.1 PCA variable loadings for basal absolute drug transporters mRNA 
expression levels in liver
Axis 1 Axis 2 Axis 3
MDRl 0.0 0.0 1.0
OATP-B 1.0 0.0 0.0
MRPl 0.0 0.0 0.0
MRP3 0.0 1.0 0.0
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3.3.S.2 Principal Component Analysis of the Drug Transporters mRNA Levels in 
Normal Lung Tissues and A549 Cells
The second result of the PCA analysis is shown in Figure 3.8 which illustrates that the 
adult lung samples were separated distinctly from both the foetal lung samples and 
A549 eells and the foetal human lung samples cluster together away from the adult 
human lung samples. The three A549 cell samples being further separated from each 
other unlike the other cell lines which cluster closer to each other. The foetal lung 
samples cluster closer to A549 eells and they cluster closer to one another and 
relatively far from the adult lung samples. Again, the adult and foetal human lung 
samples were purchased from three different sources, as mentioned earlier in table
2.3.
Figure 3.8 3D Scatter plot of principal component analysis case scores of drug 
transporters mRNA levels in A549 cells, foetal and adult human lung tissues
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PCA variable loadings for the lung drug transporter genes are listed in table 3.2. The 
major variable for axis 1 is MRPl with a percentage of total variance of 59.548, the 
major variable for axis 2 is OATP-B with a percentage of total variance of 35.355.
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And the major variable for axis 3 is MDRl with a percentage of total variance of 
3.526 respectively.
Table 3.2 PCA variable loadings for basal absolute drug transporters mRNA 
expression levels in lung
Axis 1 Axis 2 Axis 3
MDRl 0.0 0.0 1.0
OATP-B 0.0 1.0 0.0
MRPl 1.0 0.0 0.0
MRP3 0.0 0.0 0.0
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3.3.S.3 Principal Component Analysis of the Drug Transporters mRNA Levels in 
Normal Colon Tissues and Caco-2 Cells
Figure 3.9 PCA case scores shows that the foetal human colon samples are different 
from the adult human colon samples and they cluster away from each other. The 
adult colon samples were separated distinctly from both the foetal colon samples and 
Caco-2 cells. Caco-2 cells cluster together, which is expected as they represent one 
cell type. The foetal colon samples do show some similarity to Caco-2 cells and they 
cluster far from the adult colon samples. Again, the adult and foetal human colon 
samples were purchased from three different sources, as mentioned earlier in table
2.3.
Figure 3.9 3D Scatter plot of principal component analysis case scores of drug 
transporters mRNA levels in Caco-2 cells, foetal and adult human colon tissues
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PCA compares Caco-2 cells with the adult and foetal human colon and arranges them 
according to similarities in their drug transporter mRNA levels. PCA variable 
loadings for the colon drug transporter genes are listed in table 3.3. The major
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variable for axis 1 is MDRl with a percentage of total variance of 71.032, the major 
variable for axis 2 is MRP3 with a percentage of total varianee of 24.691. And the 
major variable of axis 3 is OATP-B with a percentage of total variance of 4.196 
respectively.
Table 3.3 PCA variable loadings for basal absolute drug transporters mRNA 
expression levels in colon
Axis 1 Axis 2 Axis 3
MDRl 1.0 0.0 0.0
OATP-B 0.0 0.0 1.0
MRPl 0.0 0.0 0.0
MRP3 0.0 1.0 0.0
In general, variance in a PCA can be due to differences in expression between 
samples of the same type (intra-sample variance) as well as between different types of 
samples e.g. lung and A549 cells (inter-sample variance). Samples of cells that have 
been cultured in the same way and are taken from cells of the same passage number 
should not have a large amount of intra-sample variation but samples taken from 
different humans may vary in the expression of drug transporters, as in the case of the 
in vivo foetal and adult liver, colon, lung tissue samples taken from three different 
people.
In summary, the PCA analysis of the absolute basal expression of the drug 
transporters in adult and foetal liver, colon, lung tissues and their corresponding cell 
lines reveal that there are differences between these cell types. And the overall profile 
seen is that the foetal tissues show some similarity to the cell line understudy.
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3.4 The Effects of Xenobiotie Treatment on the Expression of Major 
Drug Metabolising Enzymes, Drug Transporters and Pregnane X 
Receptor in Liver, Lung and Intestine Cell Lines
Analysis of the basal expression of the target genes in human liver, colon and lung 
tissues, and the respective cell lines (Huh7, Caco-2 and A549) indicated difference 
between cell lines and other cell types respectively with respect to drug metabolising 
enzymes and drug transporters of the cell. Inductions of the target genes were further 
investigated to highlight the CYP/transporter profile of the cell lines in the presence 
of xenobiotics. Accordingly, PCA was used to determine the major variables between 
cell lines and xenobiotie treatments.
3.4.1 The Effects of Xenobiotics on the Expression of Major Drng Metabolising 
Enzymes
Quantitative PCR was used to measure the mRNA expression of CYP3A4, CYP3A5, 
CYP3A7, CYP3A43, CYPlAl, CYP4A11, MDRl, MRPl, MRP3, OATP-B, PXR 
and GAPDH in Huh7, Caco-2 and A549 cell lines following treatment these cell lines 
with three prototypical CYP inducers: the PXR ligand/CYP3A4 inducer (rifampicin), 
the AhR ligand/CYPlAl inducer (P-naphthoflavone) and the PPARa ligand/CYP4A 
inducer (clofibric acid) at 10 pM concentration for 24 hours. The chemical structures 
of these compounds are shown in figure 3.10. Total RNA was extracted from each 
cell line that had been treated with DMSG and 10 pM of rifampicin, P- 
naphthoflavone and clofibric acid. One microgram of each total RNA was used to 
synthesise cDNA, which was used for TaqMan® reaction using gene specific primers 
and probe sets. The results of these xenobiotics treatment on the level of each target 
gene mRNA in each cell line are given in the following sections. GAPDH was used as 
the endogenous control in the measurement of target mRNAs. All results are 
normalised to GAPDH and expressed as percentage against the vehicle control 
(DMSO). The experiments were done at least twice with three biological repeats 
(n=3).
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Figure 3.10 Chemical structures of the three compounds used in this study
(A) Chemical structure of rifampicin
(B) p-naphthoflavone
(C) Clofibric acid
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3.4.2 The Effect of Rifampicin, p-naphthoflavone and Clofibric Acid on CYP3A4 
mRNA Expression
In Caco-2 and A549 cell samples, CYP3A4 mRNA expression was below the 
detection limit of the system; as the basal expression level of this gene was not 
detected, this is consistent with work done by other groups (Hukkanen et al. 2000) for 
A549 and (Borlak and Zwadlo 2003) for Caco-2 . In Huh? cells, no statistically 
significant change in the level of CYP3A4 mRNA due to rifampicin dosing was 
observed which may reflect the low basal PXR expression in these cells. Treatment 
with 10 pM p-naphthoflavone and 10 pM clofibric acid in Huh? cells caused a 
statistically significant decrease in CYP3A4 mRNA compared to the cells treated with 
DMSO (p < 0.001); GAPDH samples of these samples were expressed so this is not 
due to the toxicity of the compounds. However, a cytotoxicity assay, such as LDH 
secretion would need to be undertaken to confirm this.
Figure 3.11 CYP3A4 mRNA expression in Caco-2, A549 and Huh? following 
rifampicin, p-naphthoflavone and clofibric acid exposure
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Total RNA was extracted from Caco-2, A549 and Huh? cells following 24 hours exposure to 
10 pM rifampicin, P-naphthoflavone and clofibric acid. RNA samples were converted to 
cDNA and quantitative PCR was used to determine transcript levels for CYP3A4.Values are 
expressed as % o f control after GAPDH normalisation. Error bars represent standard error o f 
the mean for three biological repeats (n=3). The statistical significance o f changes in mRNA 
expression in treated cells compared with vehicle control (0.1% DMSO) was determined 
where *** represents p<0.001 as determined by a two-way ANOVA with Bonferonni all 
means post hoc test.
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3.4.3 The Effect of Rifampicin, p-naphthoflavone and Clofibric Acid on CYP3A5 
mRNA Expression
There were no statistieally significant changes in the expression levels of CYP3A5 
mRNA due to rifampicin, p-naphthoflavone and clofibric acid treatment in A549, and 
Huh? cell lines. The only statistically significant increase in CYP3A5 mRNA 
expression was observed following exposure to 10 pM clofibric acid in Caco-2, with 
a 183% induction.
Figure 3.12 CYP3A5 mRNA expression in Caco-2, A549 and Huh? following 
rifampicin, p-naphthoflavone and clofibric acid exposure
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Total RNA was extracted from Caco-2, A549 and Huh? cells following 24 hours exposure to 
10 pM rifampicin, P-naphthoflavone and clofibric acid. RNA samples were converted to 
cDNA and quantitative PCR was used to determine transcript levels for CYP3A5. Values are 
expressed as % o f control after GAPDH normalisation. Error bars represent standard error o f 
the mean for three biological repeats (n=3). The statistical significance o f changes in mRNA 
expression in treated cells compared with vehicle control (0.1% DMSO) was determined 
where * represents p<0.05 as determined by a two-way ANOVA with Bonferonni all means 
post hoc test.
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3.4.4 The Effect of Rifampicin, p-naphthoflavonc and Clofibric Acid on CYP3A7 
mRNA Expression
There were no statistically significant changes in the expression levels of CYP3A7 
mRNA due to rifampicin, P-naphthoflavone and clofibric acid treatment in Caco-2, 
A549, and Huh? cell lines.
Figure 3.13 CYP3A7 mRNA expression in Caco-2, A549 and Huh? following 
rifampicin, P-naphthoflavone and clofibric acid exposure
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Total RNA was extracted from Caco-2, A549 and Huh? cells following 24 hours exposure to 
10 pM rifampicin, P-naphthoflavone and clofibric acid. RNA samples were converted to 
cDNA and quantitative PCR was used to determine transcript levels for CYP3A7. Values are 
expressed as % o f control after GAPDH normalisation. Error bars represent standard error o f 
the mean for three biological repeats (n=3). The statistical significance o f changes in mRNA 
expression in treated cells compared with vehicle control (0.1% DMSO) was determined by a 
two-way ANOVA with Bonferonni all means post hoc test.
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3.4.5 The Effect of Rifampicin, p-naphthoflavonc and Clofibric Acid on CYPlAl 
mRNA Expression
Statistically significant increases in CYPlAl mRNA expression were seen in the 
three cell lines (Caco-2, A549 and Huh7), following exposure to 10 pM p- 
naphthoflavone compare to the control DMSO, with a 2933%, 2590% and 949% 
induction respectively. Whieh indicate that CYPlAl induction (via AhR receptor 
activation) is maintained in these thre eell types. No Statisteally significant changes in 
CYPlAl mRNA expression were observed due to rifampicin and clofibric acid 
dosing in the three eell lines.
Figure 3.14 CYPlAl mRNA expression in Caco-2, A549 and Huh? following 
rifampicin, p-naphlhofiavonc and clofibric acid exposure
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Total RNA was extracted from Caco-2, A549 and Huh? cells following 24 hours exposure to 
10 pM rifampicin, P-naphthoflavone and clofibric acid. RNA samples were converted to 
cDNA and quantitative PCR was used to determine transcript levels for C Y P lA l. Values are 
expressed as % o f control after GAPDH normalisation. Error bars represent standard error o f 
the mean for three biological repeats (n=3). The statistical significance o f changes in mRNA 
expression in treated cells compared with vehicle control (0.1% DMSO) was determined 
where ** represents p<0.01 and *** represents p<0.001 as determined by a two-way 
ANOVA with Bonferonni all means post hoc test.
There were no statistieally signifieant ehanges in the expression levels of CYP3A43 
and CYP4A11 mRNA due to rifampicin, P-naphthoflavone and elofibrie aeid
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exposure aceording to two-way ANOVA with Bonferonni all means post hoe test 
(data not shown).
1 0 2
3.5 The Effects of Xenobiotics on the Expression of Drug 
Transporters
Quantitative RT-PCR was used to measure the mRNA expression of MDRl, MRPl, 
MRP3 and OATP-B in Huh7, Caeo-2 and A549 eell lines after treatment these eell 
lines with 10 pM rifampiein, p-naphthoflavone and elofibrie aeid for 24 hours as 
deseribed in seetion 3.4.1.
3.5.1 The effect of Rifampicin, p-naphthoflavone and Clofibric Acid on MDRl 
mRNA Expression
There were no statistically signifieant ehanges in the expression levels of MDRl 
mRNA due to rifampiein, p-naphthoflavone and elofibrie aeid treatment in Caeo-2, 
A549, and Huh? eell lines. In A549 eell samples treated with 10 pM rifampiein, 
MDRl mRNA expression was below the detection limit of the system.
Figure 3.15 MDRl mRNA expression in Caco-2, A549 and Huh? following 
rifampicin, P-naphthoflavonc and clofibric acid exposure
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Total RNA was extracted from Caco-2, A549 and Huh? cells following 24 hours exposure to 
10 pM rifampicin, P-naphthoflavone and clofibric acid. RNA samples were converted to 
cDNA and quantitative PCR was used to determine transcript levels for M D R l. Values are 
expressed as % o f  control after GAPDH normalisation. Error bars represent standard error o f 
the mean for three biological repeats (n=3). The statistical significance o f changes in mRNA 
expression in treated cells compared with vehicle control (0.1% DMSO) was determined by a 
two-way ANOVA with Bonferonni all means post hoc test, n.d = not detected.
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3.5.2 The Effect of Rifampicin, p-naphthoflavone and Clofibric Acid on OATP-B 
mRNA Expression
There were no statistically significant changes in the expression levels of OATP-B 
mRNA due to rifampicin, P-naphthoflavone and clofibric aeid treatment in Caco-2, 
A549, and Huh? cell lines. Treatment of A549 cell samples with 10 pM rifampicin, 
caused a statistically significant decrease in OATP-B mRNA expression compared to 
the cells treated with DMSO (p < 0.05).
Figure 3.16 OATP-B mRNA expression in Caco-2, A549 and Huh? following 
rifampicin, p-naphthoflavone and clofibric acid exposure
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Total RNA was extracted from Caco-2, A549 and Huh? cells following 24 hours exposure to 
10 pM rifampicin, P-naphthoflavone and clofibric acid. RNA samples were converted to 
cDNA and quantitative PCR was used to determine transcript levels for OATP-B. Values are 
expressed as % o f control after GAPDH normalisation. Error bars represent standard error o f 
the mean for three biological repeats (n=3). The statistical significance o f changes in mRNA 
expression in treated cells compared with vehicle control (0.1% DMSO) was determined 
where* represents p<0.05 as determined by a two-way ANOVA with Bonferonni all means 
post hoc test.
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3.5.3 The Effect of Rifampicin, p-naphthoflavone and Clofibric Acid on MRPl 
mRNA Expression
Again, there were no statistieally signifieant ehanges in the expression levels of 
MRPl mRNA due to rifampicin, p-naphthoflavone and elofibrie acid treatment in 
Caco-2, and Huh? cell lines. Statistieally significant decrease in MRPl mRNA 
expression was seen following exposure to 10 pM elofibrie aeid in A549.
Figure 3.17 MRPl mRNA expression in Caco-2, A549 and Huh? following 
rifampicin, p-naphthoflavonc and clofibric acid exposure
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Total RNA was extracted from Caco-2, A549 and Huh? cells following 24 hours exposure to 
10 pM  rifampicin, P-naphthoflavone and clofibric acid. RNA samples were converted to 
cDNA and quantitative PCR was used to determine transcript levels for M R Pl. Values are 
expressed as % o f control after GAPDH normalisation. Error bars represent standard error o f 
the mean for three biological repeats (n=3). The statistical significance o f changes in mRNA 
expression in treated cells compared with vehicle control (0.1% DMSO) was determined 
where* represents p<0.05 as determined by a two-way ANOVA with Bonferonni all means 
post hoc test.
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3.5.4 The effect of Rifampicin, p-naphthoflavonc and Clofibric Acid on MRP3 
mRNA Expression
There were no statistically significant changes in the expression levels of MRP3 
mRNA due to rifampicin, p-naphthoflavone and clofibric acid treatment in Caco-2, 
and A549 cell lines. Statistically significant increase in MRP3 mRNA expression was 
seen following exposure to 10 pM p-naphthoflavone in Huh7, with a 216 % 
induction.
Figure 3.18 MRP3 mRNA expression in Caco-2, A549 and Huh? following 
rifampicin, p-naphthoflavonc and clofibric acid exposure
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Total RNA was extracted from Caco-2, A549 and Huh? cells following 24 hours exposure to 
10 pM rifampicin, P-naphthoflavone and clofibric acid. RNA samples were converted to 
cDNA and quantitative PCR was used to determine transcript levels for MRP3. Values are 
expressed as % o f control after GAPDH normalisation. Error bars represent standard error o f 
the mean for three biological repeats (n=3). The statistical significance o f changes in mRNA 
expression in treated cells compared with vehicle control (0.1% DMSO) was determined 
where *** represents p<0.001 as determined by a two-way ANOVA with Bonferonni all 
means post hoc test.
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3.5.5 The Effect of Rifampicin, p-naphthoflavone and Clofibric Acid on 
Pregnane X Receptor mRNA Expression
Human PXR is most expressed in liver and intestine, two major detoxieation organs. 
In A549 cell samples treated with DMSO, 10 pM rifimpacin, 10 pM p- 
naphthoflavone and 10 pM elofibrie acid PXR mRNA expression was below the 
detection limit of the system. In Huh? cells, no statistically signifieant change in the 
level of PXR mRNA due to rifampicin, P-naphthoflavone and clofibric acid dosing 
was observed. In Caco-2 cell samples treated with 10 pM rifimpacin and 10 pM p- 
naphthoflavone PXR mRNA expression was below the detection limit of the system. 
Statistically signifieant increase in PXR mRNA expression was seen following 
exposure to 10 pM clofibric acid in Caco-2, with a 55? % induction.
Figure 3.19 PXR mRNA expression in Caco-2, A549 and Huh? following 
rifampicin, p-naphthoflavone and clofibric acid exposure
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Total RNA was extracted from Caco-2, A549 and Huh? cells following 24 hours exposure to 
10 pM rifampicin, P-naphthoflavone and clofibric acid. RNA samples were converted to 
cDNA and quantitative PCR was used to determine transcript levels for PXR. Values are 
expressed as % o f control after GAPDH normalisation. Error bars represent standard error o f  
the mean for three biological repeats (n=3). The statistical significance o f changes in mRNA 
expression in treated cells compared with vehicle control (0.1% DMSO) was determined 
where** represents p<0.01 as determined by a two-way ANOVA with Bonferonni all means 
post hoc test, n.d = not detected.
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3.5.6 Principle Component Analysis of Gene Expression Following Xenobiotie 
Treatment
In PCA analysis of TaqMan data for each xenobiotie in each cell line, the genes 
mRNA levels under study were the variables (columns) whereas the control (DMSO) 
and the three drugs used were the cases (rows). The following sections demonstrate 
the PCA for the compound-related gene expression.
3.5.6.1 Principle Component Analysis of the Effects of Rifampicin in Huh7, 
Caco-2 and A549 Cell Lines
The results of the PCA analysis is shown in figure 3.20, which show a visual image of 
the separation of the experimental data points. This 3D scatter plot was drawn from 
the PCA of relative gene mRNA expression (CYP3A4, CYP3A5, CYP3A7, 
CYP3A43, CYPlAl, CYP4A11, MDRl, MRPl, MRP3, OATP-B and PXR) 
following treatment with 10 pM rifampicin. This plot shows that the control samples 
clustered together with the dose-treated samples for each cell line and there is no 
variability in gene expression in the three cell lines following rifampicin treatment. 
Thus, there were no major variables seen between cell lines and rifampicin treatment, 
and this is due to the lack of gene induction in the three cell lines to rifampicin. In 
other word, none of the cell line responds to rifampicin.
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Figure 3.20 3D Scatter plot of principal component analysis of CYP3A4, 
CYP3A5, CYP3A7, CYP3A43, CYPlAl, CYP3A43, CYP4A11, MDRl, OATP-B, 
MRPl, MRP3 and PXR in Huh7, Caco-2 and A549 following exposure to 10 pM 
rifampicin
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The 0.1% DMSO samples and the lOpM rifampicin treated samples cluster together for the 
three cell lines and each cell line samples is separated from the other cell line samples. Data 
are normalised to GAPDH expression.
PCA variable loadings for the genes after exposure to 10 pM rifampicin and 
percentage variabilities are listed in table 3.4. The major variables were considered 
significant with a PCA variable loading of more than 0.300. The results indicated that 
first PCA component could explain 46.9 % of the variation seen in the data, while the 
first three PCA components could explain 83.7 % of the variations in the data.
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Table 3.4 Variation in dosed relative gene mRNA expression levels after
treatment with rifampicin in the three cell lines
Gene PCA 1 Variable Loadings Percentage Variability
CYP3A4 0.260 8.17%
CYP3A5 0.328 10.30%
CYP3A7 0.377 11.84%
CYP3A43 0.324 10.18%
CYPlAl 0.405 12.72 %
CYP4A11 0.117 3^7%
MDRl 0.385 12.09 94
OATPB 0.318 9j^94
MRPl 0.207 6J094
MRP3 0.221 6^4%
PXR 0.242 7.60 %
3.S.6.2 Principle Component Analysis of the Effects of P-naphthoflavone in 
Huh7, Caco-2 and A549 Cell Lines
The results of the PCA analysis is shown in figure 3.21. This 3D scatter plot was 
drawn from the PCA of relative gene mRNA expression (CYP3A4, CYP3A5, 
CYP3A7, CYP3A43, CYPlAl, CYP4A11, MDRl, MRPl, MRP3, OATP-B and 
PXR) following exposure to 10 pM P-naphthoflavone. This plot shows that the 
control samples for Huh? and Caco-2 cells were different from the dose-treated 
samples and each control sets were clustered together and separated fi*om the 
corresponding dose-treated samples which were clustered together. On the other hand, 
A549 cells control and dose-treated samples were clustered together and no clear 
separation was seen between control and dose-treated samples. An overall, none of 
the cell lines respond to P-naphthoflavone treatments.
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Figure 3.21 3D Scatter plot of principal component analysis of CYP3A4, 
CYP3A5, CYP3A7, CYP3A43, CYPlAl, CYP3A43, CYP4A11, MDRl, OATP-B, 
MRPl, MRP3 and PXR in Huh7, Caco-2 and A549 following exposure to 10 pM 
P-naphthoflavone
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The 0.1% DMSO samples and the lOpM naphthoflavone treated samples cluster together for 
A549 cells and the 0.1% DMSO samples were separated from the lOpM naphthoflavone 
treated samples in Huh7 cells and Caco-2 cells and each cell line samples is separated from 
the other two cell lines. Data are normalised to GAPDH expression.
PCA variable loadings for the genes after exposure to 10 pM p-naphthoflavone and 
percentage variabilities are listed in table 3.5. The results indicated that first PCA 
component could explain 41.4 % of the variation seen in the data, while the first three 
PCA components could explain 81.6 % of the variations in the data.
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Table 3.5 Variation in dosed relative gene mRNA expression levels after
treatment with P-Naphthoflavone in the three cell lines
Gene PGA 1 Variable Loadings Percentage Variability
CYP3A4 0.241 7A3%
CYP3A5 0.384 11.83%
CYP3A7 0.404 12.45 %
CYP3A43 0.276 8jl% o
CYPlAl 0.214 6J9%4
CYP4A11 0.195 6.01 %
MDRl 0.291 8 j^ %
OATPB 0.301 928%
MRPl 0298 9T894
MRP3 0.349 10.76 %
PXR 0.292 9.00 %
3.5.6.3 Principle Component Analysis of the Effects of Clofibric Acid in Huh7, 
Caco-2 and A549 Cell Lines
The results of the PGA analysis is shown in figure 3.22. This 3D scatter plot was 
drawn from the PC A of relative gene mRNA expression (CYP3A4, CYP3A5, 
CYP3A7, CYP3A43, CYPlAl, CYP4A11, MDRl, MRPl, MRP3, OATP-B and 
PXR) following treatment with 10 pM clofibric acid. Again this plot shows that the 
control samples clustered with the dose-treated samples for each cell line. Similar 
pattern as was seen in the previous sections, as there were no major variables seen 
between cell lines and clofibric acid treatment. This plot shows that the control 
samples clustered together with the dose-treated samples for each cell line and there is 
no variability in gene expression in the three cell lines following clofibric acid 
treatment. Thus, there were no major variables seen between cell lines and clofibric 
acid treatment, in other word, each cell line reacted differently to the drug.
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Figure 3.22 3D Scatter plot of principal component analysis of CYP3A4, 
CYP3A5, CYP3A7, CYP3A43, CYPlAl, CYP3A43, CYP4A11, MDRl, OATP-B, 
MRPl, MRP3 and PXR in Huh7, Caco-2 and A549 following exposure to 10 pM 
clofibric acid
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The 0.1% DMSO samples and the lOpM naphthoflavone treated samples cluster together for 
HuhV cells and the 0.1% DMSO samples were separated from the lOpM naphthoflavone 
treated samples in A549 cells and Caco-2 cells and each cell line samples is separated from 
the other two cell lines. Data are normalised to GAPDH expression.
PCA variable loadings for the genes after exposure to 10 pM elofibrie acid and 
percentage variabilities are listed in table 3.6. The results indicated that first PCA 
component could explain 50.3 % of the variation seen in the data, while the first three 
PCA components could explain 85.4 % of the variations in the data.
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Table 3.6 Variation in dosed relative gene mRNA expression levels after
treatment with clofibric acid in the three cell lines
Gene PCA 1 Variable Loadings Percentage Variability
CYP3A4 0.27 8A3%
CYP3A5 0.38 11.86%
CYP3A7 0.365 11.39%
CYP3A43 0.313 9J7%
CYPlAl 0.431 13.45 %
CYP4A11 0.169 527%
MDRl 0.251 7^3
OATPB 0.300 92694
MRPl 0.198 6T894
MRP3 0.207 6A694
PXR 0.32 92994
In summary, for each drug PCA analyses there was no clear separation of the treated 
samples from the control ones. Each cell line data points segregated together and were 
distinct from the other cell lines.
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3.3 Discussion
To provide an overview of the gene expression profiles of drug metabolising enzymes 
(DMEs) and drug transporters in different tissues, real-time RT-PCR (Taqman®) was 
selected to study both the basal and induced expression mRNA levels of target genes 
due to its flexibility to look at a large number of genes in a large number of samples 
and relatively little biological material is required. Taqman® technique is also rapid, 
reliable, accurate, specific and sensitive; it can detect mRNA levels even at very low 
copy numbers due to the use of a DNA-based external standard curve. The 
disadvantages of using Taqman® are the instrumentation and reagents are expensive 
and the design of the fluorogenic probes is complicated.
Total RNA was extracted from cell lines using the QIAGEN RNeasy® kit and 
quantified using the Ribogreen™ RNA quantitation assay (Molecular Probes). This 
assay is 1000-fold more sensitive than absorbance measurements. In this fluorescent- 
based assay, a fluorescent dye (Ribogreen™ reagent) is used which is a nucleic acid 
stain so, it binds to DNA as well as to RNA in the sample. This can introduce 
inaccuracies in the measurement of RNA concentration as contaminating DNA is 
removed in the step following to RNA quantification. This problem can be solved by 
pre-treating the sample with RNase-free DNase, either into the RNA extraction 
protocol (RNase-free DNase set in combination with RNeasy mini kit; QIAGEN) or 
into the Ribogreen assay itself (Ribogreen™ RNA-specific quantitation kit with 
DNase 1; Molecular Probes) to ensure that the entire sample fluorescence is due to 
RNA only. Following this a known amount of total RNA is used in a ‘reverse 
transcriptase synthesis’, during which mRNA is converted into cDNA. This cDNA 
synthesis step is the source of most variability seen in RT-PCR reactions due to the 
risk that more RNA degradation might occur in one reaction tube than the other and 
the fact that the reverse transcriptase enzymes are highly sensitive to alcohol and salts 
remaining from the RNA extraction step (Freeman et al. 1999). All total RNA 
samples were treated in the same way whether they have been extracted from cell 
lines or obtained from commercial suppliers and the DNase 1-treatment and cDNA 
synthesis steps were also carried out in the same manner for all RNA samples in order 
to reduce the variability in reverse transcription efficiency.
The numbers of in vivo samples have been increased in this experiment to get a clear 
picture of the expression patterns in human liver, colon and lung. For that, three
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different lots of total RNA have been used for Q-PCR for both adult and foetal liver, 
colon and lung. We were not able to increase the number of total RNA donors to more 
than three due to expense and shortage of availability.
As described previously in cDNA synthesis section 2.2.4.S.2, for each sample, in 
addition to the standard reaction (RT+), a second reaction containing no reverse 
transcriptase enzyme and no RNaseOUT RNase inhibitor was also carried out (RT-). 
All RT negative controls show no evidence for DNA contamination; consequently all 
amplification results in these assays were fi-om RNA. Once total RNA had been 
converted to cDNA which is more stable than RNA, this result in increasing the 
reproducibility of this technology, in addition the conversion of total RNA into cDNA 
initially, rather than during every PCR reaction further increases the reproducibility. 
cDNA was then used in a 96-well format PCR reaction during which target is 
amplified in a similar fashion to a normal PCR reaction. However, the advantage of 
Taqman over standard PCR is twofold. Firstly, the probe and primer set used to 
amplify the target will constitute >95% of the amplicon (<10% for a standard PCR 
reaction) and this will result in a much higher degree of specifity; using such a system 
closely related targets may be distinguished (i.e. CYP3A4 vs. CYP3A7). Secondly, 
the inclusion of a fluorescent-labelled probe into the reaction allows real time capture 
of the data, increasing the accuracy and speed of quantitation.
The probe consists of a reporter and a quencher dye, and when next to each other in 
the probe light energy is transferred from the reporter dye to the quencher dye. 
However, during an amplification cycle the probe is destroyed, freeing the reporter 
dye fi-om the quencher dye. Hence, the light energy can now be emitted and measured 
by the instrument. To allow full quantitation of the emitted light, samples are 
compared to a standard curve generated fi-om genomic DNA. As the number of copies 
of target per ng input DNA can be calculated, this allows the expression of data as 
‘copies/ng input RNA’. The use of a DNA genomic standard curve required the 
primers and probes to be bound within one exon; otherwise no amplification of the 
genomic DNA standards will take place.
In xenobiotic experiment the cell lines were dosed in triplicate for 24 hours and these 
triplicate samples were used for TaqMan® reactions. This may have introduce 
experimental errors as each sample has been measured once, to eliminate this error 
and to improve the experimental procedure each cDNA sample should be measured in 
triplicate. Unfortunately, triplicate readings were not done due to large number of
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samples, time and cost constrains. However, QRT-PCR assays have been shown to be 
highly reproducible, so the lack of the triplicate readings should not affect the 
accuracy of the results (Yin et al. 2001). In this work, positive GAPDH amplification 
was measured for all cDNA samples and the levels of this gene remained 
approximately the same between samples confirming that the RNA integrity was 
maintained. Normalised dosed expression data were obtained by dividing the mean of 
gene transcript numbers by the mean of GAPDH.
Principal component analysis (PCA) is used in this project to summarise TaqMan 
experiments by reducing the dimensionality of datasets as mentioned earlier in section 
3.3.5. The 3D scatter plots produced by the PCA used to highlight the major 
variables, if any, within the system under study.
In this study, we attempted to investigate the tissue mRNA expression profiles of 
twelve genes: CYP3A4, CYP3A5, CYP3A7, CYP3A43, CYPlAl, CYP4A11, 
MDRl, MRPl, MRP3, OATP-B, PXR and GAPDH, were measured for in vivo foetal 
and adult liver, colon, lung tissue samples as well as for treated and untreated Huh7, 
Caco-2 and A549 cell lines. In adult liver, for the CYP3A subfamily, CYP3A4 
showed the highest level of mRNA expression and CYP3A5 showed the second 
highest. While CYP3A7 showed the highest level of mRNA expression in foetal liver. 
In adult liver, the expression profile of the CYP3As is 
CYP3A4>CYP3A5>CYP3A7>CYP3A43. This is in agreement with published data, 
where CYP3A4 is considered to be the major CYP3A in human adult liver (Schuetz et 
al. 1994). CYP3A5 and CYP3A7 mRNAs expression were detected in the human 
liver samples which we investigated. Low levels of CYP3A43 have been detected in 
adult human liver also appear to be confirmed by previous studies (Westlind et al. 
2001). This is also in agreement with a previous work done in our lab by Dr. Anna 
Phillips. In foetal liver, the CYP3A expression profile is 
CYP3A7>CYP3A5>CYP3A4>CYP3A43. The expression levels of these CYP3As 
appear to be consistent with data reported by other group, with CYP3A7 as the major 
CYP3A and expressed as significantly higher levels than CYP3A4 (Schuetz et al. 
1994). This is also in agreement with the previous work done in our lab by Dr. Anna 
Phillips (Phillips et al. 2005) except that in her work she found that the CYP3A 
expression profile in foetal liver was CYP3A7>CYP3A5>CYP3A43>CYP3A4. The 
difference in relative levels of the two genes may due to the fact that in my current 
work; the number of adult and foetal total RNA samples has been increased to three in
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order to minimize the inter-individual variations between the samples and to get a 
clear idea about the expression patterns in human liver. In Huh? cell line, the 
expression profile of the CYPSAs is CYP3A5>CYP3A7>CYP3A4>CYP3A43 
(Phillips et al. 2005). Again this expression profile in consistent with the previous 
work done in our lab (Phillips et al. 2005). CYP3A4 expression level was very low in 
Huh? cells. Overall the Huh? cells shows relatively low expression levels of CYP3As 
compare to adult and foetal liver cells which suggest a disruption to basal pathways of 
CYP3A regulation. CYP3A7 is expressed at higher level than CYP3A4 in Huh? cell 
line which propose that these cells may also have dedifferentiated to express a foetal 
phenotype. CYPlAl expression was higher in adult liver than foetal liver and it was 
expressed in Huh? cells. The mRNA expression of CYP4A11 in both adult and foetal 
liver was detected and this is in agreement with previously published data, (Nishimura 
et al. 2003) while it was not detected in Huh? cells. The overall expression profile of 
the CYPs gene examined in Huh? cells model is
CYP3A5>CYP3A7>CYP1 A1>CYP3A4>CYP3A43>CYP4A1 l=not detected 
In adult colon, the expression profile of the CYP3As is 
CYP3A5>CYP3A4>CYP3A7>CYP3A43. In which CYP3A43, CYPlAl and 
CYP4A11 gave very low expression levels while CYP3A5 and CYP3A4 were highly 
expressed. In foetal colon, the expression profile of the CYP3As, CYPlAl and 
CYP4A11 is the same as the profile seen in adult colon. Caco-2 cell line is widely 
used in intestinal drug absorption studies and although derived from a human colon 
adenocarcinoma, the cells spontaneously differentiate into monolayers of polarized 
entercytes under standardised cell culture conditions (Borlak and Zwadlo 2003). 
Recent studies reported the effect of different drugs on P-gp expression and function 
in intestinal T84 epithelial cells. However, such cell lines are not well characterized 
compared to Caeo-2 in terms of expression, localization and function of different drug 
transporters and metabolic enzymes as a suitable model to replicate the in vivo 
intestinal barrier (Kota et al. 2010). In Caco-2 cells, the expression profile for the 
CYP3As is CYP3A5>CYP3A7>CYP3A43>CYP3A4=not detected, with CYP3A5 as 
the major CYP3A expressed in Caco-2 and this is in agreement with a previous data 
(Ding and Kaminsky 2003). CYP3A4 was not detected in Caco-2 cells and this result 
is similar to those reported in the literature (Pfi-under et al. 2003), (Engman et al.
2001), (Aiba et al. 2005), and (Borlak and Zwadlo 2003). CYP4A11 was not detected 
as well in Caco-2. CPYlAl is the second highest mRNA expressed after CYP3A5.
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The overall expression profile of the CYPs gene examined in Caco-2 cells model is: 
CYP3A5>CYP1 A1>CYP3A7>CYP3A43>CYP3A4=CYP4A1 l=not detected.
Finally, the CYPs mRNA expression levels in human lung have been studied and the 
expression profile for the CYP3As in adult lung is: 
CYP3A5>CYP3A7>CYP3A4>CYP3A43, with CYP3A5 being the major CYP3A 
form expressed in adult lung (Hukkanen et al. 2003).
Tissue selective distribution of CYP3A4 is controlled by tissue enriched transcription 
factors, such as hepatic nuclear factor 4a (HNF4a), and ligand dependent nuclear 
receptors, most notably pregnane X receptor (PXR) and constitutive androstane 
receptor (CAR) (Raunio et al. 2005). The selective expression of CYP3A5 over 
CYP3A4 in lung cells appears to be a sum of the existence of tissue specific 
upregulating and downregulating transcription factors in these cells (Raunio et al. 
2005). CYPlAl was expressed in adult lung; CYPlAl is a major extrahepatic CYP 
enzyme. CYP4A11 was expressed at a very low level in adult lung. In foetal lung, the 
expression profile for the CYP3As is the same as the profile seen in adult lung. 
CYPlAl and CYP4A11 were both expressed at low levels.
And finally, the human A549 adenocarcinoma cell line derived from human type II 
pneumocyte is used in this study. This cell line was selected based on several studies 
which shows that A549 cell line is especially well suited for studying the control of 
expression of xenobiotic-metabolizing CYPs in the human lung because this cell line 
expresses most of the major constitutive and inducible CYP forms found in lung 
epithelial cells (Hukkanen et al. 2000). The expression profile for the CYP3As in 
these cells is CYP3A5>CYP3A7>CYP3A43>CYP3A4=not detected. The amounts of 
mRNA of CYP3A4 was below the limit of detection and this is in agreement with the 
finding of (Hukkanen et al. 2000). CYPlAl was expressed at very low level while 
CYP4A11 was not detected in this cell line. The overall expression profile of the 
CYPs gene examined in A549 cells model is:
CYP3A5>CYP3A7>CYP3A43>CYP1 A1>CYP3A4=CYP4A1 l=not detected. 
CYP3A5 was found to be the major CYP form mRNA expressed in the three cell line 
models and this is due to the fact that CYP3A5 is present constitutively in these 
tissues. The overall expression profile of the studied genes was lower in the cell lines 
compare to the in vivo tissues.
Transporters play an important role in the process of drug absorption, distribution and 
excretion, in this study the absolute basal mRNA expression profiles of drug
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transporter genes: MDRl, MRPl, MRP3, and OATP-B was measured for in vivo 
foetal and adult liver, colon, lung tissue samples as well as for untreated Huh7, Caco- 
2 and A549 cell lines. In adult liver, the expression profile of the drug transporters 
examined is: 0ATP-B>MRP3>MDR1>MRP1. OATP-B is expressed in much higher 
level than the other transporters. In foetal liver, the expression profile of the drug 
transporters is: 0ATP-B>MDR1>MRP3>MRP1. In Huh? cell line, the expression 
profile of the drug transporters is MDR1>0ATP-B>MRP3>MRP1. MRPl is the least 
expressed mRNA in the three cell types.
The expression profile of drug transporters in adult colon is MDRl>MRP3>OATP- 
B>MRP1. The expression profile in foetal colon is MRP3>0ATP-B>MDR1>MRP1. 
In Caco2 cells, the expression profile of the drug transporters is OATP- 
B>MRP3>MRP 1>MDR1.
And finally the mRNA expression profile of these transporters in adult lung cells is 
0ATP-B>MDR1>MRP3>MRP1. In foetal lung, the expression profile is OATP- 
B>MRP3>MRP1>MDR1 which resemble that observed in Caco-2 cells. In A549 cell 
line, the expression profile of these transporters is MRP1>MRP3>0ATP-B=MDR1. 
The mRNA expression level of these transporters is very low in A549 cell line 
compare to the other tested tissues and cell lines. MRPl expression level is the lowest 
in all tested samples except in foetal lung.
The human nuclear receptor, PXR was expressed higher in adult liver compare to all 
other cell types. This is consistent with the findings of another study in adult human 
tissues (Nishimura et al. 2004) which demonstrated that PXR mRNA was expressed 
at higher levels in the liver, small intestine and colon, with low levels of expression in 
other tissues. The order of expression of adult human PXR was found to be 
liver>colon>lung.
The cytochrome P-450 3A (CYP3A) enzyme family is responsible for most of the 
drug metabolism in the human liver. In this study, exposure of Huh? cells to 10 pM 
rifampicin did not elicit any statistically significant increases above control levels for 
all CYP3A genes under study and indeed this is consistent with a previous work done 
in our laboratory (Phillips et al. 2005). In Caco-2 and A549 cells, CYP3A4 mRNAs 
was not present constitutively and its amount did not increase to detectable levels 
after exposure to any of the inducing compounds studied (rifampicin, (3- 
naphthoflavone and clofibric acid). The results of dosing with 10 pM rifampicin are
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in agreement with others who have observed that rifampicin does not induce CYP3A4 
mRNA expression in A549 (Hukkanen et al. 2000).
CYPlAl is a highly inducible enzyme that plays a critical role in the bioactivation of 
certain chemicals to reactive intermediates associated with mutagenesis and 
carcinogenesis and this induction is mainly mediated by the cytosolic aryl 
hydrocarbon receptor (AhR), a ligand-activated transcription factor that plays a 
pivotal role in mediating the biological actions of a number of highly toxic chemicals 
such as polycyclic aromatic hydrocarbons (PAHs) and polychlorinated-dibenzo-/?- 
dioxins. P-Naphthoflavone a polyaromatic hydrocarbon inducer of CYPlAl and 
CYP1A2 cytochromes has been used in this project. Previous studies has shown that 
Caco-2 exhibit a highly inducible CYPlAl by P-Naphthoflavone (Le Ferrec et al.
2002) and this has been confirmed by the work presented herein were statistically 
significant increases in CYPlAl mRNA were observed in Caco-2, A549 and Huh? 
cells, producing increase of 2933%, 2590% and 949 respectively of control. It is 
noteworthy that 10 pM rifampicin was used as negative control (Lampen et al. 2004). 
These cells (Huh?, Caco-2 and A549) generally exhibit low drug metabolism 
activity. One likely reason for this situation is that the pregnane X receptor (PXR) 
which control the expression of many XMTS including CYP3 families is not 
expressed at significant level in these cell lines in contrast to AhR, the expression of 
which appears to be ubiquitous (Gerbal-Chaloin et al. 2006). Human-derived cell 
lines are suitable for induction of CYPlAl by environmental pollutants as well as 
drugs; HepG2 and Huh? (liver), Caco-2 (colon) and A549 (lung) (Krusekopf et al.
2003).
We further investigated the effects of these compounds on mRNA expression of three 
members of the human ABC drug transporter proteins superfamily (MDRl, MRPl 
and MRP3) and a member of the organic anion transporting polypeptides superfamily 
(OATP-B) in Huh?, Caco-2 and A549 cell lines. As mentioned before all drug 
transporters are expressed at the basal level in the three cell lines. The overall 
induction of these drug transporters is diminished in the three cell lines and the only 
statistically significant increase in MRP3 mRNA expression was observed in Huh? 
cells after dosing with 10 pM P-Naphthoflavone with 216% increase over control. A 
similar results was obtained for Mrp3 induction by p-Naphthofiavone in mouse liver 
(Maher et al. 2005) and in HepG2 cells (Hitzl et al. 2003) except in this study the 
dosing time was for 48 hours which resulted in a higher fold induction; 6 fold
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induction over the control DMSO. (Huang et al. 2006) has shown that dosing Caco-2 
and A549 cells with 10 pM rifampicin for 24 hours caused no induction of MDRl in 
Caco-2 and A549 cells but 10 pM rifampicin induced both MDRl and CYP3A4 gene 
expression in LS174T cells after treatment for 24 and 48 hour. This is consistent with 
the differential expression of PXR in these three cell lines. Treatment of Huh? cells 
with various PXR activators resulted in an up-regulation of MRP3 mRNA levels in a 
time- and dose-dependent manner (Teng et al. 2003) in which rifampicin caused 
greater than 4 fold induction using 25 pM. Maximal induction of MRP3 was seen at 
24 hours of rifampicin time course treatment (10 pM). Induction of MRP3 by P- 
Naphthoflavone and rifampicin suggests that MRP3 might be regulated via AhR or 
PXR, respectively (Maher et al. 2005). Unlike our results in which no induction in 
MRP3 mRNA levels was observed with rifampicin.
Finally to confirm PXR activation we examined PXR mRNA expression levels in the 
tested cell lines after dosing them with the above compounds. PXR expression is 
regulated by a number of chemicals at the transcriptional level and the majority of 
these chemicals are ligands for PXR and substrates for its target genes. The human 
pregnane-X receptor (PXR, NRH2) is an essential regulator of a large and growing 
array of drug disposition genes which correspond to all phases of drug metabolism. 
These include phase I, phase II enzymes and transporters (Hariparsad et al. 2009). Our 
results showed that rifampicin treatment did not induce PXR expression in Huh?, 
Caco-2 and A549 cells as these three cell lines express low PXR. Huang et al. 2006 
revealed that after rifampicin treatment (10 pM, 24 hour) PXR mRNA expression in 
Caco-2 and A549 cells did not induce as well. Many studies have shown that 
rifampicin can induce MDRl and CYP3A4 expression through a mechanism that is at 
least partly dependent on PXR activation. Geick et al. have demonstrated a time and 
concentration dependent induction of MDRl by rifampicin in LS174T cells. 
Rifampicin induction of MDRl mRNA expression has also been observed in human 
lymphocytes. Therefore, 10 pM rifampicin treatment was used as a PXR dependent 
positive control (Huang et al. 2006). We found that the expression of PXR mRNA 
was only significantly induced after treatment with 10 pM clofibric acid (well-known 
synthetic ligand/activotors of PPARa; CYP4A inducer) in Caco-2 cells. Caco-2 cells 
endogenously expressed the mRNA of peroxisome proliferator-activated receptor a 
(PPARa) (Suzuki et al. 1998), (Huin et al. 2002) reported that PPARa expression is 
increased during Caco-2 cell differentiation. The activation of PXR gene expression
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by clofîbrate and perfluorodecanoic acid, ligands for the fatty acid sensor PPARa, is 
difficult to explain as these chemicals do not seem to be PXR ligands nor does their 
metabolism seem to be regulated upon PXR target genes, although some more potent 
PPARa agonist do seem to be able to activate PXR (Aouabdi et al. 2006). Based upon 
the findings of Aouabdi et ah, they identified putative binding sites for a number of 
ligand-activated transcription factors which suggest that these factors may regulate the 
gene expression of PXR and the analysis of this regulatory region has shown that 
transcriptional activation of PXR by PPARa is via a binding site located 
approximately 1.3 kb upstream of the putative binding site. This might explain the 
increased expression of PXR mRNA in Caco-2 cell line after dosing it with clofibric 
acid.
3.4 Summary
In summary, both drug metabolising enzymes (DMEs) and drug transporters play a 
crucial role in the process of drug absorption, distribution and excretion. Therefore, 
validation of our tissue models by TaqMan assay, which is a very powerful method 
for studying gene expression profiles, was an essential step in the investigation of the 
coordinate regulation of drug metabolising enzymes (DMEs) and drug transporters. 
The results presented here for both absolute basal mRNA expression profiles; which 
were measured for in vivo foetal and adult liver, colon, lung tissue samples as well as 
for untreated Huh7, Caco-2 and A549 cell lines and the induction studies on selected 
CYPs and drug transporter genes revealed that whereas some cell lines have 
maintained their ability to show genome-base activations of gene expression, others 
are refractory. In addition, the results of this preliminary work suggests the need to 
use a reporter gene assay of MDRl (chapter 4) to further investigate the coordinate 
regulation of our selected two genes: MDRl and CYP3A4 in response to PCBs 
exposure (chapter 5).
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4 Transcriptional Regulation of CYP3A4 and MDRl Gene 
Expression in Liver, Lung and Intestine Cell Lines
4.1 Introduction
My initial investigation on the coordinate regulation between CYP3A4 and MDRl 
gene involved the generation of MDRl reporter gene assay to complement the 
existing CYP3A4 reporter assay (provided by Dr El-Sankary already in lab). Current 
evidence suggests that these two genes function co-ordinately to prevent the 
accumulation of toxic chemical compounds. The MDRl multidrug transporter 
represents one of the better characterized drug transporters that play an important role 
in protecting the body against xenobiotic insults. The MDRl (ABCBl) gene codes for 
P-glycoprotein, an ATP-dependent membrane transporter, which pumps many 
cytotoxic drugs out of the cells and when overexpressed can confer resistance to 
chemotherapy (Raguz et al. 2004). The MDRl gene is located on the long arm of 
chromosome 7 and consists of a core promoter region and 29 exons (Bodor et al. 
2005), numbered from -1 to 28; introns are numbered as the preceding exons. This 
numbering system reflects the fact that MDRl mRNA can be transcribed from two 
different promoters, an upstream and a downstream promoter. The upstream promoter 
is found at the beginning of exon -1 and the downstream promoter is located within 
exon 1. The portion of exon 1 located 5’from the downstream promoter is designated 
exon la, and the 3’ portion of this exon is called exon lb. The ATG translation codon 
is located within exon 2 (Chen et al. 1990). Thus transcription from MDRl can start 
at two promoters: a major downstream promoter [DSP (which is used by most cell 
lines and tissues expressing the MDRl gene)] and a minor upstream promoter (USP), 
which were originally described in highly drug- resistant derivatives of human 
cervical carcinoma KB cell lines. Although lacking a TATA-box, the DSP promoter 
has a CAAT box and an inverted CCAAT element/Y-box upstream from the 
transcription start site (tsp), where an initiator element (Inr) is found (Raguz et al. 
2008). Reporter gene expression studies have identified an array of transcription 
factor binding sites including among others, 2 GC boxes, 2 p53 elements, an ETS- 
binding element, a heat shock element, several T-cell factor, a nuclear factor for 
interleukin-6 (NF-IL6) element and an active protein-1 site (Scotto and Johnson
124
2001). In addition an enhancer element has been identified in the MDRl DSP (Geick 
et al. 2001), enhancer elements usually increase the promoter activity in orientation 
independent and over considerable distances and often act in tissue-specific manner 
even with heterologous promoters (Kohno et al. 1990). In acute lymphoblastic 
leukemic patients who over express P-glycoprotein, the MDRl USP represents the 
major promoter (and in some patients, the only promoter) used by mononuclear cells 
(Raguz et al. 2004). The MDRl USP is not well characterized like the DSP however 
Raguz et. al group reported the detection of tissue-specific MDRl USP-derived 
transcripts in normal human tissues, the characterization of this promoter in drug- 
resistant cells and its activation by the interleukin-6 (IL6)/NFIL6 pathways (Raguz et 
al. 2008). In this study, for each promoter and the enhancer, an approximately 1 
kilobase of sequence was amplified by PCR and the resulting approximate 1 kilobase 
of the regulatory region was cloned into a reporter vector upstream of the SEAP gene. 
Regulation of MRDl was examined into the three cell lines which allowed 
quantitation of the control exerted by the cloned regulatory region through the 
production of a secretable alkaline phosphotase into the growth medium which can be 
assayed by using a chemiluminescent method.
4.2 Reporter Constructs Analysis of Gene Promoter Activity
The MDRl promoters and enhancer sequences were identified using both literature 
and from NCBI database (National Centre for Biotechnology Information). They were 
amplified from human genomic DNA (Promega). Initially, the promoters were cloned 
separately into a secretory alkaline phosphatase (SEAP) reporter gene and then the 
enhancer was cloned upstream of each promoter. The following describes the details 
for cloning the two promoters and the enhancer and the results of the subsequent 
transfections.
4.2.1 Identification of MDRl Promoters and the Enhancer Region
The MDRl mRNA reference sequence (NM 000927) was identified and its 
corresponding position within the human genome was located using the BLAST 
algorithm (http://www.ncbi.nlm.nih.gov/BLAST). The gene was found to run 
opposite to its contig. To investigate the regulation of expression of MDRl gene, we 
have isolated a 1-kb genomic sequence which includes the major downstream
125
transcription initiation sites (accession number NT_079595). This 1-kb fragment 
contains the major transcription initiation sites of the downstream promoter which 
was previously identified in exon lb and the minor transcription initiation sites in 
exon la  (Ueda et al. 1987a), (Ueda et al. 1987b), (Chen et al. 1990) and (Madden et 
al. 1993). This fragment also has the CAAT box and two GC box-like sequences in 
exon la  but no TATA sequence. Because the downstream promoter appears to be the 
usual site at which MDRl RNA is synthesized, we inserted a DNA fragment 
containing sequences upstream from the transcription initiation site into a secretory 
alkaline phosphatase (SEAP) plasmid vector to test its function by a transfection 
assay. In addition, to gain insights into the mechanisms by which the MDRl USP is 
activated, this promoter (accession number NT 007933) has been characterized. We 
isolated a genomic DNA fragment of 982 bp, 809 bp upstream from MDRl exon -1, 
which includes the region (-350 to +1) that contains all the elements necessary for 
promoter activity, sequence of exon -1 appears in the GeneBank data base with the 
accession number AY425007. Several putative transcription factor binding elements 
were located in this region, including NF-Y, NF-IL6, H-APFl and ETS, and there 
was a high degree of conservation between the human and mouse MDRl USP 
regions. As for the MDRl DSP, no TATA box was apparent immediately upstream of 
the tsp. Two Inr elements (consensus PyPyPA+iN(T/A)PyPy) were identified close to 
the 2 regions where transcription initiates: +4 to +10 and +52 to +58. No other core 
promoter elements were present in the vicinity of the MDRl USP tsp (Raguz et al. 
2008). Finally, about 1 kb of the MDRl sequence (accession number NT 079595) 
that has been identified previously (Geick et al. 2001), figure 4.1, as an enhancer 
region has been cloned. This 1 kb fragment includes the potential regulatory cluster at 
about -8 kb upstream the transcription start site and includes the cluster from -7864 to 
-7817 which contains several nuclear receptor binding motifs to which PXR binds.
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Figure 4.1 Position of MDRl promoter elements 
(A)
-7975 -7013
J J  MDRl
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transcrip tion  start s ite
-7864 -7817DR4(II) DR4(1II)
ACGTTACCTCATTGAACTAACTTGACCT TGCTCCTGGGAGAGAGTTCATTTG AGATTAAA( AAGTTC AAAG 
TGCAATGGAGTAACTTGAIT G A ACTGGAACGAGGACCCTCTCTCAAGTAAACTCTAATTTGATCAAGT TTC
DR3 DR4(I) ER6
Adapted from: Geick, A. et al. J. Biol. Chem. 2001; 276:14581-14587
(B)
MDRl USP
112 M) -Skb
Enhancer MDRl DSP
4.2.2 Isolation of MDRl Promoters and the Enhancer Region
About 1 kb of the human MDRl downstream promoter, upstream promoter and the 
enhancer regions were amplified from human genomic DNA by PCR using Pfa DNA 
polymerase. The primer sequences used for PCR are given in table 2.10. Figures 4.2 
to 4.4 show the amplicon obtained from these PCR reactions correlated with the 
expected sizes of 1000 bp.
127
Figure 4.2 Amplification of the 1 kb downstream promoter region of the human 
MDRl
Marker Ladder
1 kb
PCR amplification o f human M D Rl downstream promoter region was carried out using 
genomic DNA template. PCR amplification was performed using P/A  DNA polymerase at 50° 
C annealing temperature. The products were separated on a 1% agarose gel together with 1 kb 
step ladder and a molecular weight marker (values are size o f bands in kilobases). The four 
bands represent the M DRl dsp amplicon for four PCR reactions.
Figure 4.3 Amplification of the 1 kb upstream promoter region of the human 
MDRl
Marker
1.1 kb
PCR amplification o f human M DRl upstream promoter region was carried out using genomic 
DNA template. PCR amplification was performed using PfiC DNA polymerase at 55° C 
annealing temperature. The products were separated on a 1% agarose gel together with a 
molecular weight marker (values are size o f bands in kilobases). The four bands represent the 
M DRl usp amplicon for four PCR reactions.
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Figure 4.4 Amplification of the 1 kb enhancer region of the human MDRl
Marker
1.1 kb
PCR amplification o f human M D Rl enhancer region was carried out using genomic DNA 
template. PCR amplification was performed using PJX DNA polymerase at 55° C annealing 
temperature. The products were separated on a 1% agarose gel together with a molecular 
weight marker (values are size o f  bands in kilobases). The four bands represent the M D R l 
enhancer amplicon for four PCR reactions.
4.2.3 Cloning of MDRl Promoters and the Enhancer into Vector
The PCR products of MDRl downstream and upstream promoters were digested and 
ligated into the expression vector pSEAP (for vector maps see appendix 8). The 
vector and insert were transformed into DH5a E.coli cells and plasmid DNA was 
prepared using Qiagen Miniprep kit. The presence of the correct insert was confirmed 
by diagnostic digest. Digests were designed to cut at one point within the cloned 
region using a specific restriction enzymes cutting site, with the other site falling 
outside the cloned region, to allow confirmation of both the identity of the cloned 
region and its orientation. Tables 4.1-4.3 show the restriction digests used for the 
constructs for 15 pi reaction. The MDRl downstream promoter-SEAP was digested 
with four different enzymes: Pst I, Pvu II, Xba I and Xho I. It gave the expected digest 
bands as shown in figure 4.5. The MDRl upstream promoter-SEAP was digested with 
three different enzymes: Xmn I, Bln I and Bam HI and it gave the expected digest 
bands as shown in figure 4.6. Finally, the enhancer region has been successfully 
cloned upstream of each promoter. The two promoter constructs were digested with 
Nhe I, BamW 1 and EcoBA. The results of this diagnostic digest showed that the 
enhancer has been cloned in the opposite direction as shown in figure 4.7; the 
orientation of the sequence has been inverted in the Vector NTI 4.0 to match the
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results o f the diagnostic digest. It should be noted that the enhancer enhances
transcription o f the response promoter is independent o f  orientation and position.
Table 4.1 Diagnostic digest for pSEAP2-MDRl dsp
DNA (0.25 pg) 1.25 pi
W ater 11.75 pi
Buffer 1.5 pi H D B D
Enzyme 0.5 pi P s t\ X h o \ Pvu  11 X ba I
15 pi
Fragments size 611 bp 849 bp 475 bp 1767 bp
5051 bp 4813 bp 5187 bp 3985 bp
Table 4.2 Diagnostic digest for pSEAP2-MDRl usp
DNA (0.25 pg) 1.25 pi
W ater 11.75 pi
Buffer 1.5 pi B 10 X Buffer SH E
Enzyme 0.5 pi Xm n  1 Bln  1 Bam  HI
15 pi
Fragments size 1573 bp 
4070 bp
685 bp 
4958 bp
1575 bp 
4068 bp
Table 4.3 Diagnostic digest for pSEAP2-MDRl (dsp+en) and pSEAP2-MDRl 
(usp+en)
DNA (0.25 pg) 0.20 pi
W ater 12.8 pi
Buffer 1.5 pi B E H
Enzyme 0.5 pi Nhe  1 BamYi 1 EcoBX
15 pi
Fragments size MDRl dsp+en 
MDRl usp+en
1049 bp, 5662 bp 
1049 bp, 5643 bp
1575 bp, 5136 bp 
1575 bp, 5117 bp
1296 bp, 5415 bp 
1277 bp , 5415 bp
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Once cloned, the sequence of the regions were confirmed using DNA sequencing, to 
ensure no mutations had been incorporated during PCR (data not shown).
Figure 4.5 Diagnostic digests of MDRl DSP-SEAP
3.3 kb
1.58 kb 
791 bp
Diagnostic digests o f M D Rl DSP-SEAP using four enzymes for confirmation o f cloned 
region. Lane 1 contains the construct digested with P st I producing two bands o f  size 611 bp 
and 5051 bp. Lane 2 contains the construct digested with Pvu 11 producing two bands o f size 
475 bp and 5187 bp. Lane 3 contains construct digested with X ba  1 producing two bands o f 
size 1767 bp and 3985 bp. Lane 4 contains the construct digested with A//o I producing two 
bands o f size 849 bp and 4813 bp. M = molecular weight marker (values are size o f bands in 
kilobases).
Figure 4.6 Diagnostic digests of MDRl USP-SEAP
3.3 kb
1.58 kb
Diagnostic digests o f M DRl USP-SEAP using three enzymes for confirmation o f cloned 
region. Lanes 1, 2 contains the construct digested with Xmn  1 producing two bands o f  size 
1573 bp and 4070 bp. Lanes 3, 4 contains the construct digested with Bln I producing two 
bands o f size 685 bp and 4958 bp. Lanes 5, 6 contains construct digested with Bam  HI 
producing two bands o f size 1575 bp and 4068 bp. M = molecular weight marker (values are 
size o f  bands in kilobases).
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Figure 4.7 Diagnostic digests of MDRl DSP+EN and MDRl USP+EN plasmids
3.3 kb
1.58kb
1.3 kb
Diagnostic digests o f M D Rl DSP+en (lanes 3, 5, 7) and M D Rl USP+en (lanes 4, 6, 8) using 
three enzymes for confirmation o f  cloned region. Lane 1 contains the undigested M DRl 
DSP+en. Lane 2 contains the undigested M D Rl USP+en. Lane 3 contains the M DRl 
DSP+en digested with Nhe 1 producing two bands o f size 1049 bp and 5662 bp. Lane 4 
contains the M D Rl USP+en digested with Nhe I producing two bands o f size 1049 bp and 
5643 bp. Lane 5 contains the M DRl DSP+en digested with Bam  HI producing two bands o f  
size 1575 bp and 5136 bp. Lane 6 contains the M DRl USP+en digested with Bam  HI 
producing two bands o f size 1575 bp and 5117 bp. Lane 7 contains the M D Rl DSP+en 
digested with EcoKl producing two bands o f size 1296 bp and 5415 bp. Lane 8 contains the 
M DRl USP+en digested with EcoBA producing two bands o f size 1277 bp and 5415 bp. M = 
molecular weight marker (values are size o f  bands in kilobases).
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4.3 Optimisation of the Reporter Gene Assay in the Three Cell Lines
The promoter in eukaryotes is a series of transcriptional regulation elements located 
around the binding site of RNA polymerase. It consists of the transcription initiation 
site and functional elements, among which there are some typical elements such as 
TATA box (TATAAAA), CAAT box (GCCAAT) and GC box (GGGCGG) etc. The 
promoter is located upstream of the translational region and responsible for the 
accurate transcription of the target gene via the interaction between the elements and 
transcription factors accordingly. Therefore, the analysis of the activity of promoters, 
which has been proven to be a highly sensitive and time-saving technique, is widely 
used in the study of transcriptional regulation (Xue et al. 2007). Based on this 
knowledge preliminary reporter gene assay experiments were thus carried out to 
establish the optimum conditions and to ensure robust, reproducible experiments in 
the cell lines used in this study: Huh7, Caco-3 and A549 respectively. Several cell 
concentrations and FuGENE: DNA ratios have been tested for the three cell lines. 
Cell concentration tested were 5 x 10\ I x 10^  and 2x10^ cells/ml and the FuGENE: 
DNA ratios tested were 3:1, 3:2, 6:1, 6:2, 6:3, 12:1 and 12:2. The optimum condition 
for transfection Huh7 cells was identified as FuGENE: DNA ratio 6:2 and for Caco-2 
and A549 cells was 6:3 and a cell seeding concentration of 1 x 10^  cells/ml (data not 
shown). The DNA concentration used was 0.1 pg/well for Huh7 and 0.150 pg/well for 
Caco-2 and A549 cells. Furthermore, from previous work undertaken in our lab, it 
was shown that measurement of SEAP activity at 48 rather than 72 hours post 
transfection produced the most reproducible effects (Dr S. Aouabdi, personal 
communication). Consequently, a 48 hours reading was chosen as the time for SEAP 
activity to be measured.
4.4 Basal Activity of CYP3A4 and MDRl Promoters Using Reporter 
Gene Assay
Prior to investigating the drug-induced response for each of the MDRl promoters it 
was necessary to analyse the basal function of each promoter. Initially, the activity of 
both, the MDRl downstream promoter, and the MDRl upstream promoter were 
examined in Huh7, Caco-2 and A549 cells. Following this, expression plasmids for 
liver-enriched transcription factors (LETFs) and ligand-activated transcription factors 
(LATFs) were co-transfected, and their effect on the basal MDRl activity was
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examined. The results of basal SEAP activity which was measured following 
transfection of Huh7, Caco-2 and A549 cells with CYP3A4 and the generated MDRl 
promoters are shown in figures 4.8- 4.10. In liver, intestine and lung cells, the MDRl 
downstream promoter (dsp) shows significantly higher basal SEAP activity over 
control (pSEAP). MDRl downstream promoter (dsp) proven to be a strong promoter 
inducing SEAP expression at a higher level than the SV40 promoter. The activity of 
the MDRl downstream promoter (dsp) is repressed by over-expression of PXR, 
confirming a role for this factor in regulation MDRl gene expression. The increase of 
MDRl upstream promoter (usp) activity over control (pSEAP) was not significant in 
the three cell lines; the expression of this promoter was less than the downstream 
promoter i.e. it is a weaker promoter. The order of MDRl upstream promoter (usp) 
expression in the three cell lines is similar to that observed in downstream promoter. 
In liver and intestine cells CYP3A4 gene co-transfected with PXR shows significant 
basal activity over control (pSEAP) while no significant CYP3 A4 activity was seen in 
the lung cells. In summary, the basal expression of MDRl downstream promoter is 
higher than both CYP3A4 gene and MDRl upstream promoter in the three tested cell 
lines and its expression was down-regulated with over expressing PXR which allow 
us to further examine the effect of over expressing other receptors on MDRl 
regulation.
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Figure 4.8 Basal activity of SEAP under control of cloned gene promoters in 
Huh?
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Basal levels o f SEAP activity in growth medium were measured 48 hours post-transfection 
into HuhV cells for each promoter construct as described in materials and methods. Each data 
point represents the mean, plus SEM, for 4 biological repeats (n=4). Significant difference in 
M DRl activity compared to negative control (empty pSEAP vector) was calculated by one­
way ANOVA with Bonferroni’s multiple comparison post hoc test where ***= p<0.001. 
pSEAP under the control o f the SV40 promoter was included as a positive control during 
transfection. RLU= relative light unit. M D Rl dsp+EN=M DRl downstream promoter plus the 
enhancer. M D Rl usp+EN=M DRl upstream promoter plus the enhancer.
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Figure 4.9 Basal activity of SEAP under control of cloned gene promoters in 
Caco-2
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Basal levels o f SEAP activity in growth medium were measured 48 hours post-transfection 
into Caco-2 cells for each promoter construct as described in materials and methods. Each 
data point represents the mean, plus SEM, for 4 biological repeats (n=4). Significant 
difference in M DRl activity compared to negative control (empty pSEAP vector) was 
calculated by one-way ANOVA with Bonferroni’s multiple comparison post hoc test where 
***= p<0.001. pSEAP under the control o f  the SY40 promoter was included as a positive 
control during transfection. RLU= relative light unit. M D R l dsp+EN=M DRl downstream 
promoter plus the enhancer. M D Rl usp+EN=M DRl upstream promoter plus the enhancer.
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Figure 4.10 Basal activity of SEAP under control of cloned gene promoters in 
A549
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Basal levels o f SEAP activity in growth medium were measured 48 hours post-transfection 
into A549 cells for each promoter construct as described in materials and methods. Each data 
point represents the mean, plus SEM, for 4 biological repeats (n=4). Significant difference in 
M D Rl activity compared to negative control (empty pSEAP vector) was calculated by one­
way ANOVA with Bonferroni’s multiple comparison post hoc test where ***= p<0.001. 
pSEAP under the control o f the SV40 promoter was included as a positive control during 
transfection. RLU= relative light unit. M DRl dsp+EN=M DRl downstream promoter plus the 
enhancer. M D Rl usp+EN=M DRl upstream promoter plus the enhancer.
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4.5 Effect of Liver Enriched and Ligand Activated Transcription 
Factors on the Basal Expression of MDRl
Following the measurement of the basal SEAP activity after transfection of Huh7, 
Caco-2 and A549 cells with CYP3A4 and the generated MDRl promoters and the 
fact that the MDRl gene expression was down regulated with PXR, it was interesting 
to investigate the effects of liver-enriched transcription factors (LETFs) and other 
ligand activated transcription factors (LATFs) on the MDRl expression due to their 
importance as metabolic and toxicological sensors. This investigation was done in two 
steps, the first step was done with MDRl downstream and upstream promoter 
plasmids without the enhancer cloned into them. The following ligand activated 
expression plasmids were used: PXR, GRa, CAR, PPARa, VDR and RXRa. Figures 
4.11, 4.13 and 4.15 show the results of these different ligand activated transcription 
factors on the MDRl downstream promoter expression (MDRl DSP) (A) and on the 
MDRl upstream promoter expression (MDRl USP) (B) after transfection into the 
three cell lines. In Huh? cells, PXR, GRa, CAR, PPARa and VDR over expression 
resulted in down regulations for both promoters and it was statically significant. Over 
expressing RXRa caused up-regulation of both MDRl promoters and the same 
pattern was observed in A549 cells. But in Caco-2 cells over expressing of RXRa 
caused down regulation in MDRl downstream promoter and up regulation in 
upstream promoter but this was not statically significant. The MDRl upstream 
promoter expression in Caco-2 was slightly increased after co-expressing with 
PPARa, VDR and RXRa, which is different form the pattern seen in the other cell 
lines. These data imply that RXRa up regulate MDRl gene expression in Huh? and 
A549 cells but not in Caco-2 which ftirther implies that this effect is tissue specific. 
The second step was done with MDRl downstream and upstream promoter plasmids 
with the enhancer cloned upstream of each promoter. The liver enriched HNF4a and 
the following ligand activated expression plasmids were used: PXR, GRa, CAR, 
PPARa, VDR, ERa and RXRa. Figures 4.12, 4.14 and 4.16 show the results of liver 
enriched and ligand activated transcription factors on the MDRl downstream 
promoter + enhancer expression (MDRl DSP+EN) (A) and on the MDRl upstream 
promoter + enhancer expression (MDRl USP+ER) (B) after transfection into the 
three cell lines. In Huh?, over expression with HNF4a, PXR, GRa, CAR, PPARa, 
VDR, ERa, RXRa and PXR+RXRa resulted in down regulation of MDRl
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downstream promoter expression. Similar pattern was observed in A549 cells for the 
MDRl upstream promoter. Interestingly, over expression of CAR in Huh? and in 
Caco-2 resulted in up regulation of MDRl upstream promoter in Huh? and up 
regulation of both promoters in Caco-2 cells. On the other hand, over expression of 
HNF4a in Huh? resulted in up regulation of the MDRl upstream promoter and down 
regulation of the downstream promoter. The opposite pattern was seen in A549 cells 
while in Caco-2 HNF4a over expression enhanced up regulation of both MDRl 
promoters. The regulation of MDRl basal gene transcription is a complex process and 
the two promoters activity were different in different tissues. It seems that this 
influence could depend on the cell context.
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Figure 4.11 Effect of ligand activated transcription factors on the basal
expression of MDRl in Hnh7
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Basal levels o f SEAP activity in growth medium were measured 48 hours post-transfection 
into Huh? cells for each promoter construct as described in materials and methods. Each data 
point represents the mean, plus SEM, for 4 biological repeats (n=4). Significant difference in 
M DRl downstream promoter (A) and M DRl upstream promoter (B) activity co-transfected 
with expression plasmids o f ligand-activated transcription factors compared to M DRl 
down/upstream promoters was calculated by one-way ANOVA with Bonferroni’s multiple 
comparison post hoc test where *=p<0.05, **=p<0.01 and ***= p<0.001. Expression levels 
are expressed as a percentage o f M DRl down/upstream promoters. M DRl DSP = M DRl 
downstream promoter, M DRl USP = M DRl upstream promoter.
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Figure 4.12 Effect of liver enriched and ligand activated transcription factors on
the basal expression of MDRl+EN in Hnh7
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Basal levels o f SEAP activity in growth medium were measured 48 hours post-transfection 
into Huh? cells for each promoter construct as described in materials and methods. Each data 
point represents the mean, plus SEM, for 4 biological repeats (n=4). Significant difference in 
M DRl downstream+EN promoter (A) and M DRl upstream+EN promoter (B) activity co­
transfected with expression plasmids o f liver enriched and ligand-aetivated transcription 
factors compared to M DRl down/upstream+EN promoter was calculated by one-way 
ANOVA with Bonferroni’s multiple comparison post hoc test where *=p<0.05, and ***= 
p<0.001. Expression levels are expressed as a percentage o f M DRl down/upstream+EN 
promoters. M DRl DSP+EN=MDR1 downstream promoter plus the enhancer, M D Rl 
USP+EN=MDR1 upstream promoter plus the enhancer.
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Figure 4.13 Effect of ligand activated transcription factors on the basal
expression of MDRl in Caco-2
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Basal levels o f SEAP activity in growth medium were measured 48 hours post-transfection 
into Caco-2 cells for each promoter construct as described in materials and methods. Each 
data point represents the mean, plus SEM, for 4 biological repeats (n=4). Significant 
difference in M DRl downstream promoter (A) and M D Rl upstream promoter (B) activity co­
transfected with expression plasmids o f  ligand-activated transcription factors compared to 
MDRl down/upstream promoter was calculated by one-way ANOVA with Bonferroni’s 
multiple comparison post hoc test where ***= p<0.001. Expression levels are expressed as a 
percentage o f M DRl down/upstream promoters. M D Rl DSP =MDR1 downstream promoter, 
M DRl USP=M DR1 upstream promoter.
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Figure 4.14 Effect of liver enriched and ligand activated transcription factors on
the basal expression of MDRl+EN in Caco-2
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Basal levels o f SEAP activity in growth medium were measured 48 hours post-transfection 
into Caco-2 cells for each promoter construct as described in materials and methods. Each 
data point represents the mean, plus SEM, for 4 biological repeats (n=4). Significant 
difference in M DRl downstream+EN promoter (A) and M DRl upstream+EN promoter (B) 
activity co-transfected with expression plasmids o f liver enriched and ligand-activated 
transcription factors compared to M DRl down/upstream+EN promoter was ealculated by 
one-way ANOVA with Bonferroni’s multiple comparison post hoc test where **=p<0.01, and 
***= p<0.001. Expression levels are expressed as a percentage o f M DRl down/upstream+EN 
promoters. M DRl DSP+EN=MDR1 downstream promoter plus the enhancer, M D Rl 
USP+EN=MDR1 upstream promoter plus the enhancer.
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Figure 4.15 Effect of ligand activated transcription factors on the basal
expression of MDRl in A549
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Basal levels o f SEAP activity in growth medium were measured 48 hours post-transfection 
into A549 cells for each promoter construct as described in materials and methods. Each data 
point represents the mean, plus SEM, for 4 biological repeats (n=4). Significant difference in 
M DRl downstream promoter (A) and M D Rl upstream promoter (B) aetivity co-transfected 
with expression plasmids o f ligand-activated transcription factors compared to M DRl 
down/upstream promoter was calculated by one-way ANOVA with Bonferroni’s multiple 
comparison post hoc test where ***= p<0.001. Expression levels are expressed as a 
percentage o f M DRl down/upstream promoters. M DRl DSP =MDR1 downstream promoter, 
M DRl USP=M DR1 upstream promoter.
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Figure 4.16 Effect of liver enriched and ligand activated transcription factors on
the basal expression of MDRl+EN in A549
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Basal levels o f SEAP activity in growth medium were measured 48 hours post-transfection 
into A549 cells for each promoter construct as described in materials and methods. Each data 
point represents the mean, plus SEM, for 4 biological repeats (n=4). Significant difference in 
M DRl downstream+EN promoter (A) and M DRl upstream+EN promoter (B) activity co­
transfected with expression plasmids o f  ligand-activated transcription factors compared to 
M DRl down/upstream+EN promoter was calculated by one-way ANOVA with Bonferroni’s 
multiple comparison post hoc test where ***= p<0.001. Expression levels are expressed as a 
percentage o f M DRl down/upstream+EN promoters. M DRl DSP+EN=MDR1 downstream 
promoter plus the enhancer, M DRl USP+EN=MDR1 upstream promoter plus the enhancer.
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4.6 Effect of Rifampicin on Transcriptional Activation of MDRl
Following assessment of the basal activity of the MDRl gene promoters, and for the 
reason that CYP3A4 and MDRl are often co-induced, it was necessary to investigate 
the effect of dosing MDRl downstream and upstream promoters with rifampicin, a 
potent inducer of human CYP3A4 expression, both in vivo and in cultured 
hepatocytes (Goodwin et al. 1999) and a powerful inducer of intestinal Pgp both in 
human duodenal biopsies and in cell line (Geick et al. 2001). Each promoter was 
transfected into Huh7, Caco-2 and A549 cells with or without PXR expression 
plasmids then dosed on the following day with 50 pM rifampicin and DMSO control 
for a 48 hour period. This had previously been shown to represent a period of 
maximal induction of gene expression (Aouabdi et al. 2006). The results for the 
dosing experiments are shown in Figures 4.17- 4.19. The Induction of CYP3A4 co­
transfected with the PXR expression plasmid with 50 pM rifampicin was used as a 
positive control in the three cell lines understudy. Results were considered significant 
if the net fold change/induction is > to 2. Rifampicin induces both CYP3A4 and 
MDRl promoters in the three cell lines and the induction of the genes occurred after 
co-transfecting with PXR expression plasmids. These results show that the induction 
of MDRl promoters could be PXR dependent. It is noteworthy, that the three cell 
lines express low levels of PXR. The MDRl upstream promoter in Caco-2 gave 
higher induction than the downstream promoter and similar induction level to 
CYP3A4. Interestingly, MDRl downstream promoter in A549 cell line gave 10 fold 
induction and CYP3A4 gave 11 fold induction, while MDRl upstream promoter gave 
4 fold induction similar to its induction in Caco-2 cells, this higher induction could be 
tissue specific. A549 cells express glucocoticoid receptor (GR) and low pregnane X 
receptor (PXR) (Huang et al. 2006), also (Hukkanen et al. 2003) showed that in A549 
cell line GR is present and both PXR and CAR are absent, hence the increase 
induction seen in A549 cells could be due to GR, as GR has been shown to induce 
expression of PXR (Pascussi et al. 2000) and this might enhance the induction of 
CYP3A4 and MDRl by rifampicin. It is, however not known whether the GR is 
directly mediating the activation of PXR by binding to its promoter or involving 
other, unknown factors. Although on the basal level these three promoters gave much 
lower basal levels in A549 cells compare to Huh7 and Caco-2 cells. The results for 
MDRl downstream promoter induction is in agreement with others who have
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observed that rifampicin does induce MDRl and this induction is mediated by a 
particular DR4 motif in the upstream enhancer to which PXR binds in the MDRl 
promoter in LS174T human colon carcinoma cell line (Geick et al. 2001). This 
confirms that our in vitro reporter gene system is reliable and confirms that MDRl 
gene to be a PXR target gene.
Figure 4.17 Pilot study: Effect of rifampicin on transcriptional activation of 
MDRl in Huh7
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Huh? cells were transfected with the CYP3A4 and M DRl reporter genes and a PXR 
expression plasmid before being exposed to 0.1% DMSO (vehicle only) and 50 pM  
rifampicin. SEAP activity was measure 48 hours post administration o f rifampicin. The level 
o f  induction was assessed by measuring the luminescence from the reporter gene product. 
Data was adjusted for background luminescence and expressed as a net fold change. Each 
data point represents net fold change in which the fold induction o f  the reporter gene over 
DMSO (post/pre) is divided by the fold induction o f the expression plasmid over DMSO 
(post/pre) for 4 biological repeats (n=4). Results were considered significant if  the net fold 
induction is > to 2. M DRl DSP+EN=MDR1 downstream promoter plus the enhancer, M D Rl 
USP+EN=MDR1 upstream promoter plus the enhancer.
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Figure 4.18 Pilot study: Effect of rifampicin on transcriptional activation of
MDRl in Caco-2
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Caco-2 cells were transfected with the CYP3A4 and M D Rl reporter genes and a PXR 
expression plasmid before being exposed to 0.1% DMSO (vehicle only) and 50 pM  
rifampicin. SEAP activity was measure 48 hours post administration o f rifampicin. The level 
o f induction was assessed by measuring the luminescence from the reporter gene product. 
Data was adjusted for background luminescence and expressed as a net fold change. Each 
data point represents net fold change in which the fold induction o f the reporter gene over 
DMSO (post/pre) is divided by the fold induction o f  the expression plasmid over DMSO 
(post/pre) for 4 biological repeats (n=4). Results were considered significant if  the net fold 
induction is > to 2. M DRl DSP+EN=MDR1 downstream promoter plus the enhancer, M D R l 
USP+EN=MDR1 upstream promoter plus the enhancer.
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Figure 4.19 Pilot study: Effect of rifampicin on transcriptional activation of
MDRl in A549
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A549 cells were transfected with the CYP3A4 and M DRl reporter genes and a PXR 
expression plasmid before being exposed to 0.1% DMSO (vehicle only) and 50 pM  
rifampicin. SEAP activity was measure 48 hours post administration o f rifampicin. The level 
o f  induction was assessed by measuring the luminescence from the reporter gene product. 
Data was adjusted for background luminescence and expressed as a net fold change. Each 
data point represents net fold change in which the fold induction o f the reporter gene over 
DMSO (post/pre) is divided by the fold induction o f the expression plasmid over DMSO 
(post/pre) for 4 biological repeats (n=4). Results were considered significant if  the net fold 
induction is > to 2.
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4.7 Discussion
Drug response is a complex event involving interactions of several different players 
such as drug metabolizing enzymes (phase I and phase II), drug transporters (phase 
III) and regulatory factors. The existence of additional or alternative promoters is a 
common feature in mammalian genomes, and as estimated 18% of all genes show 
evidence of differential promoter usage (Landry et al. 2003). These include genes for 
transporters such as ABCGl, ABCG2 and ABCAl. In most cases, transcripts from 
alternative promoters have identical ORFs and do not give rise to different proteins, 
their role being tissue-and/or developmental stage-specific, and provide a means to 
implement transcriptional and regulatory complexity (Raguz et al. 2008).
As mentioned earlier MDRl gene has two promoters and an enhancer element. In 
tissues and cultured cells the expression of the MDRl downstream promoter is 
usually found. Thus this promoter is considered as a basic element regulating the 
activity of this gene. However, the MDRl upstream promoter has not been 
characterized in detail, and (Raguz et al. 2008) reported the detection of tissue- 
specific MDRl USP derived transcripts in normal tissues, the characterization of this 
promoter in drug resistant cells and its activation by the interleukin-6 (IL6)/NF-IL6 
pathways.
The regulatory regions of both promoters were inserted upstream of the SEAP vector 
and the enhancer element was inserted upstream of each promoter. The MDRl 
downstream promoter region has a consensus CAAT box and two GC box-like 
sequences but no TATA sequence (Ueda et al. 1987a). In a long regulatory region of a 
gene, the region closer to the transcription initiation site often contributes more to the 
transcriptional level. Thus, it is not compulsory and necessary to apply the ftill length 
of the promoter in constructing the plasmid especially if related data has been 
reported before. Accordingly, about 1 kb ftagment with only 37 bp of exon lb was 
cloned in the MDRl downstream promoter not the whole exon but this fragment has 
the two major transcription initiation sites (Ueda et al. 1987b) and previously it has 
been shown that only 17 nucleotides spanning the transcription initiation site (-6-+11) 
are sufficient for transcriptional initiation and this region was included in the 
promoter. This sequence shares a strong homology with the TdT initiator {Inr) 
sequence. Inr elements are located at the transcription initiation site and can direct
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transcription from a RNA polymerase II promoter in the absence of a TATA box (van 
Groenigen et al. 1993).
For MDRl USP, about 1 kb of the promoter was cloned which include exon -1 (+1 to 
+173) within it but it was 27 bp less than exon -1 (+1 to +200) sequence reported by 
(Raguz et al. 2008), but the clone contains the genomic fragment (-350 to +1) which 
contains all elements necessary for promoter activity (Raguz et al. 2008). Raguz 
group had developed a highly sensitive PCR method for detecting transcripts derived 
from the MDRl USP to detect MDRl expression in a panel of RNAs isolated from 
healthy human tissues including peripheral blood mononuclear cells (PBMCs) and 
they found the highest levels of MDRl-USP derived transcripts were detected in adult 
and foetal brain, prostate, testis, thyroid gland and uterus. RNA derived from adult or 
foetal liver, heart, kidney, skeletal muscle, trachea and peripheral blood mononuclear 
cells did not express MDRl USP-derived transcripts (or they were below the 
detection level of the assay) and previously they reported a low frequency of MDRl 
USP activation in normal breast tissues. Interestingly, tissue-specific promoter usage 
was observed in some tissues such as adrenal gland and PBMCs, where no MDRl 
USP-derived transcripts, but high levels of DSP-derived MDRl mRNA, were 
detected (Raguz et al. 2008). And finally, about 1 kb of the MDRl sequence that has 
been identified previously (Geick et al. 2001) as an enhancer region has been cloned. 
This I kb fragment includes the potential regulatory cluster at about -8 kb upstream 
the transcription start site and includes the cluster from -7864 to -7817 which contains 
several nuclear receptor binding motifs to which PXR binds.
After the successful cloning of the MDRl two promoters, a validation of their basal 
and induced expression is essential. Reporter genes are used to define a gene with a 
readily measurable phenotype that can be distinguished easily from a background of 
endogenous proteins. Because of its activity and easy detectability, the technology of 
using reporter genes has been commonly applied in many areas such as drug selection 
and promoter activity analysis (Xue et al. 2007). A reporter gene assay has been used 
in this project to study the activity of MDRl gene and to study its coordinate 
regulation with CYP3A4 gene. A reporter gene assay was carried out in Huh7, Caco-2 
and A549 cells. Although PXR expression levels in the three cell lines are much 
lower than in vivo (as shown in chapter 3), the cell lines were selected as in vitro 
models to understand the control mechanisms underlying MDRl transcription and
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thereby determine the coordinate regulation of MDRl and CYP3A4 in the three cell 
lines.
On the basal level MDRl downstream promoter proven to be a strong promoter 
inducing SEAP expression at a higher level than the SV40 promoter, its basal level 
was much higher than CYP3A4 and the upstream promoter in the three cell lines. 
SEAP activity from a reporter carrying the MDRl DSP was ~36 fold higher than that 
from MDRl USP in Huh7, -17 fold higher in Caco-2 and -47 higher in A549 cells, 
indicating that in Huh7, Caco-2 and A549 cells MDRl USP is weaker than the DSP. 
The results of the MDRl downstream promoter is in consistent with previously 
published results which showed that MDRl downstream promoter is the major 
promoter in normal tissues and many cell lines. The activity of the MDRl 
downstream promoter (dsp) is repressed by over-expression of PXR, confirming a 
role for this factor in regulation MDRl gene expression.
In summary, the basal expression of MDRl downstream promoter is higher than both 
CYP3A4 gene and MDRl upstream promoter in the three cell lines and its expression 
was down-regulated with over expressing PXR which allow us to ftirther examine the 
effect of overexpressing other receptors on MDRl regulation. MDRl has been 
believed to be regulated by a variety of tissue-specific transcription factors, however, 
several transcription factors implicated in the regulation of the MDRl gene belong to 
general transcription factors that also regulate many other genes (Chen et al. 2004). 
Therefore, the two MDRl promoter expression needs to be examined with response to 
transcription factors in the three cell lines, as transcription factors have been shown to 
be the key mediators of drug-induced changes in phase 1 and phase 11 metabolizing 
enzymes as well as phase 111 transporters involved in efflux mechanisms. First, we 
investigated the effects of these ligand activated transcription factors (LATFs): PXR, 
GRa, CAR, PPARa, VDR and RXRa on the activity of MDRl promoters alone 
without the enhancer fused to the promoter plasmid; this was done to study the effect 
of the transcription factors on the promoter itself and to compare the results between 
the three cell lines and later to compare the differences between the promoter and 
promoter enhancer expression in the three cell lines. In Huh7 cells, PXR, GRa, CAR, 
PPARa and VDR over expression resulted in down regulations for both promoters 
and it was statically significant. Over expressing RXRa caused up-regulation of both 
MDRl promoters and the same pattern was observed in A549 cells. But in Caco-2 
cells over expressing of RXRa caused down regulation in MDRl downstream
152
promoter and up regulation in upstream promoter but this was not statically 
significant. The retinoids are known to be involved into the regulation of the cell 
growth, differentiation and apoptosis. Retinoids act via two families of receptors 
RARs (RARa, RARp, RARy) and RXRs (RXRa, RXRp, RXRy) (Stromskaya et al. 
2005). RARa gene overexpression in leukemic cells could results in MDR 
(Stromskaya et al. 2005). RXRa is noticeably abundant in liver, kidney, lung, spleen 
and muscle and expression is also observed in heart, brain, intestine, testes and 
adrenal glands. RXR can form heterodimers with RAR and with many other nuclear 
receptors such as VDR, PXR and CAR, allowing binding to their respective response 
elements. Because RXRs have a broad binding ability with most other orphan nuclear 
receptors and affect the subsequent regulation of their target genes so the RXRs are 
involved in the regulation of most drug metabolizing enzymes and transporter directly 
or in directly (Xu et al. 2005). A number of studies have suggested a role of 
glucocorticoids in the transcription of MDRl homologues but the responses appear to 
be cell type specific; MDRl transcription can also be repressed by GR in some cell 
types (Scotto 2003). Similar results to what we got in the three cell lines in which 
MDRl expression was repressed by overexpressing GR. The MDRl upstream 
promoter expression in Caco-2 was slightly increased after co-expressing with 
PPARa, VDR and RXRa, which is different from the pattern seen in the other cell 
lines. These data imply that RXRa up regulate MDRl gene expression in Huh? and 
A549 cells but not in Caco-2 which further implies that this effect is tissue specific. 
The second investigation was done with MDRl downstream and upstream promoter 
plasmids with the enhancer cloned upstream of each promoter. The liver enriched 
HNF4a and the following ligand activated expression plasmids were used: PXR, 
GRa, CAR, PPARa, VDR, ERa and RXRa. In Huh7, over expression with HNF4a, 
PXR, GRa, CAR, PPARa, VDR, ERa, RXRa and PXR+RXRa resulted in down 
regulation of MDRl downstream promoter expression. Similar pattern was observed 
in A549 cells for the MDRl upstream promoter. Interestingly, over expression of 
CAR in Huh? and in Caco-2 resulted in up regulation of MDRl upstream promoter in 
Huh? and up regulation of both promoters in Caco-2 cells. The constitutive 
androstane receptor (CAR; NRH3) belongs to the same nuclear receptor family as 
PXR, and shares the same heterodimerisation partner RXRa. In contrast to PXR, and 
indeed almost every other LATF, CAR is constitutively active in cell lines. CAR is 
expressed abundantly in the liver with expression also observed in the small intestine,
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lung, heart and muscle. (Burk et al. 2005) demonstrated by gel shift and transfection 
experiments that CAR plays a role in the regulation of intestinal MDRl expression by 
binding to distinct receptors response elements in the -7.8 kbp enhancer of MDRl and 
transactivates MDRl expression through DR4 motifs to which the receptor binds as a 
heterodimer with RXR or as a monomer, respectively. Both MDRl promoters have 
been up regulated in Caco-2 cells after overexpressing CAR in our work. On the other 
hand, over expression of HNF4a (HNF4a, NR2A1) in Huh7 resulted in up regulation 
of the MDRl upstream promoter and down regulation of the downstream promoter. 
The opposite pattern was seen in A549 cells while in Caco-2, HNF4a over expression 
enhanced up regulation of both MDRl promoters. HNF4a is a liver-enriched nuclear 
receptor with a crucial role in hepatocyte differentiation and maintenance of hepatic 
gene expression. HNF4a is most highly expressed in liver and intestine tissues also 
abundantly express drug metabolizing enzymes and drug transporters. HNF4a is a 
master transcriptional regulator for a large number of genes in hepatocytes and 
pancreatic cells. HNF4a is central to cholesterol and glucose/energy metabolism 
because it is a key activator for basal hepatic expression of CYP7A1 and CYP8B1 
genes and glucose-6-phosphotase and PEPCK genes, which play central role in bile 
acid biosynthesis and hepatic gluconeogenesis, respectively. These genes all contain 
functional HNF4a-binding sites in promoter and mutation of these sites substantially 
disrupt promoter activity (Bhalla et al. 2004). A functional binding site for HNF4a 
was identified in the XREM of the CYP3A4 distal promoter, which enhanced both 
PXR and CAR mediated basal and drug induced of CYP3A4 gene expression (Tirona 
et al. 2003). A putative molecular mechanism for the induction of PXR by HNF4a 
was proposed by (Kamiya et al. 2003) who showed that HNF4a binds to the proximal 
promoter of the PXR. (Tegude et al. 2007) have identified two previously unknown 
HNF4a binding sites in two widely separated regions, which mediate HNF4a 
dependent transactivation within the CYP3A4 5’ upstream regulatory sequence and 
their results support the hypothesis that HNF4a is directly regulating basal CYP3A4 
expression at least in intestine. Our in silico analysis (data not shown), identified a 
putative transcription factor binding site for HNF4a within the MDRl enhancer 
sequence, whether this site is functional needs to be further examined.
The reported co-induction of CYP3A4 and MDRl and the involvement of PXR in 
xenobiotic induction of these two genes prompted us to investigate whether PXR is 
also involved in induction of MDRl in Huh7, Caco-2 and A549 cell lines. Rifampicin
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has been shown to significantly decrease oral drug bioavailability of P-gp substrates 
due to induction of intestinal P-gp expression (Kota et al. 2010). Treatment of the 
three cell lines with 50 pM rifampicin induced both CYP3A4 and MDRl promoters 
and this induction took place after co-transfecting with PXR expression plasmid. This 
provides evidence that PXR is probably the factor responsible for induction of MDRl 
in the three cell lines. Of particular interest is the high fold induction of the three 
promoters in the A549 cell line at 50 pM rifampicin, which suggests that a host cell- 
specific effect is mediating the response, and that this factor(s) is present in A549, but 
not be at the same level in Huh7 and Caco-2 cells. This increase induction seen in 
A549 cells could be due to glucocorticoid receptor (GR) as described in section 4.6 as 
A549 cells express GR. The glucocorticoid receptor (GR, NR3C1) can induce 
expression of PXR and CAR and their heterodimeric partner RXR in cultured cells 
(Pascussi et al. 2000), (Pascussi et al. 2000). The results presented here provide 
evidence that a similar mechanism is responsible for induction of CYP3A4 and 
MDRl. Many studies have revealed that pregnane X receptor (PXR, NR1I2) can 
function as a master regulator to control the expression of phase I and phase II drug- 
metabolizing enzymes as well as some members of the drug transport family, 
including multiple drug resistance 1 (MDRl). (Masuyama et al. 2005) reported that 
PXR ligands enhanced PXR-mediated transcription in a ligand and promoter 
dependent fashion, which in turn differentially regulated the expression of individual 
PXR targets especially CYP3A4 and MDRl in endometrial cancer. In the next 
chapter, we tested the hypothesis whether selected polychlorinated biphenyls (PCBs) 
compounds have the potential to alter the expression of CYP3A4 and MDRl genes 
via pregnane X receptor (PXR).
4.8 Summary
In summary, the regulation of MDRl basal gene transcription is a complex process 
and the two promoters activities were different in different tissues. Tissue and cell line 
specific expression of unknown factor may encounter for the differences observed 
between the cell lines. It seems that this influence could depend on the cell context. 
Indeed the regulation of the metabolizing enzymes and xenobiotic transporters is very 
complex on a molecular level and some genes are regulated preferentially by a single 
nuclear receptor while others are co-regulated by multiple nuclear receptors.
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5 Coordinate Regulation of CYP3A4 and MDRl in Response 
to Polychlorinated Biphenyls (PCBs)
5.1 Introduction
A large variety of synthetic chemicals have entered the environment in the last 
decades due to their use in industrial, agricultural and household applications. The 
entry of these chemicals into the environment can be intentional such as pesticides or 
herbicides or unintentional such as polybrominated diphenyl ethers (PBDEs), 
polychlorinated dibenzo-p-dioxins (PCDDs) and polychlorinated biphenyl (PCBs). 
These compounds have entered the environment by leakage or leaching during the 
product’s lifetime or after disposal or by-products of the industrial manufacturing or 
combustion process. Polychlorinated biphenyls (PCBs) are members of halogenated 
aromatic group of environmental pollutants that have been identified worldwide in 
diverse environmental matrices (Safe 1994). There are 209 PCBs congeners and their 
biological and toxic effects depend on their chlorination pattern (Safe 1984), (Safe 
1994). Among the 209 PCBs (McFarland and Clarke 1989) suggested 36 congeners to 
be environmentally threatening due to their environmental prevalence, relative 
abundance in animal tissues and potential toxicity. These 36 PCBs are listed in table 
5.1.
Table 5.1 Environmentally important PCBs
PCB 18 PCB 74 PCB 105 PCB 128 1 PCB 158 1 PCB 180
; PCB 37 PCB 77 : PCB 114 1 PCB 138 1 PCB 167 1 PCB 183
i PCB 44 ! PCB 81 PCB 118 1 PCB 151 1 PCB 168 1 PCB 187
PCB 49 PCB 87 PCB 119 ; PCB 153 PCB 169 PCB 189
PCB 52 PCB 99 PCB 123 1 PCB 156 PCB 170 PCB 194
PCB 70 PCB 101 : PCB 126 1 PCB 157 PCB 177 PCB 201
(Adapted from McFarland and Clarke 1989)
Numbering of congeners in this thesis follows the International Union of Pure and 
Applied Chemists (lUPAC). lUPAC number, structure and isomer group for each
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congener are given in Appendix 8. The system for numbering and the nomenclature 
{ortho-, meta-, para-) convention for the biphenyl is shown in figure 5.1.
Figure 5.1 Structure and positional nomenclature (A) and numbering (B) for 
biphenyl
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PCBs have been structurally divided into three groups: non-ortho PCBs with dioxin­
like properties and a co-planar configuration, mono-ortho- substituted PCBs with 
some dioxin-like properties and a multiple-ortho- substituted PCBs with a non-planar 
configuration and no or very low affinity for the aryl hydrocarbon receptor (AhR) , 
consequently lacking dioxin-like effects. Technical PCB products are complex 
mixtures containing over 50 individual PCB congeners with different chemical 
structures and physiochemical properties. Exposure to those chemicals nearly always 
occurs from mixtures rather than from individual PCBs. Human populations have 
been exposed to PCBs via three major pathways, i.e., environmental exposure of 
populations through contaminated food, air and water, occupational exposure of 
workers who produced PCBs or utilized PCB-containing products and accidental 
exposure of individual (Safe 1984). The human health effects observed after exposure 
to PCBs include liver disorders (elevated hepatic enzymes), elevated blood lipids, and 
gastrointestinal cancers. The most frequently detected à\-ortho- chlorine substituted 
PCBs in general populations are 138, 153 and 180 (Safe 1994; Patterson et al., 1994). 
Because of its predominance, PCB 153 has been used as a marker of exposure for the 
other PCBs. Depending on their structures, PCB congeners bind to different cellular
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target sites, and thus cause adverse effects by different mechanisms. For example, 
PCB congeners with zero or one ortho-chlorine substituent can bind to the aryl 
hydrocarbon receptor (AhR receptor), thus mimicking the action of 2,3,7,8- 
tetrachlorodibenzo-p-dioxin (TCDD) (Safe 1994). These dioxin-like PCB congeners ( 
such as PCB 77 , 126 and 169) are the most toxic congeners and are of particular 
regulatory interest because of their mammalian and human toxicity, which appears to 
be mediated primarily via the AhR receptor (Shaikh et al. 2008). PCB congeners with 
ortho chlorine substituents can bind to the constitutive androstane receptor (CAR) 
and/or the pregnane X receptor (PXR) (Schuetz et al. 1998), (Jacobs et al. 2005) and 
they are called phénobarbital (PB)-type PCBs (for example PCB 87, 99, 153, 180, 183 
and 194). PCB 153 has been utilized as a prototypical “ PB-type” inducer. Other 
ortho substituted PCB congeners interact with both the aryl hydrocarbon (AhR) and 
the CAR receptor and they are called mixed type PCBs (for example, PCB 128, 138, 
170). It is assumed that PB-like PCBs induce CYP3A4 in humans by activation of the 
human pregnane X receptor (hPXR). The pregnane X receptor (PXR) is regarded as 
the master regulator of the mammalian xenobiotic response. PXR is activated by an 
array of structurally distinct endogenous and xenobiotic compounds that vary in size 
from small compounds such as phénobarbital (232 Da) to large drugs like the 
macrocyclic rifampicin (823 Da). In addition, PXR can be activated by a variety of 
chemically distinct ligands in a species dependent manner including endogenous 
hormones such as pregnenolone and progesterone and their synthetic derivatives such 
as pregnenolone 16 a-carbonitrile (PCN), rifampicin, dexamethasone, corticosterone, 
phénobarbital and hyperforin (the active constituent of St. John’s wort (Jacobs et al.
2003). The hPXR is activated by a wide variety of lipophilic compounds including 
agents that induce CYP3A4 and CYP2B6 (Lemaire et al. 2004). After activation, 
hPXR binds to specific DNA sequence motifs in the CYP3A4 gene and function as a 
transcription factor for gene regulation. PXR regulates the metabolism and 
elimination of steroids, bile acids and xenobiotics from the body. Species differences 
in PXR ligand activation have been well documented, for example; rifampicin 
activates human and rabbit PXR but had virtually no activity on the mouse and rat 
PXR. The sequence of the PXR ligand binding domain differs between species; 
therefore it is importance to test compounds in human derived cell lines, since there 
could be large inter-species variability in this mechanism of action. The PB-like 
properties of PCBs were examined by looking at the possible induction of CYP3A4
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and MDRl through the human pregnane X receptor (hPXR) in transiently transfected 
Huh7, Caco-2 and A549 cell lines. In this chapter, we have assessed the ability of 
individual PCBs (PCB 99, 138, 153, 180, and 194) and the non-ortho PCB 77 to 
interact with CYP3A4 and MDRl genes in human Huh7, Caco-2 and A549 cell lines. 
Efforts to elucidate the molecular structures of individual PCB congeners are 
extremely desirable because of the relationship between their three dimensional 
structures and their toxicity.
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5.2 Assessment of Compounds Toxicity by the Lactate 
Dehydrogenase Release Assay
Lactate dehydrogenase (LDH) is a cytosolic enzyme present within all mammalian 
cells. The normal plasma membrane is impermeable to LDH, but damage to the cell 
membrane results in a change in the membrane permeability and subsequent leakage 
of LDH into the extracellular fluid. In vitro release of LDH from cells provides an 
accurate measure of cell membrane integrity and cell viability as a consequence LDH 
has proven to be an extremely useful in vitro marker for cellular toxicity. It is an 
important control whenever cells are dosed with a potentially toxic chemical is to 
ensure that the concentration used does not lead to high levels of cell death which is 
achieved through measuring the LDH activity in medium. To confirm that the 
compounds used in this work did not cause any cellular toxicity; Huh7, Caco-2 and 
A549 cells were first dosed with the tested compounds according to the dosing 
scheme for the reporter gene assay and assayed for lactate dehydrogenase (LDH) 
release. The media was checked for the presence of LDH. No statically significant 
increase in LDH was seen when cells were dosed with compounds compared to 
control, so none of the compounds tested were toxic in incubations up to 48 hrs by the 
LDH assay as illustrated in figures 5.2-5.4. In untreated cells a small degree of cell 
death was seen over the culture time. The DMSO (vehicle) control samples show no 
significant effect on LDH release compared to untreated cells across all cell lines, 
demonstrating that it has no affect on cell viability. All other drugs caused minor cell 
death. As positive control, untreated cells were subjected to complete lysis as induced 
by addition of Triton X-100 (2 %) and set as 100% LDH release.
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Figure 5.2 Effect of exposure of test compounds on cultured Huh? cell viability
by LDH assay
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Toxicity o f all compounds used in transfection assays was assessed by LDH release assay. 
Huh? cells were incubated with compound in growth medium at the maximum dose used in 
transfection assays. Medium was removed for assay and fresh medium containing control or 
compound replaced. Values are percentage o f total LDH release as induced by incubation 
with 2% Triton X-100 in growth medium for 10 minutes. These results are the mean for four 
biological repeats (n=4). R if = rifampicin, PB = phénobarbital and prog = progesterone.
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Figure 5.3 Effect of exposure of test compounds on cultured Caco-2 cell viability
by LDH assay
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Toxicity o f all compounds used in transfection assays was assessed by LDH release assay. 
Caco-2 cells were incubated with compound in growth medium at the maximum dose used in 
transfection assays. Medium was removed for assay and fresh medium containing control or 
compound replaced. Values are percentage o f total LDH release as induced by incubation 
with 2% Triton X-100 in growth medium for 10 minutes. These results are the mean for four 
biological repeats (n=4). R if = rifampicin, PB = phénobarbital and prog = progesterone.
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Figure 5.4 Effect of exposure of test compounds on cultured A549 cell viability
by LDH assay
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Toxicity o f all compounds used in transfection assays was assessed by LDH release assay. 
A549 cells were incubated with compound in growth medium at the maximum dose used in 
transfection assays. Medium was removed for assay and fresh medium containing control or 
compound replaced. Values are percentage o f total LDH release as induced by incubation 
with 2% Triton X-100 in growth medium for 10 minutes. These results are the mean for four 
biological repeats (n=4). R if = rifampicin, PB = phénobarbital and prog = progesterone.
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5.3 Effect of Polychlorinated Biphenyls (PCBs) on CYPlAl mRNA 
Expression in Three Mammalian Cell Lines
Our initial investigation in polychlorinated biphenyls (PCBs) research involved 
studying the effect of the selected PCBs on induction of mRNA levels of CYPlAl 
gene in liver, intestine and lung cells; we were interested in PCBs because they were 
an important group of environmental contaminants. Much interest has centred on 
CYPlAl because of the ability of CYPlAl to activate a large group of environmental 
compounds such as the polycyelie aromatic hydrocarbons (PAH), benzo[a]pyrene and 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) to biologically reactive metabolites that 
interact with DNA resulting in chemical carcinogenesis. CYPlAl is eonstitutively 
expressed in human enteroeytes at relatively low levels. However, it should be 
remembered that CYPlAl expression is highly enhanced after exposition to chemical 
inducers and this modulates cellular susceptibility to procarcinogens (Scree et al.
2004). CYPlAl is mainly regulated by the aryl hydrocarbon receptor (AhR), a ligand- 
activated transcription factor that can be found in the cytoplasm of almost all 
vertebrate cells and plays a pivotal role in mediating the biological actions of a 
number of highly toxic chemicals including polyehlorinated-dibenzo-/>-dioxin (of 
which 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD; dioxin) is a prototype ligand), 
polychlorinated-dibenzofurans, eoplanar biphenyls and polycyelie aromatic 
hydrocarbons (PAHs), such as benzo[a]pyrene and 3-methyIcholanthrene (MC). Upon 
binding of a ligand to this receptor, the ligand: AhR complex migrates to the nucleus 
of the cell where it forms a dimer with Amt (the AhR nuclear translocator). The AhR 
and Arnt form a heterodimer and then bind to specific DNA recognition sites referred 
to as Ah-response elements (AhRE, XRE: xenobiotie response element or DRE: 
dioxin response element) located in the 5’-flanking region of target genes (Anderson 
et al. 2006). CYPlAl enhances the detoxification of lipophilic substrates (many of 
which are AhR ligands) that might otherwise accumulate to toxic concentrations in a 
cell. Induction of CYPlAl only occurs when necessary, upon removal of the stimulus 
which is the ligand by metabolism, CYPlAl gene expression is no longer 
upregulated. Six congeners had been selected from table 5.1 to test their induction on 
CYPlAl gene. Table 5.2 shows the PCBs used in this project and figure 5.5 shows 
the chemical structures of the PCBs used in our study. CYPlAl induction had been 
examined by RT-PCR (TaqMan). The same protocol as in section 2.2.4.1 was used;
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where primer and probe sets for QRT-PCR were designed to amplify CYPlAl gene. 
HuH7, Caco-2 and A549 cells were exposed for 48 hrs to 10 pM of rifampicin, 500 
pM of phénobarbital or 10 pM of PCBs: 77, 99, 138, 153, 180, 194 and vehicle (0.1 
% DMSO). cDNA was synthesised from extracted total RNA, and QRT-PCR 
reactions performed using an ABlPrism 7000 Sequence Detection System. All PCBs 
were prepared in DMSO.
Table 5.2 Names of PCBs and their molecular weight
N um ber FOB M W  (g/mol)
1 3,3',4,4'-Tetrachlorobiphenyl (PCB 77) 291.99
2 2,2',4,4',5-Pentachlorobiphenyl (PCB 99) 326.432
3 2,2',3,4,4',5'-Hexachlorobiphenyl (PCB 138) 360.88
4 2,2',4,4',5,5'-Hexachlorobiphenyl (PCB 153) 360.876
5 2,2', 3,4,4', 5,5'-Heptachlorobiphenyl (PCB 
180)
395.30
6 2,2',3,3',4,4',5,5'-Octachlorobiphenyl (PCB 
194)
429.766
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Figure 5.5 Structures of the PCBs used in this study; PCB 77,99,138,153,180 
and 194
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The effect of polychlorinated biphenyls (PCBs) on induction of CYPlAl mRNA 
expression in the three cell lines is illustrated in figures 5.6-5.8. Of eight chemicals 
examined, only PCB 77 caused statistically significant induction in CYPlAl mRNA 
expression level in the three cell lines following exposure to 10 pM PCB 77 compare 
to the control DMSO. The higher fold induction was seen in Caco-2 cells. No 
statically significant induction of CYPlAl was observed in liver, intestine and lung 
cells after 48 hours exposure to the other chemicals. Ten micromolar rifampicin and 
500 pM phénobarbital were used as negative control. PCB 77, which is a dioxin-like 
PCB congener, is a co-planar compound and is known to induce CYPlAl through 
AhR-dependent mechanisms which indicate that CYPlAl induction (via AhR 
receptor activation) is maintained in these three cell types and this is in agreement 
with the previous work done in section 3.4.5 where P-naphthoflavone has induced 
CYPlAl mRNA expression . Our results confirm previous findings that PCB 77 can 
binds and activates AhR and induce CYPlAl. In contrast, none of the non-coplanar 
PCBs used were able to signicantly increase the level of CYPlAl.
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Figure 5.6 C Y PlA l mRNA expression in Huh7 ceils following PCBs exposure
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Total RNA was extracted from Huh? cells following 48 hours exposure to 10 pM rifampicin, 
500 pM phénobarbital or 10 pM o f PCBs: 77, 99, 138, 153, 180 and 194. RNA samples were 
converted to cDNA and quantitative PCR was used to determine transcript levels for 
C Y P lA l. Values are expressed as % o f control after GAPDH normalisation. Error bars 
represent standard error o f the mean for three biological repeats (n=3). The statistical 
significance o f changes in mRNA expression in treated cells compared with vehicle control 
(0.1% DM SO) was determined where *** represents p<0.001 as determined by a one-way 
ANOVA with Bonferonni multiple comparison post hoc test.
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Figure 5.7 C YPlA l mRNA expression in Caco-2 cells following PCBs exposure
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Total RNA was extracted from Caco-2 cells following 48 hours exposure to 10 pM 
rifampicin, 500 pM phénobarbital and 10 pM  o f PCBs: 77, 99, 138, 153, 180 and 194. RNA 
samples were converted to cDNA and quantitative PCR was used to determine transcript 
levels for C Y P lA l. Values are expressed as % o f control after GAPDH normalisation. Error 
bars represent standard error o f the mean for three biological repeats (n=3). The statistical 
significance o f changes in mRNA expression in treated cells compared with vehicle control 
(0.1% DMSO) was determined where *** represents p<0.001 as determined by a one-way 
ANOVA with Bonferonni multiple comparison post hoc test.
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Figure 5.8 C Y PlA l mRNA expression in A549 cells following PCBs exposure
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Total RNA was extracted from A549 cells following 48 hours exposure to 10 pM rifampicin, 
500 pM phénobarbital and 10 pM o f  PCBs: 77, 99, 138, 153, 180 and 194. RNA samples 
were converted to cDNA and quantitative PCR was used to determine transcript levels for 
C Y P lA l. Values are expressed as % o f control after GAPDH normalisation. Error bars 
represent standard error o f the mean for three biological repeats (n=3). The statistical 
significance o f changes in mRNA expression in treated cells compared with vehicle control 
(0.1% DMSO) was determined where *** represents p<0.001 as determined by a one-way 
ANOVA with Bonferonni multiple comparison post hoc test.
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5.4 Effect of PCBs on Transcriptional Activation of CYP3A4 and
MDRl Genes by Reporter Gene Assay
The impact of individual PCB congeners (PCB 77, 99, 138, 153, 180 and 194) to 
induce human CYP3A4 and MDRl through activation of the human pregnane X 
receptor (hPXR) was next investigated. CYP3A4 co-transfected with PXR expression 
plasmid and each of MDRl promoter with PXR expression plasmid were transfected 
into Huh7, Caco-2 and A549 cells; then dosed on the following day with 10 pM 
rifampicin, 500 pM phénobarbital, 10 pM of PCBs or 0.1 % DMSO (vehicle control) 
for a 48 hour period. The results for the dosing experiments are shown in figures 5.9- 
5.11. The induction of CYP3A4 co-transfected with the PXR expression plasmid with 
10 pM rifampicin and 500 pM phénobarbital were used as a positive control in the 
three cell lines understudy. Phénobarbital (PB) and rifampicin are classic inducers of 
CYP2B and CYP3A gene expression. Phénobarbital is a ligand for both PXR and 
CAR (Moore et al. 2000).
In Huh7 cell line, rifampicin and phénobarbital activated expression of CYP3A4 
reporter gene by 10 and 6 fold respectively compared to vehicle control (0.1% 
DMSO). On the other hand, no effect was observed for both the downstream or 
upstream MDRl promoter reporters after dosing with rifampicin and phénobarbital. 
Next, the effect of each PCB for their ability to induce CYP3A4 and MDRl 
promoters was tested. Only PCB 153 gave statically significant increase on CYP3A4 
gene expression with a 7.6 fold induction compared to the vehicle control (figure 5.9). 
All other PCBs tested had no effect on the three reporter genes examined.
In Caco-2 cell line, again both rifampicin and phénobarbital increased CYP3A4 
reporter gene expression by 9 and 4 fold respectively compared to control. They also 
significantly activated the MDRl upstream promoter reporter by 2.5 and 3.5 fold 
respectively compared to the control. PCB 153 was again able to increase CYP3A4 
reporter gene activity by 5.6 fold compared to vehicle control, and also increased the 
MDRl upstream promoter activity by 3.8 fold compared to vehicle control. But PCB 
153 had no effect on the MDRl downstream promoter. Among the other PCBs, PCB 
194 produced a significant 2.6 fold increase in CYP3A4 reporter gene expression but 
had no effect on the other MDRl reporter genes (figure 5.10).
Finally, in A549 cell line, the effects were of smaller magnitude compared to the other 
tested cell lines. Unlike what has been observed before, rifampicin did not increase
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CYP3A4 reporter gene expression but on the other hand has increased MDRl 
upstream promoter expression by 3 fold change compared to vehicle control. In 
comparison, phénobarbital had significantly increased CYP3A4 reporter gene 
expression by 4.3 fold compared to control but had no effect on either MDRl reporter 
gene expression. Both PCB 138 and PCB 153 increased CYP3A4 reporter gene 
expression by 3.2 and 4 fold respectively compared to control. Both PCB 153 and 
PCB 180 increased expression of MDRl reporter gene, where PCB 153 showed a 
pattern similar to its induction in Caco-2 as it increased the upstream prompter 
reporter by 3.5 fold compared to control vehicle while PCB 180 increased the 
downstream promoter reporter by 3 fold compared to DMSO control (figure 5.10).
The different PCBs gave different response in the three cell lines. There was no 
overall pattern seen in the three cell lines after dosing with the tested PCBs except for 
PCB 153, in which an induction in CYP3A4 was observed in all three cell types and 
the higher fold induction was seen in Huh? ~8 fold, while in Caco-2 ~6 fold and in 
A549 it was 4 fold. The overall pattern observed with dosing with PCB 153 in the 
three cell lines is similar to the dosing scheme with the positive control phénobarbital. 
In summary, the transfection results presented in this section indicate that there are a 
chemical specific effect and tissue specific effect. In addition this study demonstrates 
clearly that CYP3A4 induction by the di-ortho chlorine substituted conger PCB 153 is 
consistent in the three different cell lines understudy.
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Figure 5.9 Effect of PCBs on transcriptional activation of CYP3A4 and MDRl in 
Huh?
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Huh? cells were transfected with a SEA? reporter gene under the control o f  the CYP3A4 and 
M DRl downstream (dsp) or upstream (usp) regulatory regions. Cells were then exposed to 
0.1% DMSO (vehicle control), 10 pM rifampicin, 500 pM  Phénobarbital and lOpM o f  PCBs 
for 48 hours, SEAP activity was measured, corrected for transfection efficiency and presented 
as fold induction relative to vehicle control. Each data point represents n=6 and statistical 
analysis was done via one way ANOVA where *** represents p<0.001 relative to vehicle 
control.
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Figure 5.10 Effect of PCBs on transcriptional activation of CYP3A4 and MDRl
in Caco-2
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Caco-2 cells were transfected with a SEAP reporter gene under the control o f  the CYP3A4 
and M DRl downstream (dsp) or upstream (usp) regulatory regions. Cells were then exposed 
to 0.1% DMSO (vehicle control), 10 pM rifampicin, 500 pM Phénobarbital and lOpM of 
PCBs for 48 hours, SEAP activity was measured, corrected for transfection efficiency and 
presented as fold induction relative to vehicle control. Each data point represents n=6 and 
statistical analysis was done via one way ANOVA where * represents p<0.05, ** p<0.01 and
*** p<0.001.
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Figure 5.11 Effect of PCBs on transcriptional activation of CYP3A4 and MDRl
in A549
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A549 cells were transfected with a SEAP reporter gene under the control o f the CYP3A4 and 
M DRl downstream (dsp) or upstream (usp) regulatory regions. Cells were then exposed to 
0,1% DMSO (vehicle control), 10 pM rifampicin, 500 pM Phénobarbital and lOpM o f PCBs 
for 48 hours, SEAP activity was measured, corrected for transfection efficiency and presented 
as fold induction relative to vehicle control. Each data point represents n=6 and statistical 
analysis was done via one way ANOVA where * represents p<0.05 and ** p<0.01.
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5.5 Reporter Gene Assay for the Assessment of PCBs on the Human 
PXR Gene Expression
The nuclear pregnane X receptor (PXR; NR 112) is an important component of the 
body’s adaptive defence mechanism against toxic substances including foreign 
chemicals (xenobiotics) (Kliewer et al. 2002). Due to its importance role as a master 
regulator in the regulation of phase I (cytochrome P450), phase II (conjugating) and 
phase III (ABC family transporters) (Tabb et al. 2004) we next examined the effects 
of the six PCBs on the regulation of the human PXR gene expression. The 2.2 kb 
region of human PXR proximal promoter was cloned from human genomic DNA and 
confirmed by sequencing, and then a SEAP hPXR proximal promoter reporter gene 
construct was prepared in our laboratory by Dr. Sihem Aouabdi. (Aouabdi et al. 2006) 
identified putative binding sites, as shown in figure 5.12, for factors involved in the 
general transcription process particularly the TATA binding protein and putative 
binding sites for transcription factors associated with maintaining the basal expression 
of genes. The factors identified in this group were the hepatic nuclear factors (HNF 
la, 4a, SP), CCAAT enhancer binding protein (C/EBPa), CCAAT, specificity protein 
1 (SPl) and tumour suppressor protein p53. In addition, a large number of ligand 
activated transcription factors including vitamin D receptor (VDR), glucocorticoid 
receptor (GRa), progesterone receptor (PR), BARBIE box, aryl hydrocarbon receptor 
(AhR), the peroxisome proliferator activated receptor alpha (PPARa) and the 
famesoid X receptor (FXR) were identified. This suggest that the PXR proximal 
promoter is a complex promoter with binding sites for many regulatory transcription 
factors, consisting with the paradigm of PXR as a master xenobiotic/metabolite sensor 
capable of responding to many different stimuli (Aouabdi et al. 2006). The construct 
containing the PXR promoter cloned into the SEAP reporter plasmid was transfected 
into the three cell lines and the six PCBs were examined by this reporter assay to 
identify as to whether or not they could increase the PXR dependent transcriptional 
activity. Progesterone was used as a positive control since progesterone is an activator 
of PXR (Kliewer et al. 1998) and substrate for the CYP3A4 enzyme (Gibson et al. 
2002). As a result of this reporter analysis, progesterone substantially induced the 
SEAP activity in Huh? and A549 cells with a six fold induction (Figure 5.13 and 
Figure 5.15). On the other hand, dosing with 10 pM progesterone in Caco-2 cell line 
which is illustrated in Figure 5.14 did not cause activation of PXR.
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The effect of PCBs on PXR-dependent transcriptional activity in the three cell lines 
was examined. In Huh? cells, PCB ??, 99, 180 and 194 induced PXR gene expression 
with the respective net fold 4, 6, 3 and 2. PCB 99 gave the highest induction which is 
equivalent to progesterone; the positive control used, while PCB 138 and 153 had no 
such inducing effect. In Caco-2 cells, all the tested PCBs had no inducing effect on 
PXR promoter. Finally, in A549 cells, two PCBs, PCB 99 and 194 induced PXR gene 
expression and PCB 194 gave a 10.3 fold induction which is higher than the positive 
control and their induction profile is opposite to that in HuH? cells. No induction was 
observed after dosing with PCBs ??, 138, 153 and 180. PCB 153 which had induced 
the CYP3A4 promoter in Huh?, Caco-2 and A549 in section 5.4 and it induced both 
MDRl promoters after co-transfecting with PXR did not induce the PXR gene 
expression itself. Unfortunately, statistical analysis could not be done to these graphs 
due to the loss of the original data.
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Figure 5.13 Effect of PCBs on transcriptional activation of hPXR in Huh?
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Huh? cells were transfected with the 2.2 kb hPXR reporter gene before being exposed to 0.1% 
DMSO (vehicle only) and 10 pM  progesterone and PCBs. SEAP activity was measure 48 
hours post administration o f  chemicals as described in materials and methods. The level o f 
induction was assessed by measuring the luminescence from the reporter gene product. Data 
was adjusted for background luminescence and expressed as a net fold change. Each data 
point represents net fold change in which the fold induction o f  the reporter gene over DMSO 
(post/pre) is divided by the fold induction o f the expression plasmid over DMSO (post/pre) 
for 4 biological repeats (n=4). Results were eonsidered significant i f  the net fold induction is 
> to 2.
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Figure 5.14 Effect of PCBs on transcriptional activation of hPXR in Caco-2
oO)c
(0.c
O
2
ou_
Q>
O)o N o>N o>
CO 00
u Ü
0_ Q .
s s
3 3
O O
0 0 CO o
CO lO CO o >
CO CO CO CO
O Ü Ü Ü
o _ Q_ 0_ Û .
S s S s
3 3 3 3
O O O o
Caco-2 cells were transfected with the 2.2 kb hPXR reporter gene before being exposed to 
0.1% DMSO (vehicle only) and 10 pM progesterone and PCBs. SEAP activity was measure 
48 hours post administration o f chemicals as described in materials and methods. The level o f 
induction was assessed by measuring the luminescence from the reporter gene product. Data 
was adjusted for background luminescence and expressed as a net fold change. Each data 
point represents net fold change in which the fold induction o f  the reporter gene over DMSO 
(post/pre) is divided by the fold induction o f the expression plasmid over DMSO (post/pre) 
for 4 biological repeats (n=4). Results were considered significant if  the net fold induction is 
> to 2.
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Figure 5.15 Effect of PCBs on transcriptional activation of hPXR in A549
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A549 cells were transfected with the 2.2 kb hPXR reporter gene before being exposed to 0.1% 
DMSO (vehicle only) and 10 pM progesterone and PCBs. SEAP activity was measure 48 
hours post administration o f chemicals as described in materials and methods. The level o f 
induction was assessed by measuring the luminescence from the reporter gene product. Data 
was adjusted for background luminescence and expressed as a net fold change. Each data 
point represents net fold change in which the fold induction o f  the reporter gene over DMSO 
(post/pre) is divided by the fold induction o f  the expression plasmid over DMSO (post/pre) 
for 4 biological repeats (n=4). Results were considered significant if  the net fold induction is 
> to 2.
181
5.6 Discussion
Every day the body must defend itself against myriad xenobiotics that are either 
ingested in the diet, inhaled, or otherwise absorbed (Kliewer et al. 2002). An 
important way of the body to defend itself is by using cytochromes P450 (CYPs). The 
cytochromes P450 comprise a superfamily of heme-containg monooxygenases that 
play a crucial role in the metabolism of natural compounds and xenobiotics, including 
environmental pollutants and drugs.
Transcription of several of the CYP gene families is induced by xenobiotics. For 
example, the barbiturate phénobarbital (PB) and the antibiotic rifampicin are classic 
inducers of CYP2B and CYP3A gene expression, respectively (Moore et al. 2000). 
Two members of the nuclear receptor family of ligand-activated transcription factors, 
termed the pregnane X receptor (PXR; NR 112) and constitutive androstane receptor 
(CAR; NR 114) are expressed in the liver, intestine, lung and other tissues, where they 
have important roles in detecting xenobiotics and stimulating genes encoding 
cytochrome P450 (CYPs) and other proteins involved in their detoxification and 
elimination from the body (Honkakoski and Negishi 2000); (Waxman 1999).
Drug transporters play a crucial role in protecting the body from xenobiotics as well. 
Among drug transporters, the ATP-binding cassette (ABC) transporters are expressed 
in most tissues in human, and play protective roles; reducing drug absorption from the 
gastrointestinal tract, enhancing drug elimination into bile and urine and imbedding 
the entry of drugs into the central nervous system and placenta (leiri 2011). 
Polychlorinated biphenyls (PCBs) are a group of widespread environmental 
pollutants. Environmental pollutants are classically associated with increased drug 
metabolism. Although there is a broad base of experimental data concerning the 
toxicity of PCBs in laboratory animals and animal-derived primary cells and cell 
lines, only few experiments data are available for cells of human origin (Zeiger et al.
2001).
Huh7, Caco-2 and A549 cell lines were used as models to study the effects of 
polychlorinated biphenyls (PCBs) on human drug metabolizing enzymes (CYPlAl 
and CYP3A4), a drug transporter (MDRl) and a nuclear receptor (PXR). As these in 
vitro models generate mechanistic information from which predictions of the in vivo 
situation can be made.
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Membrane integrity was evaluated and cell death was assayed with LDH assay to 
ensure that the concentration used does not lead to unacceptably high levels of cell 
death. This is an important control whenever cells are dosed with a potentially toxic 
chemical. No significant increase in LDH was seen in the three cell lines understudy 
when the cells were dosed with drugs compared to control.
Several papers have demonstrated the possibility to use cell-based reporter gene 
assays to identify compounds that are able to activate human PXR (hPXR) (Vignati et 
al. 2004; Jacobs et al. 2005). These assays provide a robust, high throughput screen 
with easy interpretable results to allow the ranking of compounds for their ability to 
induce CYP3A transcription. Apart of the biological variation of the reporter gene 
assays, the activation of PXR might be seriously affected by the cytotoxicity of the 
test compounds (Vignati et al. 2004). Any tested compound with the potential to 
decrease the number of viable cells significantly within the assay will confer the risk 
of a false-negative result. The LDH results demonstrated the importance of cell 
viability measurements as part of the reporter gene assay and in particular of the PXR 
assay as significant cytotoxicity or inhibition of cell proliferation might underestimate 
the potential for PXR activation. PXR activation measurements using an in vitro 
reporter gene assay approach appears to provide a fast and relatively inexpensive 
means for predicting whether compounds will induce CYP3A levels in vivo.
In this study, the selected PCBs were studied for their potential capacity to activate 
human PXR using a reporter gene assay. Data demonstrated that progesterone 
activated hPXR gene expression in Huh? and A549 cells but not in Caco-2 cells. In 
Caco-2 none of the tested compounds was able to activate hPXR gene expression. In 
Huh? cell line, four PCBs induced PXR expression and the order of induction was 
PCB 99 >PCB 11 > PCB 180 > PCB 194. In A549 cells only PCB 99 and 194 
induced PXR expression and their order of induction was revered to that seen in 
Huh?. PCB 194 gave the highest induction among all tested compounds even higher 
that the positive control progesterone. These results suggest that PXR is regulated at 
the molecular level by PCB ??, 99, 180 and 194 in Huh? cells, while it is regulated at 
the molecular level by PCB 99 and 194 in A549 cells.
Induction of CYP I AI is a characteristic biochemical response of exposure to a 
selected group of halogenated and polyaromatie organic compounds that proceeds 
toxicity. As a consequence, induction of hepatic CYP 1 A-associated enzyme activity 
has become the most widely used biomarker of exposure to environmental PCB
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mixtures in diverse speeies ineluding fish, birds and mammals. As a parameter of 
AhR activation, induction of CYPlAl mRNA expression was determined in the 
human Huh7, Caco-2 and A549 cell lines treated with the PCBs lUPAC Nos. 77, 99, 
138, 153, 180 and 194 by RT-PCR. Measurements of CYPlAl mRNA levels using 
RT-PCR is a sensitive method that had been used commonly in biomonitoring 
programs. It should be noted that CYPlAl is predominantly expressed in extra- 
hepatic tissue (particularly human lung) and is present in low amounts in non-induced 
liver. As expected, dosing with 10 pM rifampicin and 500 pM phénobarbital caused 
no statistically significant induction in CYPlAl mRNA expression level in the three 
cell lines. Of eight chemicals examined, only PCB 77 caused statistically significant 
induction in CYPlAl mRNA expression level in the three cell lines, with higher fold 
induction seen in Caco-2 cells. No statically significant induction of CYPlAl was 
observed in liver, intestine and lung cells after 48 hours exposure to the other tested 
PCBs. This result clearly confirms that PCB 77 can bind and activates AhR and 
induce CYPlAl mRNA expression level in liver, colon and lung cell lines.
PCBs effects on CYP3A4 and MRDl reporter genes in each type of cultured cells 
were examined and compared. There was no overall pattern seen with dosing with 
PCBs, different PCBs gave different response expect with PCB 153 which caused 
induction of CYP3A4 in the three cell lines.
5.7 Summary
Over the past decades, the biochemistry of xenobiotie metabolisms and the roles 
played by phase I, phase II metabolizing enzymes and what is considered now as 
phase III transporters have been studied extensively in drug metabolism, toxification 
and detoxification of different xenobiotie that prevalent in environment. The current 
work addresses an important aspect of the congener specific action of selected 
polychlorinated biphenyls (PCBs) which are a class of lipophilic inert compounds the 
on gene expression profile of CYP3A4, MDRl and PXR. The present study results 
highlight the advantage of using several types of cell lines to evaluate the short-term 
toxicity of environmental pollutants in vitro and constitute a useful model for 
predicting the potential toxicity of polychlorinated biphenyls (PCBs) in humans Huh7, 
Caco-2, and A549 cells. Taken together, these results show that the regulation of
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CYP3A4, MDRl and PXR genes expression at the transcriptional level is under the 
control of many factors and it is a complex process.
6 General Discussion and Future Directions
6.1 Discussion
In order to maintain cellular homeostasis, the expression of phase I, phase II enzymes 
and drug transporters must be under tight control. The regulation of transporters of 
basal expression occurs by several mechanisms. First, transcription can be induced or 
suppressed via transcription factors. Second, post-translational modifications can be 
made to proteins which results in regulating the activity level of the translated protein. 
Transporters can be expressed by their substrates which can act as ligands for 
members of the nuclear receptor superfamily of ligand activated transcription factors. 
On the other hand, these same transcription factors are also involved in the regulation 
of other genes involved in drug metabolism, allowing a coordinate response to 
xenobiotics at a transcriptional level, ensuring drugs are cleared jftom cells effectively, 
which minimises the risk of toxicity (Gibson and Skett, 2001).
PXR is central in the regulation and maintenance of cellular homeostasis and it is 
regarded as the principal regulator of the most abundant and important drug 
metabolising enzymes, the CYP3As (Bertilsson et al. 1998; Chen et al. 2012). In 
addition to this role, PXR also regulates other phase I drug metabolising enzymes, as 
well as phase II metabolism enzymes and membrane transporters (Maglich et al.
2002), as part of an entire program of genes involved in the metabolism and 
elimination of potentially toxic chemicals fi-om the body. PXR plays a key role in 
coordinating the distribution, metabolism and excretion of endogenous and exogenous 
compounds. The ability of PXR to induce a range of genes and the fact that it is 
activated by a whole set of unrelated xenobiotics and endobioties suggest that it is 
under a complex regulation.
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PXR and CAR share significant similarities in ligand binding and recognizing 
structurally different compounds and they cross communicate during the 
transcriptional activation of their target genes. PXR and CAR also have important 
roles as master transcription regulators of a broad range of genes that encode phase I, 
phase II DMEs and efflux transporters (Chen et al. 2012).
Reporter gene assays is a method used by molecular biologists to investigate the 
transcriptional regulation of a gene of interest. This method has been previously used 
in our lab to investigate the molecular mechanisms underlying the regulation of the 
CYP3A4 using different hepatic cell lines (El-Sankary et al. 2000; El-Sankary et al. 
2001; Bombail et al. 2004). The use of cell lines may be not the best method to 
investigate the mechanisms of regulation of genes, as the expression of the LETT was 
reported to be decreased 30 to 60 % of the normal hepatocytes. In addition, the 
expression of different CYP enzymes was reported to represent only 0.1 to 2% mRNA 
of the primary hepatocytes (Jover et al. 2001; Cheung et al. 2003).
Indeed, work carried out previously in our lab by Dr. Phillips has demonstrated that 
levels of some transcription factors are significantly reduced in Huh? cells compared 
to primary hepatocytes, including PXR (Phillips et al. 2005). Which indicate that 
these cells may have lost some important regulatory elements. Yet, these methods are 
considered important tools to investigate the potential role of TFs in regulating the 
expression of target genes and the molecular mechanisms of regulation of genes of 
interest.
The difference in expression of eo-activators and their levels in different cell and 
tissue types may contribute as well to the differences in response to drugs or the 
response to a co-transfected plasmid in a reporter gene assay (Leo and Chen 2000). 
For example, the difference in induction between CYP3A4 and MDRl in response to 
different PXR ligands has been demonstrated to be due to the difference in 
recruitment of co-activators to PXR. In which, SRCl was detected with PXR bound to 
the PXR response element of CYP3A4 gene, while AIB-1 was detected with PXR on 
the PXR response element of MDRl gene (Masuyama et al. 2005).
The profile of these co-activators and co-repressors are not yet fully described in the 
Huh? cells, and this open a door for an important future research topic. This
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knowledge may help to understand to what level co-activators or co- repressors effect 
PXR gene expression.
In my work, the non-coplanar PCBs were examined by looking at the possible 
induction of CYP3A4 and MDRl through the human pregnane X receptor (hPXR) in 
transiently transfected Huh7, Caco-2 and A549 cell lines. The ability of individual 
PCBs (PCB 99, 138, 153, 180, and 194) and the non-ortho PCB 77 was assessed to 
interact with CYP3A4 and MDRl genes in human Huh7, Caco-2 and A549 cell lines. 
Previous work has provided indirect evidence for the interaction of non-coplanar 
PCBs with the nuclear receptors PXR and CAR. Tabb et al. (2004) demonstrated that 
highly chlorinated non-coplanar PCBs were able to influence on PXR mediated 
transcription. This group demonstrated that these highly chlorinated PCBs were able 
to activate reporter gene expression of target genes in mouse and rat PXR but 
inhibited human PXR transcription. PCB 153 was shown to bind to human PXR by a 
scintillation proximity assay; this assay is a binding assay and does not distinguish 
between agonist and antagonist behaviour. In our work, we demonstrated the ability 
of non-coplanar PCBs to activate PXR in vitro and linked this to tissue-specific 
activation of target gene expression. While our data presented herein may initially 
appear contradictory to the suggestion that non-coplanar PCBs act as inhibitors of 
human PXR- mediated transcription. However, it is worth noting that the results 
demonstrated by Tabb et al. were done at low micromolar concentrations while we 
demonstrated activation of reporter gene expression at concentrations of 10 pM.
The differential effects of PCBs in human liver, intestine and lung cell lines is of 
interest and may be important to future risk assessments. Each tissue may act different 
due to the different coregulator pool present in them which reflects the most efficient 
response to chemical stimuli. The data presented here is consistent with previous 
works that shows tissue-specific induction profile and this is important because oral 
exposure is the most common route of non-occupational PCB exposure. Exposure to 
PCBs by inhalation is only a minimal non-occupation exposure route and in this work 
we demonstrated that lung cells were less sensitive to the PXR mediated effects of 
non-coplanar PCBs. It is important to remember that some caution must be applied 
when interpreting these data as the in vitro experiments done here used transformed 
cell lines, which does not reflect fully the in vivo tissue (Lin et al., 2012). 
Accumulation of different xenobiotics such as therapeutic drugs, carcinogens and 
environmental pollutions within the body can affect human health (Chen et al., 2012).
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Since the human body is capable of responding to different stimuli this response occur 
in a harmony way by complex interaction networks of the responding factors that 
result in the most effective alteration of the body to the stimuli. The ligand- activated 
transcription factors such as PXR and CAR are important for achieving this 
interaction.
In summary, my work done herein, demonstrate that non-coplanar PCBs could act as 
direct activators of an important nuclear receptor, PXR, and these PCBs are able to 
activate target gene expression in a tissue and substituents dependent manner as 
shown in section 5.4. It is important to consider these effects in risk assessments 
studies as these effects occur at concentrations that have been measured in humans 
where chronic activation of PXR has been linked to metabolic dysfunction and 
disease.
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6.2 Future Direction
In this work, the impact of individual PCBs congeners (PCB 77, 99, 138, 153, 180 
and 194) have been tested for their ability to induce CYP lA I, CYP3A4 and MDRl 
genes expression in three different human cell lines with emphasis on the role of PXR 
activation by these chemicals.
The work undertaken in this thesis has concentrated on the effect of non-coplanar 
PCBs on activating the nuclear receptor PXR and the preliminary results presented 
here showed that these PCBs acts as activator of PXR and are able to elicit 
transcriptional activation of target genes such as CYP3A4 and MDRl in a tissue and 
substituents dependent manner.
Therefore, a very important aspect of this work is to repeat the same experiments with 
CAR expression plasmid in the three cell lines to study if these chemicals can activate 
CAR as well. Burk et. al., investigated the role of CAR in the regulation of MDRl 
gene expression and demonstrated by gel shift and transfection experiments that CAR 
binds to distinct nuclear receptor response elements in the -7.8 kbp enhancer of 
MDRl and transactivate MDRl expression through DR4 motifs to which the receptor 
binds as a heterodimer with RXR or monomer, respectively (Burek et.al., 2005). 
Another very important future work to be explored is to examine the effect of simple 
mixture on the transcriptional activation of PXR and also testing with a commercial 
mixture such as Ardor 1260 which contain a high di-ortho PCBs including PCB 99, 
138, 153 and 180. This is important aspect to consider as many of these compounds 
exist in nature as mixtures and not as a single compound.
Another potential future direction is to continue the work done with the effects of 
PCBs on the transcriptional activation of CYP3A4 and MDRl genes by using primary 
hepatocytes, which will give indication whether the immortalized cell lines used in 
this work are valid in vitro models as well.
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8 Appendix
Figure 8.1 Agarose gel electrophoresis analysis of total RNA isolated from Huh? 
cells using RNeasy Kits.
1 kb DNA Step Ladder
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The integrity and size distribution of total RNA purified with RNeasy Kits was 
checked for all RNA samples by denaturing agarose gel electrophoresis and eithidium 
bromide staining. The ribosomal bands should appear as sharp bands on the stained 
gel. 28S ribosomal RNA bands present with an intensity approximately twice that of 
the 18S RNA bands. Higher molecular weight bands indicate DNA contamination. If 
the ribosomal bands in a given lane are not sharp, but appear as a smear of smaller 
sized RNAs, it is likely that the RNA sample suffered degradation during preparation.
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Figure 8.2 Amplification plots of RNA samples without reverse transcriptase 
enzyme (RT -) for GAPDH gene.
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Ail RNA samples were performed with and without reverse transeriptase. The above 
amplification plot is for RNA samples without reverse transacriptase (RT-). All RT 
negative control show no evidence for DNA contamination and consequently all 
amplification results from TaqMan assays were from RNA only. The amplification in 
this plots are the human genomic DNA standards only.
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Figure 8.3 MDRI dsp+en plasmid
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Figure 8.4 MDRI usp+en plasmid
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Figure 8.5 SEAP plasmid
Transcription blocker MCS
SEAP
|)SEAP2-Basic
4677 bpAnipr
SV40 polyA
MCS: multiple cloning site, SEAP: secretory alkaline phosphatase, SV40 polyA: 
SV40 polyadenylation, Ampr: lactamase conferring resistance to ampicillin.
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Figure 8.6 Expression plasmids for PXR, GRa, ERa and PPARa in pSG5
SV40
intron
hPXR
PolyA
Ainpr
SV40
b-globin intron
T7
hPPARa
Polÿ A
Ampr on
on
SV40
fl
b-globin intron
17
PolyA
Ampr
SV40
hERa fj
on
b-globùi intron
pSG5-hGRa 
8020 bp ïiGRa
Ampr
on
SV40: SV 40 promoter, P-globin: P-globin intron, T7: T7 promoter, hPXR: cDNA 
conding for the human PXR, hPPARa: cDNA coding for the human PPAR alpha, 
hGRa: cDNA coding for the human OR alpha, hERa: cDNA coding for the human ER 
alpha, ori: origin of replication, Ampr: lactamase conferring resistance to ampicillin, 
fl: origin of replication of the filamentous phage fl.
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Figure 8.7 Expression plasmid for RXRa in pSVL
SV40
Ampr
pSVL-hRXRa 
6300 bp
hRXRa
SV40: SV40 promoter, hRXRa; cDNA coding for the human RXR alpha, Ampr: 
lactamase conferring resistance to ampicillin.
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Figure 8.8 Expression plasmids for HNF4a
Anipr
EF-la
SV40 polyA
PEF6A/5 His-hHNF4a 
6822 bp
IiHNF4a
Blasticidin 
EM-7 promoter 
SV40 pomoter
V5 
I His 
BGH polyA
f l
EF-la: promoter of human elongation factor 1 alpha, T7: T7 promoter, hVDR: cDNA 
coding for the human vitamin D receptor, hHOTla: cDNA coding for the human 
hepatocyte nuclear factor 1 alpha, hHNF4a: cDNA coding for the human heptocyte 
nuclear factor 4 alpha, V5: V5 epitope. His: polyhistidine sequence, BGH polyA: 
bovine growth hormone polyadenylation, fl : origin of replication of the filamentous 
phage fl, EM-7 promoter: promoter for blasticidin, Blasticidin: blasticidin resistance 
gene, SV40 polyA: SV40 polyadenylation, Ampr: lactamase conferring resistance to 
ampicillin.
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8.9 Genomic DNA standards calculation
The human genome has 3.22 x 10  ^bp and the molecular weight of 1 bp is 660 g, so 
the molecular weight of the human genome is 3.22 xlO^x 660 = 2.1252 x 10^  ^g.
The human genome is diploid and 1 genome contains 2 copies, therefore a molar 
solution of the haploid genome contains 1.06 x 10^  ^g/1.
One mole contains 6.02 x 10^  ^molecules according to Avogadro’s number, but since 
DNA contains two single strands so each mole of the human haploid gene contains 
1.2 X 10^ "^  single strands. Therefore, 1.06 x 10^  ^ g contains 1.2 x 10^ "^  single strands, 
and so 1 g contains 1.13 x 10^  ^single strands.
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Figure 8.10 PCB NOMENCLATURE: DIOXIN-LIKE PCBs
lUPAC# lUPAC Name CASRN lUPAC # lüPAC Name CASRN
77 3,3',4,4'-Tetrachlorobiphenyl 32598-13-3 118 2,3',4,4',5-Pentachlorobiphenyl 31508-00-6
81 3,4,4',5-Tetrachlorobiphenyl 70362-50-4 123 2,3',4,4',5'-Pentachlorobiphenyl 65510-44-3
126 3,3 ',4,4',5-Pentachlorobiphenyl 57465-28-8 156 2,3,3',4,4',5-Hexachlorobiphenyl 38380-08-4
169 3,3',4,4',5,5'-Hexachlorobiphenyl 32774-16-6 157 2,3,3',4,4',5'-Hexachlorobiphenyl 68782-90-7
105 2,3,3',4,4'-PentachIorobiphenyl 32598-14-4 167 2,3',4,4',5,5'-Hexachlorobiphenyl 52663-72-6
114 2,3,4,4’,5-Pentachlorobiphenyl 74472-37-0 189 2,3,3',4,4',5,5'-Heptachlorobiphenyl 39635-31-9
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Figure 8.11 PCB NOMENCLATURE & log Kows: CONGENERS
lUPAC#^ lUPACNamc CASRN log Ko, lUPAC# lUPACNamc CASRN logKrt,
Monochloroblphciçls 35 32',4-TricHorob%)hcnyI 37680-69-6 5.82
1 2-CHorûbfbei^'l 2051-60-7 4.46 36 32'2-Trich!erob^henyl 38444-87-0 5.88
2 3’CHorobybcnyl 2051-61.8 469 37 3,4,4'-Tri(hîorob^henyl 38444-90-5 5.83
3 4Ch!ûrob%)hmyI 2051-62.9 4.69 38 3.4,5-Trichbn)biphcnyl 53555-66-1 5.76
Dîcbloroblpljeijyls 39 3,4'2-Trid]lorob%)bcnyl 38444-88-1 5.89
4 2,2-DscWorob|)haiy! 13029-08.$ 4.65 TctracblorHlMphoiyls
5 23'DichloiyKplen)1 16605-91-7 4.97 40 22'23'-Teirachîorobsphetiyl 38444-93-8 5.66
6 23-Dschiorobfhcnyl 25569-80.6 5.06 41 22'2,4-Teffâchlorobîphcnyî 52663-59-9 5.69
7 2,4'DicblomWpknyl 33284-50-3 5JD7 42 22'2,4'-T cirachlorobiplici^l 36559-22-5 5.76
8 2,4*Dichlcrobfhcnyî 3488343-7 5.07 43 22'22*Tclrâch!orobîphcnyl 70362-46-8 5.75
9 2,5-DkhloroKptenyl 34883-39-1 5.06 44 22'22'-Tc(mchlornb:plicnyl 41464-39-5 5.75
10 2,6'DkhloioWpknyl 3314645-1 464 45 22'2,6-Tclrachîûrob!pkn)l 70362-45-7 5.53
11 33-K cblorob|ihcnyl 2050-67-1 528 46 22'2,6'-T ctrachlorobiflicryl 41464-47-5 5.53
12 3,4-DichîoroKpten>l 2974-92-7 522 47 22',4,4’-Tetrach!orobii4ictij'l 2437-79-8 5.85
13 3,4*Dichlorob|ihaiyl 2974-90-5 529 48 22',42  -Tctrachîofobîphcny! 70362-47-9 5.78
14 33*DichloroKplKnyl 3488341-5 528 49 2 2 ',4 2 ’-Tctr3ch!or6biphenyl 41464-40-8 5.85
15 4,4-Kc!)l(rob^hœy! 2050-68-2 520 50 22',4,6-Tetrachlorobipteny{ 62796-65-0 5.63
Tricliloroblpbenjls 51 22',4,6’-T d  rachîorobîphcrç’l 68194-01-7 5.63
16 22  *3 -Trichiorolsphenyi 38444-78-9 5.16 52 2 2 '2 2 ’-Tdrachlorobiphcnyl 35693-99-3 5.84
17 22',4 -TrichlorolBphcnyl 37680-66-3 525 53 22'2.6'-T d  rachlorobiitieny 1 41464-41-9 5.62
18 22'4*Trich!ôn)Kphenyl 37680-65-2 524 54 2,2’,6,6'*Tdrat'hîorûbîphciç1 15968-05-5 5.21
19 2 2 ’,6 •TrichloroHphcnyl 38444-734 5.02 55 22,3',4-Tctrachla-ôbiplienyl 74338-24-2 6.11
20 2 3 3 '’TrîchîotüKpbcnyl 38444-84-7 527 56 22,3\4'.Tdrach!ùrnb:pbcnyl 41464-43-1 6.11
21 22.4*Trk'hlorobi{4ici^'l 5570246-0 521 57 23,3'2-Tclrachlarobiptenyl 70424-67-8 6.17
22 2 3 ,4'-îriehlorolsphenyl 38444-85-8 528 58 22,3'2'.Tdrâchîôrûbiphcnyl 41464-49-7 6.17
23 23 3*TricbIo»bî flicriy'l 5572044-0 527 59 22,3',6-Tctfachlofôbiphenyl 74472-33-6 5,95
24 23,6'Tncb!ombl|4ienyl 5570245-9 525 60 22,4,4-Telrachlarobiptcnyl 33025-41-1 6.11
25 23',4 -Trichlorofe’phenyl 55712-37-3 5.67 61 23,42-T  dwbbrobiphcnyl 33284-53-6 6.04
26 23 '3 •Trichlorolsphcnyl 38444-814 5.66 62 22,4,6-Tctrach torobi pliényl 54230-22-7 5.89
27 2 3 ',6 •TrichloroHphcnyl 38444-76-7 5.44 63 22,4" 2"Tctrachlwobipknyl 74472-34-7 6.17
28 2 4 ,4'-TrichtoroHphcnyl 7012-37-5 5.67 64 22,4',6.Tdrachlcrobiphenyl 52663-58-8 5.95
29 243*Trich!orobiplieny’l 15862-074 5.60 65 22,5,6-TctrachloroHplicr^'l 33284-54-7 5.86
30 24,6-Triclilûn)biphcnyl 35693-92-6 5.44 66 22',4,4'-Tdrachlûrûbiplicrç1 32598-10-0 6.20
31 24'3,'T  rkhloroHpl)Cn>'l 16606-02-3 5.67 67 22',42-Tclrachlorobiphcn)l 73575-53-8 6.20
32 24  ',6 •TrichloroHphcnyl 38444-77-8 5.44 68 2 2',42 ’-Tdrach!ûrtÆ)ipltcnyl 73575-52-7 6.26
33 23  ',4 '-T rich broH i^icny ! 38444-86-9 5.60 69 22',4,6-Tclrach!orobiplicnyl 60233-24-1 6.04
34 23'3'"Trich!oroH|*cryI 37680-68-5 5.66 70 22',4',5-Tdrachlorobiphctiyl 32598-11-1 6.20
71 23  ',4 ',6 •Tclradilorobiphcnyl 41464-164 5.98 107 22.3',4’2-PcniachlorobipI)cn)l 70424-68-9 6.71
72 23'ii'*Tctnichlor(ibinhcnvl 4146442-0 6.26 108 22.3’.4.5'-Penlachlorobinhcnvl 70362-41-3 6.71
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Il PAC# U PAC Name CASRN logK„, Il PAC# llPACNana- CASRN H  K o,
73 Z3',5'.6-Tci rachlirobiphcn) 1 74338-23-1 6.04 109 23 J ,4 ,6 -P  cm ach brobi phenyl 74472-35-8 6.48
74 Z4,4’.5-TtiradibroHptKnyi 32690 93-0 6Z0 110 2 3  3 ,4 .6 -Pen taeh lorobiphenyl 38380-03-9 6.48
75 Z4,4’,6-Tciradi broHphcnyl 32598-12-2 63)5 111 233,5,5'-Pcntaehlürobiphcnyi 39635-32-0 6.76
76 Z3',4'4 '-T ctrachliïubf hrnyi 70362-48-0 6.13 112 2 3  3,5,6-Pcntaeh brnHphcnyl 74472-364) 6.45
77 3,3*4,4’-Tctrachkfob)phcnyl 32598-13-3 6J6 113 2 3 3,5',6-Pmtaeh krobiphenyl 68194-10-5 6.54
78 3,3'.44*Tdrach broHphcny! 70362-49-1 635 114 23,4,4'.5-PcrtachbroWf4iertyl 74472-37-0 6.65
79 3,3',4,5'-Tctrachkirobiphcny! 4146448-6 6.42 115 2 3 .4.4',6'Pcrt ach br(iK(4ici^l 74472-38-1 6.49
80 3,3’,5,5'-Tctrachlürt4»ipheny! 33284 52-5 6.48 116 23,4,5,6 -Pentachkr «ibipheny 1 18259-05-7 6.33
81 3,4,4',5-TetradibraHphenyl 70362-504 6.36 117 23.4’,5,6'PertachbroHpheml 68194-11-6 6.46
Pinlachloniiiiphcn,>i!> 118 23',4,4',5 -Pentaeh krobiphenyl 31508-00-6 6.74
82 Z2'.33*,4 -Pen üch bw H pkny i 52663-62-4 6Z0 119 23',4,4%6-PentachkTobiphenyl 56558-17-9 6.58
83 Z2',33',5-Pentach bntHpheny! 60145-20-2 6Z6 120 2 3  ',4,5.5'- Pentazh lorobiphenyl 68194-12-7 6.79
84 Z2',33',6'Pentachbrt»Hphenyl 52663410-2 6.04 121 23',4,5',6-Pen tach Itrobiphenyl 56558-18-0 6.64
85 Z2'3,4,4'-PeniadibroHphcm*l 6551045-4 630 122 2 3 J .4 '3 ’-Pcntaehlorob!phcny! 76842-07-4 6.61
86 Z2'3,4,5-Pcniach!ürübiphcnyl 55312-69-1 633 123 23*,4,4'3''Pentachlorobî|4icny! 6551044-3 6.74
87 Z2'3,4,5'-Penlachbrob!phen)’l 3838(M)2. 6.29 124 23',4'33'-Pcntach!orobiphenyl 70424-70-3 6.73
88 Z2'3,4,6-Pen{achlorobiphem'î 55215-17-3 6.07 125 2 3 ',4'3',6-Pcolachîurübîpheiçl 74472-39-2 6.51
89 Z2'3,4.6'- Pen taeh broH phenyl 73575-57-2 6.07 126 33.4,4' 3-Pentaehlürobipheny4 57465-28-8 6.89
90 Z2'3.4'3 'Pen mcb broH phenyl 68194-07-0 636 127 3 3  '.4,5,5'- Pai taeh kruhipknyl 39635-33-1 6.95
91 Z2'3,4'.6'PcnüchbroHplKnyl 68194-05-8 6.13 Htxachlorohiphcnyls
92 Z 2'33 ,5 ‘'Penüchbrt)Hpheny 1 52663-61-3 635 128 2Z'3.3,4,4'-Hexaehlorobiphenyl 38380-07-3 6.74
93 Z2'33,6-Pentaehîorobî{4icnyl 73575-56-1 6.04 129 2Z'3.3'.4.5-Hmehlurühÿhonyl 55215-184 6.73
94 Z2',33,6''PentiehbroHpknyi 73575-55-0 6.13 130 2Z'3.3',4,5'HexaelW obyhenyl 52663-66-8 6.80
95 Z2'.33’,6-PentachbroHpheny! 38379-99-6 6.13 131 2Z'3,3,4,6-Hcxachlorob phenyl 61798-70-7 6.58
96 Z2'3,6,6''Pen tach broH plieny 1 73575-54-9 5.71 132 2 3  '3,3’.4,6'-Hc.xachl trob^hcnyl 38380-05-1 6.58
97 Z2',3,4’3'-PenlachUrnbiphcnyt 41464-51-1 639 133 23'33'3.5'-He.vacHorob|vhcnyl 35694-M-3 6.86
98 Z2'.3,4’,6'-Penlachkr()b5phenvi 60233-25-2 6.13 134 23'3,3'3,6'Hexaehlorob%ihmyl 52704-70-8 6.55
99 Z2',4,4'3-PenlachbrüHphctç'î 383804)1-7 639 135 23'3,33,6'-He.xâchitîri)b^henyi 52744-13-5 6.64
100 Z2',4,4',6'Pen taeh brohs pbcny ! 39485-83-1 633 136 23'3 .3’,6,6'-Hexach!orobfheny! 38411-22-2 6.22
101 Z2’,43,5''PentachbroHphet^l 37680-73-2 6.38 137 2 3 '3 ,4,4',5-Hcxachlorob^hcny! 35694-06-5 6.83
102 2,2’,4 3,6'Pen tach broH phe nyl 68194-06-9 6.16 138 23'3 ,4 ,4’,5'-HexachliTübphcnyl 35065-28-2 6.83
103 Z2',43'.6 Pen tach broH phenyl 60145-21-3 632 139 2 3  '3.4.4',6-H exachiorob iph oiy 1 56030-56-9 6.67
104 Z2',4,6,6-Pen i;tch broH phenyl 56558-16-8 5.81 140 23'3.4.4',6'4le.xaehl(rob%)henyl 59291-644 6.67
105 Z33',4,4'*Pentachbrobiphcml 325984 44 6.65 141 2 3  '3.4.53 '-He xaehlornbiphenyl 52712-04-6 6.82
106 Z33'.4,5-Penlaeh!orièiphei^'l 70424-69-0 6.64 142 23'3,4,5,6-Hexachlorobipheny! 41411-614 6.51
143 Z2'.3,4,5,6'-HexachkTobiphenyl 68194-15-0 6.60 179 23'3 ,3’,5,6,6’-lleptaehkm)Hphenyl 52663-64-6 6.73
144 Z2',3,4,5'.6-Hcxachba)biphenyi 68194-14-9 6.67 180 23'3.4.4'.53''Hc|itachlon)biphenyl 35065-29-3 7.36
145 Z2’.3,4.6.6'*Hexachlorobiphcnyl 7447240-5 6.25 181 23'3.4.4',5,6 Heptæhbrobiphenyl 74472-47-2 7.11
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H PAC# llPA C N aint CASRN k K m Il PAC# lUPACNamc CASRN kgK pw
146 Z2',3,4'5,5''Hexaélomb%ihenyl 51908-16.8 6.89 182 22’2,4.4’,5,6-HepiachlomWphenyi 60145-23-5 7.20
147 2,2',3,4',5,6-Hcxachk)tüb!phen)'l 68194 13-8 6.64 183 22’J,4,4',5',6-Hep{ach!trtèi{ticnyl 52663-69-1 7.20
148 2,2',3,4',5,6'-Hexadilon)biphL*n^ 7447241-6 6.73 184 22'2.4.4',6,6'-Hepiachloru biphenyl 74472-48-3 6.85
149 Z2',3,4'3',6- Hcxachlwwbipbcnyl 383804M-0 607 185 22'3,4,52',6'Heptaehlorobiphenyi 52712-05-7 7.11
150 Z2',3.4',6,6’-li‘xaàli)n)h^kn)l 68194-08-1 6J2 186 22'2,4.5,6.6’-lkplachlirobiphenyl 74472-494 6.69
151 Z2',3,5,5',6-Hcxachbn)biphcnyl 52663-63-5 6.64 187 22'3,4'2,5',6-Heplachlorob!|ticnyl 52663 68-0 7.17
152 Z2',3,5,6,6’-Hcx8cbl(iobiphcnyl 68194-09-2 622 188 22'2,4’,5,6,6'-Heptaehioml»pheny! 74487-85-7 6.82
153 Z2',4,4'4,y-Ht‘xaèlorubfkn>l 35065-27-1 6.92 189 22J,4,4',52-Hep(aehlomWphcnyl 39635-31-9 7.71
154 Z2’,4,4'5,6'>lkxadiion)hîpkn)l 60145-22-4 6.76 190 222,4,4',5,6 -Heptaeh lorobipbcny! 41411-64-7 7.46
155 Z2',4,4',6,6'-lkxaéloR)b^ kny! 33979-03-2 6.41 191 222',4,4',5',6*Hep$acbkrt)biphcnyl 74472-50-7 7.55
a,l56 Z3,3',4,4\5"HcWibmbi|[4Kn)i 3838008-4 7.18 192 222',4,5.5',6-lkpla‘hlcrobiphenyi 74472-51-8 7.52
157 Z3,3',4,4',5’-Hcxadi!on)b^ k*nyl 6X782-90-7 7.18 193 222',4'.5,5',6-Heptachlorobi [ticny t 69782-91-8 7.52
158 Z33',4,4>Hexachk)nèiphcn\i 74472-42-7 7.02 OdachliirüWjicnyls
159 Z3Z',4,53'*Hcxach!ürobiphenyi 39635.35 3 724 194 22'2,2,4,4',52’-Octachlorobiphcny! 35694-08-7 7.80
160 Z3Z',4,5,6-HcxaàbruHphcnyi 41411-62-5 6.93 195 22'22',4,4',5,6-{Xladik)roHpheny! 52663-78-2 7.56
161 Z33',4,5>Hcxachkmibiphenyl 7447243-8 7.08 196 22'2J.4,4',5,6'-<X’laàlürobiphcnyl 42740-50-1 7.65
162 Z3Z',4',5,5-Hexaélon)b‘^ knyl 39635-34-2 724 197 22’22',4,4',6,6'-()claéltrobiphcnyl 33091-17-7 7.30
163 Z33',4'3.6-Hcxachk)n>biphcnyi 7447244-9 6.99 198 22'22\4,5,5',6-(XladibroHphen)i 68194-17-2 7.62
164 Z3Z’,4'4',6' Hcxadilorobf henyl 7447245-0 7.02 199 22 '22',4,52 ',6'-0etacb lorobipheny I 52663-75-9 7.62
165 Z3Z'3,5>Hcxachk)robiphcnyi 7447246-1 7.05 200 2Z'2,3’,4,5.6,6'-(Xladik»robiphenyl 52663-73-7 7.20
166 Z3,4,4',5,6-HexaéforüMpht'ny! 41411-63-6 6.93 201 22'22',4,5',6,6'-(Jeiachlorobiphenyl 40186-71-8 7.27
167 Z3’,4.4',5,ÿ*Hcxaddori)b!pknyl 52663-72-6 727 202 22’22’22',6,6'-(ktadt lorobipheny! 2136-99-4 7.24
168 Z3',4,4'j%6- Hoxadiloroby knyl 59291-65-5 7.11 203 22'2,4.4',52',6-(XtaehbroNphenyl 52663-76-0 7.65
169 3,3’,4 4’5,f-Hc\adilorub^ hiii)l 32774-16-6 7.42 204 22’2>4,4’,5,6,6’-(XCadiforoh'phenyl 74472-52-9 7.30
HcplachiuroItlplkiiyU 205 222',4,4’,52',6-(Xladibrobiphenyi 74472-534 8.00
170 Z2'.3,3’.4,4',5’Hcplachlcfübipkny! 35065-30-6 727 N()naélori)l>iphti»yU
171 Z2',3,3'.4,4',&Hep!aebkimb!pknyl 52663-71-5 7.11 206 22'2,3',4,4’,52',6-.NonaeWorobiphem'! 40186-72-9 8.09
172 Z2’.33',4,5.5'-Hcplachlifubiphcny! 52663-74-8 723 207 22'2,3,4.4',5,6,6'-\onaehlorobiphenyl 52663 79-3 7.74
173 Z2'.3Z'.4,5,6-Hcptachbrobiplicn>i 68194-16-1 702 208 22'2,3’,422’,6,6'-Nonachlorobipheny! 52663-77-1 7.71
174 Z2',3Z',4,5,6'-Hcplachlnrobiphcnyl 38411-25 5 7.11 Dccachkirol^thenvls
175 Z2’,3,3'.4,5',6-Hcpt3clikTob!plicny! 40186-70-7 7.17 209 2,2;23',4,4’,5,5'.6,6’-DecachIorobi|)henyl 2051-24-3 8.18
176 2.2',3Z’,4,6,6’-lfcptachlr)rubiphenyl 52663-65-7 6.76 Koülnoltt:
177 Z2’,33\4,5,6'-Hcplach!ori)biplifiiyl 52663-70-4 7.08 Dbxâi-likc aingenersare imlicalcd by a^ding.
178 Z2’,3JS'i.5',6-Hcplaeh!trobiplK*nyl 52663-67-9 7.14 log values arc from Hawker and Connell, 1988.
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